

National HIV Surveillance System (NHSS)

Attachment 5.

HIV Surveillance Report



Volume 29

Diagnoses of HIV Infection in the United States and Dependent Areas, 2017



The *HIV Surveillance Report* is published annually by the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through June 2018.

The *HIV Surveillance Report* is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. <i>HIV Surveillance Report, 2017</i> ; vol. 29. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Published November 2018. Accessed [date].
--

On the Web: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>

Confidential information, referrals, and educational material on HIV infection

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

Publication of this report would not have been possible without the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

This report was prepared by the following CDC staff and contractors: Kristen Hess, Shacara Johnson, Xiaohong Hu, Jianmin Li, Baohua Wu, Chenchen Yu, Hong Zhu, Chan Jin, Mi Chen, John Gerstle, Marie Morgan, Michael Friend, Anna Satcher Johnson, Azfar Siddiqi, Angela Hernandez, the HIV Incidence and Case Surveillance Branch, and the Data Management Team of the Quantitative Sciences and Data Management Branch.

Contents

Commentary	5
Technical Notes	11
Tables	
Section 1 Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS)	
1a Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States	17
1b Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States and 6 dependent areas	18
2a Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States	19
2b Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States and 6 dependent areas	20
3a Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States	21
3b Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas	22
4a Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States	23
4b Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas	24
5a Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States	25
5b Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States and 6 dependent areas	26
6a Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States	27
6b Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States and 6 dependent areas	28
7a Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact <i>and</i> injection drug use, by selected characteristics, 2012–2017—United States	29
7b Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact <i>and</i> injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas	33
8a Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States	37
8b Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas	41
9a Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States	45
9b Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas	49
10a Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact <i>and</i> injection drug use, by selected characteristics, 2012–2017—United States	53
10b Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact <i>and</i> injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas	57
11a Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States	61
11b Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas	65
12a Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States	69
12b Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas	73
13a Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States	77
13b Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States and 6 dependent areas	77
14a Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States	78
14b Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States and 6 dependent areas	78

15	Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992–2017—United States and 6 dependent areas	79
16	Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2017—United States and 6 dependent areas	80
17	Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2017—United States and 6 dependent areas	81
Section 2 Deaths after a Diagnosis of HIV Infection or Stage 3 (AIDS) Classification		
18a	Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States	82
18b	Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States and 6 dependent areas	84
19a	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and cumulative—United States	86
19b	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and cumulative—United States and 6 dependent areas	88
20a	Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States	90
20b	Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas	92
21a	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States	94
21b	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas	96
Section 3 Persons Living with Diagnosed HIV Infection or with Infection Ever Classified as Stage 3 (AIDS) (Prevalence)		
22a	Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States	98
22b	Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States and 6 dependent areas	100
23a	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States	102
23b	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States and 6 dependent areas	104
24a	Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States	106
24b	Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas	108
25a	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States	110
25b	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas	112
Section 4 Data by Area of Residence		
26	Diagnoses of HIV infection, by area of residence, 2016 and 2017—United States and 6 dependent areas	114
27	Stage 3 (AIDS), by area of residence, 2016, 2017, and cumulative—United States and 6 dependent areas	115
28	Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas	117
29	Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas	119
30	Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico	121
31	Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico	124
Web Addresses for Reports of State and Local HIV Surveillance		129

The Centers for Disease Control and Prevention (CDC) collects, analyzes, and disseminates surveillance data on HIV infection; these data are one of the nation's primary sources of information on HIV in the United States. The annual surveillance report, published by the Division of HIV/AIDS Prevention, summarizes information about diagnosed HIV infection in the United States and dependent areas. HIV surveillance data are used by CDC's public health partners in other federal agencies, health departments, nonprofit organizations, academic institutions, and the general public to help focus prevention efforts; plan services; allocate resources; develop policy; detect, monitor, and intervene in HIV clusters; and monitor trends in HIV infection.

Numbers and rates of diagnoses of HIV infection during 2012–2016 and preliminary numbers for 2017 are based on data from all 50 states, the District of Columbia, and 6 U.S. dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands).

During 2012–2016, the annual rate of diagnoses of HIV infection in the United States decreased; the annual number of diagnoses remained stable. Numbers and rates of diagnoses of HIV infection increased in some subgroups and decreased in others. Variations in trends among groups are expected and may be due to differences in testing behaviors, targeted HIV testing initiatives, or changes in the numbers of new HIV infections (incidence) in some subgroups. (For slide sets of trends among selected populations [2010–2016], see Additional Resources.)

REPORT CHANGES

In response to our partners' requests for expanded data, the 2017 report includes tables that provide data on diagnoses and stage 3 (AIDS) classifications among adults and adolescents, by year (2012–2017), sex, and selected characteristics.

- For diagnosis data (United States/United States and dependent areas), see Tables 5a/b.
- For stage 3 (AIDS) classification data (United States/United States and dependent areas), see Tables 6a/b.

DEFINITIONS AND DATA SPECIFICATIONS

The term *diagnosis of HIV infection* is defined as a diagnosis of HIV infection regardless of the stage of disease (stage 0, 1, 2, 3 [AIDS], or unknown) and refers to all persons with a diagnosis of HIV infection. The term *HIV infection, stage 3 (AIDS)* and its condensed version—*stage 3 (AIDS)*—refer specifically to persons with diagnosed HIV whose infection was classified as stage 3 (AIDS) during a given year (for diagnoses) or whose infection has ever been classified as stage 3 (AIDS) (for prevalence and deaths). The 2008 surveillance case definition for HIV infection was used to classify cases diagnosed through 2013. The 2014 revised surveillance case definition was used to classify cases diagnosed after 2013. For more information on HIV surveillance case definitions and the stages of HIV infection, please review the Technical Notes.

The data on diagnoses of HIV infection reflect the date of diagnosis (diagnosed by December 31, 2017; reported to CDC as of June 30, 2018), not the date of report to CDC. Similarly, the data specific to stage 3 (AIDS) reflect the first date the criteria for stage 3 (AIDS) were met. HIV diagnoses do not necessarily reflect when a person became infected. HIV surveillance data may not be representative of all persons infected with HIV because not all infected persons have been (1) tested or (2) tested at a time when their infection could be detected and diagnosed. Because of reporting delays, the number of cases diagnosed in a given year may be lower than the numbers presented in later reports; however, fluctuations in the number of diagnoses for a calendar year typically subside after 2 to 3 years of reporting.

HIGHLIGHTS OF ANALYSES

All rates are per 100,000 population. The standard used for reporting trends in numbers and rates is an increase or a decrease of 5% or more during the specified time frame (e.g., when comparing 2012 and 2016). Exceptions to this standard were made where numbers were small or rates were based on small numbers. The HIV diagnosis and stage 3 (AIDS) classification data for the year 2017 are considered pre-

liminary because they are based on only a 6-month reporting delay and therefore should not be included when assessing trends.

Please read all table titles and footnotes carefully to ensure a complete understanding of the displayed data.

Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS)

Diagnoses of HIV infection

From 2012 through 2016, the rate of diagnoses of HIV infection in the United States decreased; the annual number of diagnoses remained stable (Table 1a). In 2017, the rate was 11.8.

- **Age group:** From 2012 through 2016, the rate for persons aged 25–29 years increased. The rates for children (aged less than 13 years) and persons aged 13–14, 15–19, 40–44, 45–49, 50–54, 55–59, 60–64 years, and 65 years and older decreased. The rates for persons aged 20–24, 30–34, and 35–39 years remained stable. In 2017, the highest rate (32.9) was for persons aged 25–29 years, followed by the rate (28.7) for persons aged 20–24 years.
- **Race/ethnicity:** From 2012 through 2016, the rates for American Indians/Alaska Natives and Asians increased. The rates for blacks/African Americans, Native Hawaiians/other Pacific Islanders, whites, and persons of multiple races decreased. The rates for Hispanics/Latinos remained stable. In 2017, the highest rate was 41.1 for blacks/African Americans, followed by 16.1 for Hispanics/Latinos, 12.6 for persons of multiple races, 9.9 for Native Hawaiians/other Pacific Islanders, 8.8 for American Indians/Alaska Natives, and 5.1 for both Asians and whites.
- **Sex:** From 2012 through 2016, the rates for male and female adults and adolescents decreased. In 2017, males accounted for 81% of all diagnoses of HIV infection among adults and adolescents. The 2017 rate for male adults and adolescents was 23.1; the 2017 rate for females was 5.2.
- **Transmission category:** From 2012 through 2016, among male adults and adolescents, the annual number of diagnosed HIV infections attributed to injection drug use, to male-to-male sexual contact *and* injection drug use, or to heterosexual contact decreased. The number of infec-

tions attributed to male-to-male sexual contact remained stable. Among female adults and adolescents, the number of infections attributed to injection drug use or to heterosexual contact decreased. In 2017, among all adults and adolescents, the diagnosed infections attributed to male-to-male sexual contact (70%, including 3% male-to-male sexual contact *and* injection drug use) and those attributed to heterosexual contact (24%) accounted for approximately 94% of diagnosed HIV infections in the United States.

- **Region:** From 2012 through 2016, the rates of diagnoses of HIV infection in the Northeast and the Midwest decreased. The rates in the South and the West remained stable. In 2017, rates were 16.1 in the South, 10.6 in the Northeast, 9.4 in the West, and 7.4 in the Midwest.

Stage 3 (AIDS)

From 2012 through 2016, the annual number and the rate of infections classified as stage 3 (AIDS) in the United States decreased (Table 2a). In 2017, the rate of infections classified as stage 3 (AIDS) was 5.4.

- **Age group:** Because of the change in case definition in 2014, the trend among children (aged less than 13 years) was not assessed. From 2012 through 2016, the rates for all other age groups decreased. In 2017, the highest rate (11.1) was for persons aged 30–34 years, followed by the rate (10.4) for persons aged 35–39 years. Please use caution when interpreting data for children (aged less than 13 years) and persons aged 13–14 years: the numbers are small.
- **Race/ethnicity:** From 2012 through 2016, the rate for American Indians/Alaska Natives increased. The rates for all other race/ethnicity groups decreased. In 2017, the highest rate was 20.5 for blacks/African Americans, followed by 9.3 for persons of multiple races, 6.6 for Hispanics/Latinos, 4.7 for Native Hawaiians/other Pacific Islanders, 3.0 for American Indians/Alaska Natives, 2.2 for whites, and 1.8 for Asians.
- **Sex:** From 2012 through 2016, the rates for male and female adults and adolescents decreased. In 2017, males accounted for 76% of all infections classified as stage 3 (AIDS) among adults and adolescents. The 2017 rate for males was 10.0; the 2017 rate for females was 3.0.

- **Transmission category:** From 2012 through 2016, the annual number of infections classified as stage 3 (AIDS) among male adults and adolescents with HIV infection attributed to male-to-male sexual contact, to injection drug use, to male-to-male sexual contact *and* injection drug use, or to heterosexual contact decreased. The number of infections classified as stage 3 (AIDS) among female adults and adolescents with HIV infection attributed to injection drug use or to heterosexual contact decreased. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region:** From 2012 through 2016, the rates of infections classified as stage 3 (AIDS) in the 4 regions of the United States decreased. In 2017, rates were 7.6 in the South, 5.3 in the Northeast, 3.9 in the West, and 3.3 in the Midwest.

Deaths

Deaths of persons with diagnosed HIV infection

From 2012 through 2016 in the United States, the rate of deaths of persons with diagnosed HIV infection decreased; the number of deaths remained stable (Table 18a). In 2016, the rate of deaths of persons with diagnosed HIV infection was 4.8. Deaths of persons with diagnosed HIV infection may be due to any cause (i.e., may or may not be related to HIV infection).

- **Age group:** From 2012 through 2016, the rates of deaths for persons aged 60–64 and 65 years and older increased. The rates of deaths for persons aged 20–24, 30–34, 35–39, 40–44, 45–49, and 50–54 years decreased. The rates for persons aged 25–29 and 55–59 years remained stable. Please use caution when interpreting data for children (aged less than 13 years at death) and persons aged 13–14 and 15–19 years: the numbers are small.
- **Race/ethnicity:** From 2012 through 2016, the rates of deaths for American Indians/Alaska Natives, blacks/African Americans, and Hispanics/Latinos decreased. The rates for Asians, whites, and persons of multiple races remained stable. In 2016, the highest rate of deaths was for blacks/African Americans: 16.9.

Please use caution when interpreting data for Native Hawaiians/other Pacific Islanders: the numbers are small.

- **Sex and transmission category:** From 2012 through 2016, the rates of deaths for male and female adults and adolescents decreased. The number of deaths among males with diagnosed HIV infection attributed to injection drug use or to perinatal transmission decreased. The numbers of deaths among males attributed to male-to-male sexual contact, male-to-male sexual contact *and* injection drug use, or heterosexual contact remained stable. The number of deaths among female adults and adolescents with infection attributed to perinatal transmission increased. The number of deaths among females with infection attributed to injection drug use or to heterosexual contact decreased. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region:** From 2012 through 2016, the rates of deaths in the Northeast, the Midwest, and the South decreased. The rates of deaths in the West remained stable. In 2016, rates were 6.4 in the Northeast, 6.1 in the South, 3.4 in the West, and 2.5 in the Midwest.

Deaths of persons with infection ever classified as stage 3 (AIDS)

From 2012 through 2016 in the United States, the annual number and rate of deaths of persons with infection ever classified as stage 3 (AIDS) decreased (Table 19a). In 2016, the rate of deaths of persons with stage 3 (AIDS) was 3.8. Deaths of persons with stage 3 (AIDS) may be due to any cause.

- **Age group:** From 2012 through 2016, the rates of deaths among persons aged 60–64 and 65 years and older increased. Rates of deaths among persons aged 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, and 50–54 years decreased. Rates among persons aged 55–59 years remained stable. Please use caution when interpreting data for children (aged less than 13 years) and persons aged 13–14 and 15–19 years: the numbers are small.
- **Race/ethnicity:** From 2012 through 2016, the rates of deaths for American Indians/Alaska Natives, blacks/African Americans, and Hispanics/Latinos decreased. The rates of deaths

for Asians, whites, and persons of multiple races remained stable. In 2016, the highest death rate was for blacks/African Americans: 13.4. Please use caution when interpreting data for Native Hawaiians/other Pacific Islanders: the numbers are small.

- **Sex and transmission category:** From 2012 through 2016, the rates of deaths for male and female adults and adolescents decreased. The numbers of deaths among males with infection attributed to injection drug use or to perinatal transmission decreased. The numbers of deaths among males with infection attributed to male-to-male sexual contact, male-to-male sexual contact *and* injection drug use, or heterosexual contact remained stable. The number of deaths among female adults and adolescents with infection attributed to perinatal transmission increased. Among female adults and adolescents with infection attributed to injection drug use or to heterosexual contact, the number of deaths decreased. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region:** From 2012 through 2016, the rates of deaths in the Northeast, the Midwest, and the South decreased; the rate in the West remained stable. In 2016, rates were 5.1 in the Northeast, 4.9 in the South, 2.8 in the West, and 2.0 in the Midwest.

Prevalence: Persons Living with Diagnosed HIV Infection and Persons Living with Infection Ever Classified as Stage 3 (AIDS)

Prevalence of diagnosed HIV infection

From 2012 through 2016, the number and rate of persons in the United States living with diagnosed HIV infection increased (Table 22a). At year-end 2016, 991,447 persons in the United States were living with diagnosed HIV infection. The prevalence of diagnosed HIV infection was 306.6.

- **Age group:** At year-end 2016, persons aged 50–54 years made up the largest percentage (17%) of persons living with diagnosed HIV. The highest rate (777.6) was among persons aged 50–54 years, followed by those aged 45–49 (661.6) and those aged 55–59 (630.1). From 2012 through 2016, the

largest percentage increase in rates (56%) was among persons aged 65 years and older (from 104.4 in 2012 to 162.6 in 2016).

- **Race/ethnicity:** At year-end 2016, the highest rate (1,026.6) and the largest percentage (42%) were those for blacks/African Americans. Among the remaining race/ethnicity groups, the rates were 628.4 for persons of multiple races, 372.1 for Hispanics/Latinos, 152.8 for whites, 150.4 for Native Hawaiians/other Pacific Islanders, 124.0 for American Indians/Alaska Natives, and 76.3 for Asians.
- **Sex and transmission category:** At year-end 2016, the rates were 570.1 for male adults and adolescents, 169.9 for female adults and adolescents, and 4.2 for children (aged less than 13 years at year-end 2016). Among a total of 754,218 males (aged 13 years and older at year-end 2016), 72% of infections were attributed to male-to-male sexual contact, 10% to heterosexual contact, 10% to injection drug use, 7% to male-to-male sexual contact *and* injection drug use, and 1% to perinatal transmission. Among a total of 235,004 females (aged 13 years and older at year-end 2016), 76% of infections were attributed to heterosexual contact, 21% to injection drug use, and 2% to perinatal transmission. Among a total of 2,225 children aged less than 13 years at year-end 2016, 81% of infections were attributed to perinatal transmission.
- **Region:** At year-end 2016, the rate was highest in the Northeast at 418.8, followed by 361.3 in the South, 253.7 in the West, and 174.5 in the Midwest.

Prevalence of stage 3 (AIDS)

From 2012 through 2016, the number of persons living with infection ever classified as stage 3 (AIDS) increased; the rate remained stable (Table 23a). At year-end 2016, 525,374 persons in the United States were living with infection ever classified as stage 3 (AIDS). The prevalence of infections classified as stage 3 (AIDS) was 162.5.

- **Age group:** At year-end 2016, the highest rate (480.2) and the largest percentage (20%) were those for persons aged 50–54 years, followed by persons aged 55–59 (405.2 and 17%, respectively). From 2012 through 2016, the largest per-

centage increase in rates (54%) was among persons aged 65 years and older (from 70.0 in 2012 to 107.6 in 2016).

- **Race/ethnicity:** At year-end 2016, the highest rate (538.8) and the largest percentage (41%) were those for blacks/African Americans. Among the remaining race/ethnicity groups, the rates were 366.8 for persons of multiple races, 206.0 for Hispanics/Latinos, 79.0 for whites, 73.7 for Native Hawaiians/other Pacific Islanders, 62.3 for American Indians/Alaska Natives, and 35.5 for Asians.
- **Sex and transmission category:** At year-end 2016, the rates were 303.0 for male adults and adolescents, 89.8 for female adults and adolescents, and 0.5 for children (aged less than 13 years at year-end 2016). Among a total of 400,859 males (aged 13 years and older at year-end 2016), 67% of infections were attributed to male-to-male sexual contact, 12% to injection drug use, 12% to heterosexual contact, 8% to male-to-male sexual contact *and* injection drug use, and 1% to perinatal transmission. Among a total of 124,228 females (aged 13 years and older at year-end 2016), 72% of infections were attributed to heterosexual contact, 24% to injection drug use, and 2% to perinatal transmission. Among a total of 287 children aged less than 13 years at year-end 2016, 86% of infections were attributed to perinatal transmission.
- **Region:** At year-end 2016, the rate was highest in the Northeast at 237.0, followed by 185.7 in the South, 137.1 in the West, and 87.4 in the Midwest.

ADDITIONAL RESOURCES

The following were prepared by using HIV surveillance data:

- *MMWR* articles (selected): <http://www.cdc.gov/hiv/library/reports/mmwr.html>
- Other surveillance reports: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>
- Public-use slides updated annually: <http://www.cdc.gov/hiv/library/slidesets/>

- NCHHSTP AtlasPlus [interactive tool for accessing HIV/AIDS, STD, TB, and hepatitis data]: <http://www.cdc.gov/nchhstp/atlas/>

SUGGESTED READINGS

- CDC. Establishing a holistic framework to reduce inequities in HIV, viral hepatitis, STDs, and tuberculosis in the United States. <http://stacks.cdc.gov/view/cdc/11585>. Published October 2010. Accessed September 26, 2018.
- CDC. Estimated HIV incidence and prevalence in the United States, 2010–2015. *HIV Surveillance Supplemental Report* 2018;23(No. 1). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published March 2018. Accessed September 26, 2018.
- CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2016. *HIV Surveillance Supplemental Report* 2018; 23(No. 4). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published June 2018. Accessed September 26, 2018.
- CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for HIV infection—United States, 2014. *MMWR* 2014;63(RR-03):1–10. http://www.cdc.gov/mmwr/indrr_2014.html. Accessed September 26, 2018.
- CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. *MMWR* 2008;57(RR-10):1–12. http://www.cdc.gov/mmwr/indrr_2008.html. Accessed September 26, 2018.
- CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. <http://www.cdc.gov/mmwr/index2015.html>. Accessed September 26, 2018.

CDC [Dailey AF, Hoots BE, Hall HI, et al]. Vital Signs: Human immunodeficiency virus testing and diagnosis delays—United States. *MMWR* 2017;66(47):1300–1306. <http://www.cdc.gov/mmwr/volumes/66/wr/mm6647e1.htm>. Accessed September 26, 2018.

Cohen SM, Gray KM, Ocfemia MC, Johnson AS, Hall HI. The status of the National HIV Surveillance System, United States, 2013. *Public Health Rep* 2014;129(4):335–341. doi:10.1177/003335491412900408.

Frieden TR, Foti KE, Mermin J. Applying public health principles to the HIV epidemic—how are we doing? *N Engl J Med* 2015;373:2281–2287. doi:10.1056/NEJMms1513641.

Hall HI, Song R, Tang T, et al. HIV trends in the United States: diagnoses and estimated incidence. *JMIR Public Health Surveill* 2017;3(1):e8. doi.10.2196/publichealth.7051.

SURVEILLANCE OF HIV INFECTION

This report includes case report data from 50 states, the District of Columbia, and 6 U.S. dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands) in which laws or regulations require confidential reporting to the jurisdiction (not to CDC), by name, for adults, adolescents, and children with confirmed diagnoses of HIV infection.

After the removal of personally identifiable information, data from these reports were submitted to CDC. Although AIDS cases have been reported to CDC since 1981, the date of implementation of HIV infection reporting has differed from jurisdiction to jurisdiction. All states, the District of Columbia, and 6 U.S. dependent areas had fully implemented name-based HIV infection reporting by April 2008.

Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection. In addition, testing patterns are influenced by many factors, including the extent to which testing is routinely offered to specific groups and the availability of, and access to, medical care and testing services. The data presented in this report provide minimum counts of persons for whom HIV infection has been diagnosed and reported to the surveillance system. Finally, although all jurisdictions use a uniform case report form, surveillance practices in data collection and updating of case records may differ among jurisdictions.

Based on annual standard evaluation results, the completeness of reporting of HIV infection, as of December 2017, is estimated to be at least 85% in all but 1 jurisdiction [1].

STAGES OF HIV INFECTION

Both the 2008 and 2014 HIV case definitions were used to classify HIV infection among adults and adolescents and among children [2, 3]. In the following lists, some bulleted items are paraphrases, not quotations from the published surveillance case definitions. The intention is to emphasize the differences between the 2008 and 2014 case definitions.

The 2008 case definition was used to classify cases diagnosed through 2013. For adults and adolescents, this definition incorporates an HIV infection staging system that includes AIDS (HIV infection, stage 3). The 2008 stages of HIV infection are defined as follows:

- **HIV infection, stage 1:** No AIDS-defining opportunistic illness (OI) and either CD4+ T-lymphocyte (CD4 lymphocyte) count of ≥ 500 cells/ μL or CD4 percentage of total lymphocytes of ≥ 29 .
- **HIV infection, stage 2:** No AIDS-defining OI and either CD4 lymphocyte count of 200–499 cells/ μL or CD4 percentage of total lymphocytes of 14–28.
- **HIV infection, stage 3 (AIDS):** Documentation of an AIDS-defining OI or either a CD4 lymphocyte count of < 200 cells/ μL or CD4 percentage of total lymphocytes of < 14 . Documentation of an AIDS-defining OI supersedes a CD4 lymphocyte count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification.
- **HIV infection, stage unknown:** No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

The 2014 case definition was used to classify cases diagnosed after 2013. It is similar to the 2008 case definition except for the following: (1) inclusion of criteria for stage 0, (2) the inclusion of CD4 lymphocyte testing criteria for stage 3 in children, and (3) changes in the cutoffs for CD4 percentage of total lymphocytes used for classification of stages 1 and 2 in persons aged 6 years and older [3]. The stages of HIV infection in the 2014 case definition are based on age-

specific CD4 lymphocyte counts or percentages of total lymphocytes and are defined as follows:

- **HIV infection, stage 0:** Negative (nonreactive) or indeterminate HIV-1 test result within 6 months before the first positive (reactive) HIV-1 test result, or a negative or an indeterminate HIV-1 antibody test result within 6 months before or after the first positive HIV-1 nucleic acid test result (if the latter was not the first positive HIV test). The stage remains stage 0 during the 6 months after the first positive test result; after 6 months, the stage is reclassified, depending upon CD4 lymphocyte test results (stage 1, 2, or 3), the diagnosis of an AIDS-defining OI (stage 3), or the absence of reported CD4 or OI information (stage unknown).
- **HIV infection, stages 1, 2, and 3:** Documentation of an AIDS-defining OI (excluding stage 0 as described above) is stage 3. Otherwise, the stage is determined by the lowest CD4 lymphocyte test result [3, p 7].
- **HIV infection, stage unknown:** No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

The transition to CD4 lymphocyte-based criteria for stage 3 (AIDS) among children has resulted in an increase in the number of annual stage 3 (AIDS) classifications among pediatric cases diagnosed after 2013. Before implementation of the 2014 revised case definition, an OI diagnosis was required for a pediatric case to meet the criteria for stage 3 classification.

In this report, the term *diagnosis of HIV infection* is defined as a diagnosis of HIV infection regardless of the stage of disease (stage 0, 1, 2, 3 [AIDS], or unknown) and refers to all persons with a diagnosis of HIV infection. The term HIV infection, *stage 3 (AIDS)* and its condensed version—*stage 3 (AIDS)*—refer specifically to persons with diagnosed HIV whose infection was classified as stage 3 (AIDS) during a given year (for diagnoses) or whose infection has ever been classified as stage 3 (AIDS) (for prevalence and deaths).

TABULATION AND PRESENTATION OF DATA

The data in this report include information received by CDC through June 30, 2018. The data are organized into 4 sections.

- Section 1 (Tables 1a/b–17): numbers and rates of diagnoses of HIV infection (any stage) and diagnoses of infection classified as stage 3 (AIDS)
- Section 2 (Tables 18a/b–21a/b): numbers and rates of deaths among persons with diagnosed HIV infection (any stage) and persons with infection ever classified as stage 3 (AIDS)
- Section 3 (Tables 22a/b–25a/b): numbers and rates of persons living with diagnosed HIV infection (any stage) and persons living with infection ever classified as stage 3 (AIDS) (i.e., prevalence)
- Section 4 (Tables 26–31): numbers and rates of diagnoses and prevalence of HIV infection (any stage) and diagnoses and prevalence of infection classified as stage 3 (AIDS), presented by state and metropolitan statistical area (MSA)

Many tables in the 2017 report present data in 2 formats. Tables in the first format—labeled “a”—exclude data from the dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands). Tables in the second format—labeled “b”—include data from the dependent areas.

Please use caution when interpreting numbers less than 12, and rates and trends based on these numbers.

Numbers of diagnoses for the most recent year (2017) are considered preliminary. Please use caution when interpreting these numbers, and do not include them when assessing trends.

Diagnoses of HIV Infection and Stage 3 (AIDS) Classifications

This report is based on diagnoses of HIV infection that the 50 states, the District of Columbia, and 6 U.S. dependent areas reported to CDC as of June 30, 2018. Data from all areas are included in tables displaying numbers and rates of diagnoses of HIV infection and of stage 3 (AIDS) classifications, by selected characteristics, area of residence, and MSA (Tables 1a/b–17, 26, 27, 30, and 31). For tables presenting diagnosis data, region or area of residence reflects the address at

the time of HIV diagnosis or at the time of stage 3 (AIDS) classification.

Deaths

Persons reported to the National HIV Surveillance System are assumed alive unless their deaths have been reported to CDC. Death data include deaths of persons with diagnosed HIV infection (Tables 18a/b and 20a/b) or with infection ever classified as stage 3 (AIDS) (Tables 19a/b and 21a/b) regardless of the cause of death. Because of delays in the reporting of deaths, only 5 years (2012–2016) of death data are displayed. The exclusion of data from the most recent year allowed at least 18 months for deaths to be reported to CDC. For the death tables, region or area of residence is based on residence at death. When information on residence at death is not available, the state where a person’s death occurred is used.

Prevalence: Persons Living with Diagnosed HIV Infection and Persons Living with Infection Ever Classified as Stage 3 (AIDS)

Because of delays in the reporting of deaths, only 5 years of prevalence data are displayed. The data reflect persons living with diagnosed HIV infection, regardless of stage of disease, (Tables 22a/b, 24a/b, 28, and 30) and persons living with infection ever classified as stage 3 (AIDS) (Tables 23a/b, 25a/b, 29, and 31) at the end of a given year during 2012–2016. The exclusion of data from the most recent year allowed at least 18 months for deaths to be reported and for these deaths to be factored into calculations of prevalence. For tables presenting prevalence data, region or area of residence is based on most recent known address as of the end of the specified year.

Age

The designation “adults and adolescents” refers to persons aged 13 years and older; the designation “children” refers to persons aged less than 13 years. For presentations of data on persons living with diagnosed HIV infection (Tables 22a/b, 24a/b, and 28) and presentations of data on persons living with infection classified as stage 3 (AIDS) (Tables 23a/b, 25a/b, and 29), the age-group assignment (e.g., 20–24 years) or the age designation (e.g., “adults and adolescents”) is based on the person’s age as of December 31 of the

specified year. For presentations of data on deaths of persons with diagnosed HIV infection (Tables 18a/b and 20a/b) and deaths of persons with infection classified as stage 3 (AIDS) (Tables 19a/b and 21a/b), age-group assignment is determined by the person’s age at the time of death. For all other tables, the age designation or the specific age-group assignment is based on the person’s age at the time of HIV diagnosis or at the time of stage 3 (AIDS) classification.

Age-group designations for transmission categories in tables displaying data on prevalence and on deaths are based on a person’s age at the end of the specified year or age at death, respectively. The transmission categories among “adults and adolescents” in these tables include persons who were children at the time of diagnosis but who were aged 13 years and older during the specified year or at death.

Sex

Sex designations in this report are based on a person’s sex at birth. *Transgender* is an umbrella term that is used to identify persons whose sex assigned at birth does not match current gender identity or expression. Data for transgender persons are not presented in this report because information on gender identity (a person’s internal understanding of his or her gender or the gender with which a person identifies) is not consistently collected or documented in the data sources used by HIV reporting jurisdictions. HIV surveillance personnel collect data on gender identity, when available, from sources such as case report forms submitted by health care or HIV testing providers and medical records, or by matching with other health department databases (e.g., Ryan White program data). In May 2012, CDC issued guidance to state and local programs on methods for collecting data on transgender persons and working with transgender-specific data. However, characterization of HIV infection among transgender persons may require supplemental data from special studies.

Race and Ethnicity

In the *Federal Register* [4] for October 30, 1997, the Office of Management and Budget (OMB) announced the Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity. Implementation by January 1, 2003, was mandated. At a minimum, data on the following race categories should be collected:

- American Indian or Alaska Native
- Asian
- black or African American
- Native Hawaiian or other Pacific Islander
- white

Additionally, systems must be able to retain information when multiple race categories are reported. In addition to data on race, data on 2 categories of ethnicity should be collected:

- Hispanic or Latino
- not Hispanic or Latino

The Asian or Pacific Islander category displayed in annual surveillance reports published prior to the 2007 surveillance report was split into 2 categories:

(1) Asian and (2) Native Hawaiian or other Pacific Islander. The Asian category (in tables where footnoted) includes the cases in Asians/Pacific Islanders (referred to as legacy cases) that were reported before the implementation of the new race categories in 2003 (e.g., cases of HIV infection that were diagnosed and reported to CDC before 2003 but that were classified as stage 3 [AIDS] after 2003) and a small percentage of cases that were reported after 2003 but that were reported according to the old race category (Asian/Pacific Islander). In tables of diagnoses of HIV infection during 2012–2017, the Asian category does not include Asian/Pacific Islander cases because these cases were diagnosed after 2003 and were reported to CDC in accordance with OMB’s Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity [4].

This report also presents data for persons for whom multiple race categories are reported. In this report, persons categorized by race were not Hispanic or Latino. The number of persons reported in each race category may, however, include persons whose ethnicity was not reported.

Geographic Designations

Data by region or area of residence reflect the address at the time of diagnosis of HIV infection or at the time of stage 3 (AIDS) classification for tables that present number of diagnoses (Tables 1a/b–17, 26, 27, 30, 31). For tables presenting prevalence data (22a/b–25a/b, 28–31), region or area of residence is based on most recent known address as of the end of the specified

year. For the death tables (18a/b–21a/b), region or area of residence is based on residence at death. When information on residence at death is not available, the state where a person’s death occurred is used.

The 4 regions of residence used in this report are defined by the U.S. Census Bureau as follows:

Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont

Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin

South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia

West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming

U.S. dependent areas: American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands

Metropolitan Statistical Areas

In the *Federal Register* for June 28, 2010, OMB published revised standards for defining MSAs in federal statistical activities [5]. These standards, which provided for the identification of MSAs in the United States and Puerto Rico, replaced the 2000 standards. The adoption of the new standards was effective as of June 28, 2010. On February 28, 2013, OMB announced new MSA delineations based on the new standards and Census 2010 data [6]. Tables 30 (data on diagnosed HIV infection) and 31 (data on stage 3 [AIDS]) present numbers and rates of diagnoses and prevalence, by MSA, for areas with populations of 500,000 or more. The MSAs listed in these tables were defined according to OMB’s most recent update (February 2013) of statistical areas [6].

Transmission Categories

Transmission category is the term for the classification of cases that summarizes a person’s possible HIV risk factors; the summary classification results from selecting, from the presumed hierarchical order of probability, the 1 (single) risk factor most likely to have been responsible for transmission. For surveil-

lance purposes, a diagnosis of HIV infection is counted only once in the hierarchy of transmission categories. Persons with more than 1 reported risk factor for HIV infection are classified in the transmission category listed first in the hierarchy. The exception is men who had sexual contact with other men and injected drugs; this group makes up a separate transmission category.

Persons whose transmission category is classified as male-to-male sexual contact include men who have ever had sexual contact with other men (i.e., homosexual contact) and men who have ever had sexual contact with both men and women (i.e., bisexual contact). Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

Tables of prevalence data and tables of death data include a separate transmission category of adults and adolescents with HIV infection attributed to perinatal transmission. The category includes persons infected through perinatal transmission but aged 13 years and older during the specified year or at death.

Cases of HIV infection reported without a risk factor listed in the hierarchy of transmission categories are classified as “no identified risk (NIR).” Cases classified as NIR include cases that are being followed up by local health department staff; cases in persons whose risk-factor information is missing because they died, declined to be interviewed, or were lost to follow-up; and cases in persons who were interviewed or for whom other follow-up information was available but for whom no risk factor was identified.

Because a substantial proportion of cases of HIV infection are reported to CDC without an identified risk factor, multiple imputation is used to assign a transmission category [7]. Multiple imputation is a statistical approach in which each missing transmission category is replaced with a set of plausible values that represent the uncertainty about the true, but missing, value [8]. Each resulting data set containing the plausible values is analyzed by using standard procedures, and the results from these analyses are then combined to produce the final results. In tables displaying transmission categories, multiple imputation was used for adults and adolescents, but not for children (because

the number of cases in children is small, missing transmission categories were not imputed).

Rates

Rates per 100,000 population were calculated for (1) the numbers of diagnoses of HIV infection and the numbers of infections classified as stage 3 (AIDS), (2) the numbers of deaths of persons with diagnosed HIV infection and deaths of persons with infection ever classified as stage 3 (AIDS), and (3) the numbers of persons living with diagnosed HIV infection and persons living with infection ever classified as stage 3 (AIDS).

The population denominators used to compute the rates for the 50 states, the District of Columbia, and Puerto Rico were based on the Vintage 2017 postcensal estimates file (for years 2012–2017) from the U.S. Census Bureau [9]. The population denominators for American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin Islands were based on estimates and projections from the U.S. Census Bureau’s International Data Base [10]. Each rate was calculated by dividing the total number of diagnoses (or deaths or prevalence) for the calendar year by the population for that calendar year and then multiplying the result by 100,000. The denominators used for calculating the rates specific to age, sex, and race/ethnicity were computed by applying the appropriate vintage estimates for age, sex, and race/ethnicity for the 50 states and the District of Columbia [9]. The same method was used to calculate the denominators for Puerto Rico, with the exception of race/ethnicity estimates; these data are not available for Puerto Rico (see next paragraph). For the other 5 U.S. dependent areas, estimates from the U.S. Census Bureau’s International Data Base were used for age- and sex-specific population denominators [10].

CDC currently does not provide subpopulation rates by race/ethnicity for the 6 U.S. dependent areas because the U.S. Census Bureau does not collect information from all dependent areas. Rates for transmission categories are not provided in this report because of the absence of denominator data from the U.S. Census Bureau, the source of data used for calculating all rates in this report.

REFERENCES

1. Karch DL, Chen M, Tang T. Evaluation of the National Human Immunodeficiency Virus Surveillance System for the 2011 diagnosis year. *J Public Health Manag Pract* 2014;20(6):598–607. doi: 10.1097/PHH.0000000000000033.
2. CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. *MMWR* 2008;57(RR-10):1–12.
3. CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for HIV infection—United States, 2014. *MMWR* 2014;63(RR-03):1–10.
4. Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. *Federal Register* 1997;62:58782–58790. <http://go.usa.gov/xPg4F>. Accessed September 26, 2018.
5. Office of Management and Budget. 2010 Standards for delineating metropolitan and micropolitan statistical areas. *Federal Register* 2010;75(123):37246–39052. <https://go.usa.gov/xn43u>. Accessed September 26, 2018.
6. Office of Management and Budget. Revised delineations of metropolitan statistical areas, new definitions of micropolitan statistical areas and combined statistical areas, and guidance on uses of the delineations of these areas. OMB Bulletin 13-01. <https://go.usa.gov/xn43h>. Published February 28, 2013. Accessed September 26, 2018.
7. Harrison KM, Kajese T, Hall HI, Song R. Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. *Public Health Rep* 2008;123(5):618–627.
8. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. New York: John Wiley & Sons Inc; 1987.
9. U.S. Census Bureau. Population and Housing Unit Estimates Datasets. <https://go.usa.gov/xn4cc>. Accessed September 26, 2018.
10. U.S. Census Bureau. International Data Base. <https://www.census.gov/data-tools/demo/idb/>. Updated August 2017. Accessed September 26, 2018.

Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States

	2012		2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at diagnosis (yr)												
<13	241	0.5	184	0.3	180	0.3	140	0.3	130	0.2	99	0.2
13–14	50	0.6	43	0.5	32	0.4	25	0.3	25	0.3	25	0.3
15–19	1,919	9.0	1,687	8.0	1,727	8.2	1,740	8.2	1,700	8.0	1,711	8.1
20–24	7,174	31.8	7,054	30.9	7,370	32.2	7,276	32.1	6,868	30.7	6,354	28.7
25–29	6,459	30.2	6,653	30.8	7,187	32.7	7,596	33.9	7,930	34.6	7,691	32.9
30–34	5,458	26.1	5,202	24.4	5,451	25.3	5,457	25.2	5,662	25.9	5,614	25.6
35–39	4,161	21.3	3,964	20.2	4,241	21.3	4,263	21.0	4,224	20.3	4,315	20.3
40–44	4,448	21.1	3,925	18.8	3,793	18.4	3,417	16.9	3,264	16.5	2,995	15.2
45–49	4,290	19.8	3,923	18.5	3,610	17.3	3,325	16.0	3,098	14.8	2,964	14.1
50–54	3,187	14.1	2,968	13.1	2,899	12.9	3,000	13.5	2,879	13.2	2,677	12.5
55–59	1,924	9.3	2,010	9.5	1,933	9.0	1,874	8.6	1,886	8.6	1,886	8.6
60–64	1,049	5.9	1,066	5.9	973	5.2	999	5.2	1,078	5.5	1,086	5.4
≥65	820	1.9	860	1.9	831	1.8	852	1.8	845	1.7	864	1.7
Race/ethnicity												
American Indian/Alaska Native	172	7.4	147	6.3	182	7.7	189	8.0	230	9.6	212	8.8
Asian	797	5.1	792	4.9	923	5.5	941	5.4	972	5.4	942	5.1
Black/African American	18,196	46.9	17,326	44.3	17,533	44.4	17,453	43.7	17,269	42.9	16,690	41.1
Hispanic/Latino ^b	9,196	17.3	8,986	16.6	9,549	17.3	9,643	17.1	9,831	17.0	9,461	16.1
Native Hawaiian/Other Pacific Islander	51	9.8	47	8.8	44	8.1	74	13.3	41	7.2	57	9.9
White	11,041	5.6	10,621	5.4	10,581	5.3	10,403	5.3	10,117	5.1	10,048	5.1
Multiple races	1,727	28.8	1,620	26.2	1,415	22.2	1,261	19.2	1,129	16.7	871	12.6
Transmission category^c												
Male adult or adolescent												
Male-to-male sexual contact	26,252	—	25,614	—	26,546	—	26,481	—	26,159	—	25,513	—
Injection drug use	1,440	—	1,353	—	1,272	—	1,313	—	1,226	—	1,335	—
Male-to-male sexual contact and injection drug use	1,471	—	1,361	—	1,327	—	1,336	—	1,304	—	1,241	—
Heterosexual contact ^d	3,502	—	3,337	—	3,265	—	3,258	—	3,216	—	2,744	—
Other ^e	46	—	41	—	37	—	36	—	26	—	36	—
Subtotal	32,711	25.7	31,707	24.6	32,447	25.0	32,424	24.7	31,931	24.1	30,870	23.1
Female adult or adolescent												
Injection drug use	1,146	—	978	—	952	—	1,001	—	950	—	1,009	—
Heterosexual contact ^d	7,047	—	6,621	—	6,614	—	6,370	—	6,531	—	6,259	—
Other ^e	35	—	49	—	34	—	29	—	47	—	44	—
Subtotal	8,228	6.2	7,648	5.7	7,600	5.6	7,400	5.4	7,528	5.4	7,312	5.2
Child (<13 yrs at diagnosis)												
Perinatal	175	—	122	—	134	—	106	—	104	—	73	—
Other ^f	66	—	62	—	46	—	34	—	26	—	26	—
Subtotal	241	0.5	184	0.3	180	0.3	140	0.3	130	0.2	99	0.2
Region of residence^g												
Northeast	7,509	13.4	6,967	12.4	6,938	12.3	6,481	11.5	6,205	11.0	6,011	10.6
Midwest	5,489	8.2	5,319	7.9	5,123	7.6	5,246	7.7	5,173	7.6	5,032	7.4
South	20,367	17.4	19,967	16.9	20,310	17.0	20,418	16.9	20,287	16.6	19,968	16.1
West	7,815	10.6	7,286	9.8	7,856	10.5	7,819	10.3	7,924	10.3	7,270	9.4
Total	41,180	13.1	39,539	12.5	40,227	12.6	39,964	12.4	39,589	12.2	38,281	11.8

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Data for the year 2017 should not be used when assessing trends.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States and 6 dependent areas

	2012		2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at diagnosis (yr)												
<13	241	0.5	184	0.3	180	0.3	140	0.3	130	0.2	99	0.2
13–14	51	0.6	44	0.5	32	0.4	25	0.3	25	0.3	25	0.3
15–19	1,940	9.0	1,706	7.9	1,754	8.2	1,748	8.2	1,712	8.0	1,723	8.1
20–24	7,277	31.8	7,144	30.9	7,486	32.3	7,358	32.0	6,942	30.6	6,416	28.7
25–29	6,560	30.3	6,737	30.9	7,282	32.8	7,689	33.9	8,001	34.5	7,755	32.8
30–34	5,559	26.2	5,292	24.6	5,513	25.3	5,517	25.2	5,727	26.0	5,678	25.6
35–39	4,232	21.4	4,031	20.3	4,316	21.4	4,330	21.0	4,296	20.4	4,365	20.3
40–44	4,543	21.3	3,991	18.9	3,872	18.6	3,478	17.0	3,319	16.6	3,032	15.3
45–49	4,389	20.0	4,007	18.6	3,671	17.4	3,389	16.1	3,155	14.9	3,006	14.2
50–54	3,255	14.2	3,041	13.3	2,946	12.9	3,056	13.5	2,926	13.2	2,729	12.6
55–59	1,963	9.3	2,053	9.6	1,978	9.1	1,907	8.7	1,937	8.7	1,918	8.6
60–64	1,072	5.9	1,102	6.0	1,001	5.3	1,015	5.3	1,103	5.6	1,108	5.5
≥65	860	2.0	888	2.0	857	1.8	882	1.8	869	1.7	885	1.7
Race/ethnicity												
American Indian/Alaska Native	172	—	147	—	182	—	189	—	230	—	212	—
Asian	798	—	792	—	924	—	946	—	973	—	945	—
Black/African American	18,200	—	17,343	—	17,549	—	17,462	—	17,275	—	16,694	—
Hispanic/Latino ^b	9,947	—	9,644	—	10,183	—	10,193	—	10,368	—	9,908	—
Native Hawaiian/Other Pacific Islander	54	—	48	—	46	—	77	—	47	—	59	—
White	11,042	—	10,626	—	10,588	—	10,405	—	10,120	—	10,049	—
Multiple races	1,729	—	1,620	—	1,416	—	1,262	—	1,129	—	872	—
Transmission category^c												
Male adult or adolescent												
Male-to-male sexual contact	26,561	—	25,910	—	26,882	—	26,781	—	26,448	—	25,748	—
Injection drug use	1,528	—	1,436	—	1,338	—	1,368	—	1,270	—	1,373	—
Male-to-male sexual contact and injection drug use	1,497	—	1,382	—	1,335	—	1,355	—	1,315	—	1,252	—
Heterosexual contact ^d	3,641	—	3,454	—	3,369	—	3,344	—	3,321	—	2,829	—
Other ^e	46	—	41	—	38	—	36	—	26	—	37	—
Subtotal	33,274	25.8	32,223	24.7	32,961	25.1	32,885	24.8	32,379	24.2	31,239	23.1
Female adult or adolescent												
Injection drug use	1,169	—	1,003	—	967	—	1,008	—	962	—	1,016	—
Heterosexual contact ^d	7,223	—	6,761	—	6,746	—	6,472	—	6,625	—	6,341	—
Other ^e	35	—	49	—	34	—	29	—	47	—	44	—
Subtotal	8,427	6.2	7,813	5.7	7,747	5.6	7,509	5.4	7,633	5.4	7,401	5.2
Child (<13 yrs at diagnosis)												
Perinatal	175	—	122	—	134	—	106	—	104	—	73	—
Other ^f	66	—	62	—	46	—	34	—	26	—	26	—
Subtotal	241	0.5	184	0.3	180	0.3	140	0.3	130	0.2	99	0.2
Region of residence^g												
Northeast	7,509	13.4	6,967	12.4	6,938	12.3	6,481	11.5	6,205	11.0	6,011	10.6
Midwest	5,489	8.2	5,319	7.9	5,123	7.6	5,246	7.7	5,173	7.6	5,032	7.4
South	20,367	17.4	19,967	16.9	20,310	17.0	20,418	16.9	20,287	16.6	19,968	16.1
West	7,815	10.6	7,286	9.8	7,856	10.5	7,819	10.3	7,924	10.3	7,270	9.4
U.S. dependent areas	762	18.9	681	17.0	661	16.8	570	14.7	553	14.5	458	12.3
Total	41,942	13.2	40,220	12.6	40,888	12.7	40,534	12.5	40,142	12.3	38,739	11.8

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Data for the year 2017 should not be used when assessing trends.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 2a. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States

	2012		2013		2014		2015		2016		2017		Cumulative ^a No.
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	
Age at diagnosis (yr)													
<13 ^c	12	0.0	9	0.0	70	0.1	39	0.1	39	0.1	33	0.1	9,573
13–14	28	0.3	29	0.3	15	0.2	8	0.1	14	0.2	7	0.1	1,474
15–19	360	1.7	401	1.9	187	0.9	191	0.9	215	1.0	202	1.0	9,491
20–24	1,910	8.5	2,001	8.8	1,353	5.9	1,325	5.8	1,278	5.7	1,147	5.2	54,975
25–29	2,763	12.9	2,788	12.9	2,342	10.7	2,410	10.7	2,489	10.9	2,307	9.9	147,146
30–34	3,247	15.5	2,928	13.8	2,412	11.2	2,472	11.4	2,411	11.0	2,430	11.1	230,159
35–39	2,958	15.2	2,817	14.4	2,399	12.1	2,303	11.3	2,368	11.4	2,198	10.4	247,869
40–44	3,468	16.5	3,073	14.7	2,486	12.1	2,260	11.2	2,080	10.5	1,914	9.7	208,520
45–49	3,680	17.0	3,313	15.6	2,681	12.9	2,454	11.8	2,198	10.5	2,068	9.9	145,349
50–54	2,891	12.8	2,767	12.3	2,297	10.2	2,338	10.5	2,214	10.1	2,026	9.5	89,473
55–59	1,769	8.5	1,782	8.4	1,579	7.3	1,514	7.0	1,546	7.0	1,559	7.1	50,822
60–64	1,011	5.7	1,030	5.7	847	4.6	873	4.6	920	4.7	924	4.6	27,370
≥65	728	1.7	761	1.7	736	1.6	754	1.6	782	1.6	789	1.6	23,128
Race/ethnicity													
American Indian/Alaska Native	90	3.9	84	3.6	82	3.5	91	3.8	98	4.1	72	3.0	3,576
Asian ^d	350	2.2	343	2.1	320	1.9	335	1.9	347	1.9	335	1.8	10,275
Black/African American	11,934	30.8	11,166	28.5	9,054	22.9	8,746	21.9	8,562	21.3	8,341	20.5	515,195
Hispanic/Latino ^e	5,143	9.7	4,995	9.2	4,152	7.5	4,136	7.3	4,192	7.3	3,863	6.6	230,895
Native Hawaiian/ Other Pacific Islander	22	4.2	21	3.9	17	3.1	22	4.0	15	2.7	27	4.7	821
White	6,085	3.1	5,866	3.0	4,842	2.4	4,792	2.4	4,579	2.3	4,321	2.2	443,580
Multiple races	1,201	20.0	1,224	19.8	937	14.7	819	12.5	761	11.3	645	9.3	40,921
Transmission category^f													
Male adult or adolescent													
Male-to-male sexual contact	13,134	—	12,944	—	10,396	—	10,380	—	10,296	—	9,712	—	606,446
Injection drug use	1,505	—	1,317	—	1,146	—	1,008	—	921	—	941	—	184,519
Male-to-male sexual contact and injection drug use	1,216	—	1,037	—	795	—	832	—	797	—	761	—	89,331
Heterosexual contact ^g	2,709	—	2,567	—	2,181	—	2,046	—	2,089	—	1,837	—	88,985
Other ^h	106	—	126	—	75	—	90	—	76	—	70	—	11,679
Subtotal	18,670	14.6	17,990	14.0	14,593	11.2	14,356	10.9	14,178	10.7	13,321	10.0	980,960
Female adult or adolescent													
Injection drug use	1,171	—	1,014	—	833	—	787	—	742	—	735	—	91,152
Heterosexual contact ^g	4,867	—	4,549	—	3,818	—	3,680	—	3,485	—	3,428	—	157,539
Other ^h	105	—	137	—	90	—	80	—	110	—	87	—	6,125
Subtotal	6,143	4.6	5,700	4.2	4,741	3.5	4,546	3.3	4,337	3.1	4,250	3.0	254,816
Child (<13 yrs at diagnosis)													
Perinatal	9	—	8	—	60	—	30	—	32	—	26	—	8,694
Other ⁱ	3	—	1	—	10	—	9	—	7	—	7	—	879
Subtotal	12	0.0	9	0.0	70	0.1	39	0.1	39	0.1	33	0.1	9,573
Region of residence^j													
Northeast	4,714	8.4	4,315	7.7	3,512	6.2	3,314	5.9	3,164	5.6	2,977	5.3	355,402
Midwest	3,118	4.6	2,950	4.4	2,480	3.7	2,433	3.6	2,428	3.6	2,217	3.3	134,163
South	12,800	10.9	12,510	10.6	10,112	8.4	9,777	8.1	9,557	7.8	9,406	7.6	508,306
West	4,193	5.7	3,924	5.3	3,300	4.4	3,417	4.5	3,405	4.4	3,004	3.9	247,478
Total^k	24,825	7.9	23,699	7.5	19,404	6.1	18,941	5.9	18,554	5.7	17,604	5.4	1,245,349

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2017.

^b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^c The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^e Hispanics/Latinos can be of any race.

^f Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^g Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^h Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

ⁱ Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^j Data are based on residence at time of stage 3 (AIDS) classification.

^k Cumulative total includes persons whose race/ethnicity is unknown.

Table 2b. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States and 6 dependent areas

	2012		2013		2014		2015		2016		2017		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Age at diagnosis (yr)													
<13 ^c	12	0.0	9	0.0	70	0.1	39	0.1	40	0.1	33	0.1	10,002
13–14	29	0.3	30	0.4	15	0.2	8	0.1	14	0.2	7	0.1	1,534
15–19	361	1.7	406	1.9	192	0.9	191	0.9	217	1.0	203	0.9	9,733
20–24	1,929	8.4	2,022	8.7	1,372	5.9	1,338	5.8	1,293	5.7	1,158	5.2	56,435
25–29	2,797	12.9	2,817	12.9	2,362	10.6	2,432	10.7	2,503	10.8	2,315	9.8	151,407
30–34	3,288	15.5	2,976	13.8	2,451	11.3	2,497	11.4	2,436	11.0	2,453	11.1	237,127
35–39	3,014	15.3	2,868	14.4	2,448	12.1	2,335	11.3	2,413	11.5	2,219	10.3	255,167
40–44	3,541	16.6	3,131	14.8	2,543	12.2	2,295	11.2	2,112	10.6	1,939	9.8	214,405
45–49	3,761	17.1	3,384	15.7	2,734	12.9	2,494	11.8	2,243	10.6	2,092	9.9	149,394
50–54	2,948	12.9	2,834	12.4	2,344	10.3	2,384	10.6	2,251	10.2	2,066	9.5	91,939
55–59	1,808	8.6	1,830	8.5	1,617	7.4	1,537	7.0	1,575	7.1	1,579	7.1	52,304
60–64	1,032	5.7	1,056	5.8	869	4.6	881	4.6	935	4.7	934	4.6	28,203
≥65	759	1.7	783	1.7	752	1.6	772	1.6	800	1.6	805	1.6	24,137
Race/ethnicity													
American Indian/Alaska Native	90	—	84	—	82	—	91	—	98	—	72	—	3,578
Asian ^d	351	—	343	—	321	—	336	—	348	—	337	—	10,340
Black/African American	11,944	—	11,171	—	9,062	—	8,755	—	8,567	—	8,344	—	515,685
Hispanic/Latino ^e	5,583	—	5,436	—	4,505	—	4,384	—	4,459	—	4,054	—	266,602
Native Hawaiian/ Other Pacific Islander	23	—	21	—	18	—	24	—	19	—	29	—	851
White	6,087	—	5,867	—	4,844	—	4,794	—	4,580	—	4,322	—	443,701
Multiple races	1,201	—	1,224	—	937	—	819	—	761	—	645	—	40,944
Transmission category^f													
Male adult or adolescent													
Male-to-male sexual contact	13,255	—	13,078	—	10,498	—	10,472	—	10,387	—	9,781	—	612,861
Injection drug use	1,599	—	1,394	—	1,214	—	1,054	—	969	—	968	—	198,078
Male-to-male sexual contact and injection drug use	1,237	—	1,052	—	806	—	846	—	817	—	766	—	91,982
Heterosexual contact ^g	2,785	—	2,653	—	2,252	—	2,095	—	2,150	—	1,877	—	93,163
Other ^h	109	—	128	—	76	—	92	—	78	—	70	—	11,886
Subtotal	18,985	14.7	18,305	14.1	14,846	11.3	14,559	11.0	14,401	10.8	13,462	10.0	1,007,969
Female adult or adolescent													
Injection drug use	1,196	—	1,044	—	861	—	795	—	752	—	740	—	94,269
Heterosexual contact ^g	4,979	—	4,650	—	3,896	—	3,729	—	3,528	—	3,478	—	163,271
Other ^h	107	—	139	—	96	—	81	—	111	—	90	—	6,276
Subtotal	6,282	4.6	5,832	4.3	4,853	3.5	4,605	3.3	4,391	3.1	4,308	3.1	263,816
Child (<13 yrs at diagnosis)													
Perinatal	9	—	8	—	60	—	30	—	33	—	26	—	9,097
Other ⁱ	3	—	1	—	10	—	9	—	7	—	7	—	905
Subtotal	12	0.0	9	0.0	70	0.1	39	0.1	40	0.1	33	0.1	10,002
Region of residence^j													
Northeast	4,714	8.4	4,315	7.7	3,512	6.2	3,314	5.9	3,164	5.6	2,977	5.3	355,402
Midwest	3,118	4.6	2,950	4.4	2,480	3.7	2,433	3.6	2,428	3.6	2,217	3.3	134,163
South	12,800	10.9	12,510	10.6	10,112	8.4	9,777	8.1	9,557	7.8	9,406	7.6	508,306
West	4,193	5.7	3,924	5.3	3,300	4.4	3,417	4.5	3,405	4.4	3,004	3.9	247,478
U.S. dependent areas	454	11.2	447	11.2	365	9.3	262	6.8	278	7.3	199	5.3	36,438
Total^k	25,279	7.9	24,146	7.5	19,769	6.1	19,203	5.9	18,832	5.8	17,803	5.4	1,281,787

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2017.

^b Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^c The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^e Hispanics/Latinos can be of any race.

^f Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^g Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^h Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

ⁱ Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^j Data are based on residence at time of stage 3 (AIDS) classification.

^k Cumulative total includes persons whose race/ethnicity is unknown.

Table 3a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States

	American Indian/ Alaska Native		Asian		Black/African American		Hispanic/Latino ^a		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b
Age at diagnosis (yr)																
<13	0	0.0	3	0.1	60	0.8	19	0.1	1	0.9	10	0.0	6	0.3	99	0.2
13–14	0	0.0	0	0.0	13	1.2	7	0.3	0	0.0	3	0.1	2	0.6	25	0.3
15–19	3	1.7	28	2.6	1,047	35.3	354	7.2	1	2.5	234	2.1	44	6.1	1,711	8.1
20–24	24	12.8	167	12.9	3,197	99.5	1,513	31.3	8	18.2	1,272	10.7	173	27.2	6,354	28.7
25–29	54	27.4	179	11.3	3,471	102.3	1,996	41.6	14	27.0	1,786	13.9	191	36.3	7,691	32.9
30–34	36	21.5	128	8.0	2,278	79.9	1,614	35.6	12	23.9	1,424	11.5	122	30.1	5,614	25.6
35–39	26	17.0	131	8.7	1,651	60.6	1,214	27.5	6	13.2	1,197	10.0	90	25.5	4,315	20.3
40–44	21	15.0	91	6.3	1,164	46.9	829	20.4	7	18.1	820	7.3	63	21.9	2,995	15.2
45–49	16	11.0	94	6.9	1,078	41.4	752	20.4	3	8.2	959	7.5	62	23.3	2,964	14.1
50–54	19	12.3	50	4.2	1,016	38.4	541	16.9	3	8.6	990	7.1	58	24.4	2,677	12.5
55–59	5	3.2	33	3.1	812	31.2	311	11.7	1	3.0	691	4.5	33	14.4	1,886	8.6
60–64	6	4.5	22	2.3	502	22.6	162	7.9	0	0.0	378	2.6	16	8.4	1,086	5.4
≥65	2	0.7	16	0.7	401	8.7	149	3.5	1	1.9	284	0.7	11	2.9	864	1.7
Transmission category^c																
Male adult or adolescent																
Male-to-male sexual contact	125	—	747	—	9,806	—	7,208	—	37	—	6,982	—	608	—	25,513	—
Injection drug use	16	—	13	—	431	—	322	—	1	—	527	—	24	—	1,335	—
Male-to-male sexual contact and injection drug use	19	—	18	—	263	—	275	—	2	—	625	—	39	—	1,241	—
Heterosexual contact ^d	7	—	40	—	1,716	—	513	—	4	—	420	—	45	—	2,745	—
Other ^e	0	—	1	—	19	—	7	—	0	—	9	—	0	—	36	—
Subtotal	167	17.4	819	11.1	12,235	77.6	8,325	36.4	44	18.7	8,564	10.2	716	32.5	30,870	23.1
Female adult or adolescent																
Injection drug use	14	—	6	—	356	—	135	—	1	—	471	—	25	—	1,009	—
Heterosexual contact ^d	31	—	113	—	4,007	—	978	—	11	—	998	—	121	—	6,259	—
Other ^e	0	—	1	—	32	—	4	—	0	—	4	—	3	—	44	—
Subtotal	45	4.5	120	1.4	4,395	24.9	1,117	5.0	12	5.1	1,474	1.7	149	6.4	7,312	5.2
Child (<13 yrs at diagnosis)																
Perinatal	0	—	1	—	47	—	10	—	1	—	9	—	5	—	73	—
Other ^f	0	—	2	—	13	—	9	—	0	—	1	—	1	—	26	—
Subtotal	0	0.0	3	0.1	60	0.8	19	0.1	1	0.9	10	0.0	6	0.3	99	0.2
Region of residence^g																
Northeast	2	1.6	177	4.6	2,455	38.4	1,800	21.9	7	32.3	1,377	3.7	193	20.4	6,011	10.6
Midwest	22	5.3	111	4.9	2,419	34.0	609	11.3	0	0.0	1,734	3.4	137	10.4	5,032	7.4
South	60	7.5	224	5.2	10,569	44.8	4,123	18.6	14	15.6	4,596	6.5	382	16.6	19,968	16.1
West	128	12.0	430	5.4	1,247	35.3	2,929	12.6	36	8.3	2,341	6.0	159	6.7	7,270	9.4
Total	212	8.8	942	5.1	16,690	41.1	9,461	16.1	57	9.9	10,048	5.1	871	12.6	38,281	11.8

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Hispanics/Latinos can be of any race.

^b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas

	American Indian/ Alaska Native No.	Asian No.	Black/African American No.	Hispanic/ Latino ^a No.	Native Hawaiian/ Other Pacific Islander No.	White No.	Multiple races No.	Total No.
Age at diagnosis (yr)								
<13	0	3	60	19	1	10	6	99
13–14	0	0	13	7	0	3	2	25
15–19	3	28	1,047	365	1	235	44	1,723
20–24	24	167	3,197	1,575	8	1,272	173	6,416
25–29	54	179	3,471	2,060	14	1,786	191	7,755
30–34	36	130	2,280	1,674	12	1,424	122	5,678
35–39	26	132	1,651	1,262	6	1,197	91	4,365
40–44	21	91	1,165	865	7	820	63	3,032
45–49	16	94	1,079	793	3	959	62	3,006
50–54	19	50	1,016	592	4	990	58	2,729
55–59	5	33	812	342	2	691	33	1,918
60–64	6	22	502	184	0	378	16	1,108
≥65	2	16	401	170	1	284	11	885
Transmission category^b								
Male adult or adolescent								
Male-to-male sexual contact	125	750	9,807	7,436	39	6,982	609	25,748
Injection drug use	16	13	431	360	1	527	25	1,373
Male-to-male sexual contact and injection drug use	19	18	263	286	2	625	39	1,252
Heterosexual contact ^c	7	40	1,717	597	4	420	45	2,829
Other ^d	0	1	19	7	0	9	0	37
Subtotal	167	822	12,237	8,686	46	8,564	717	31,239
Female adult or adolescent								
Injection drug use	14	6	356	141	1	472	25	1,016
Heterosexual contact ^c	31	113	4,008	1,058	11	999	121	6,341
Other ^d	0	1	32	4	0	4	3	44
Subtotal	45	120	4,397	1,203	12	1,475	149	7,401
Child (<13 yrs at diagnosis)								
Perinatal	0	1	47	10	1	9	5	73
Other ^e	0	2	13	9	0	1	1	26
Subtotal	0	3	60	19	1	10	6	99
Region of residence^f								
Northeast	2	177	2,455	1,800	7	1,377	193	6,011
Midwest	22	111	2,419	609	0	1,734	137	5,032
South	60	224	10,569	4,123	14	4,596	382	19,968
West	128	430	1,247	2,929	36	2,341	159	7,270
U.S. dependent areas	0	3	4	447	2	1	1	458
Total	212	945	16,694	9,908	59	10,049	872	38,739

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12 should be interpreted with caution.

^a Hispanics/Latinos can be of any race.

^b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^e Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^f Data are based on residence at time of diagnosis of HIV infection.

Table 4a. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c
Age at diagnosis (yr)																
<13	2	0.4	0	0.0	23	0.3	6	0.0	1	0.9	0	0.0	1	0.0	33	0.1
13–14	0	0.0	0	0.0	3	0.3	4	0.2	0	0.0	0	0.0	0	0.0	7	0.1
15–19	0	0.0	2	0.2	125	4.2	49	1.0	0	0.0	18	0.2	8	1.1	202	1.0
20–24	3	1.6	25	1.9	690	21.5	229	4.7	2	4.5	163	1.4	35	5.5	1,147	5.2
25–29	12	6.1	48	3.0	1,231	36.3	557	11.6	4	7.7	368	2.9	87	16.5	2,307	9.9
30–34	7	4.2	51	3.2	1,140	40.0	671	14.8	7	13.9	472	3.8	82	20.2	2,430	11.1
35–39	10	6.5	46	3.0	993	36.4	553	12.5	1	2.2	515	4.3	80	22.7	2,198	10.4
40–44	9	6.4	40	2.8	877	35.3	465	11.5	4	10.3	453	4.0	66	22.9	1,914	9.7
45–49	11	7.5	47	3.5	901	34.6	455	12.3	5	13.7	566	4.4	83	31.2	2,068	9.9
50–54	12	7.8	33	2.8	831	31.4	384	12.0	1	2.9	688	4.9	77	32.3	2,026	9.5
55–59	1	0.6	23	2.1	709	27.2	234	8.8	1	3.0	530	3.5	61	26.6	1,559	7.1
60–64	3	2.2	9	0.9	460	20.7	149	7.3	0	0.0	272	1.9	31	16.3	924	4.6
≥65	2	0.7	11	0.5	358	7.8	107	2.5	1	1.9	276	0.7	34	8.9	789	1.6
Transmission category^d																
Male adult or adolescent																
Male-to-male sexual contact	30	—	238	—	3,829	—	2,498	—	16	—	2,757	—	343	—	9,712	—
Injection drug use	8	—	6	—	417	—	234	—	0	—	239	—	37	—	941	—
Male-to-male sexual contact and injection drug use	9	—	9	—	207	—	173	—	1	—	317	—	45	—	761	—
Heterosexual contact ^e	4	—	24	—	1,201	—	317	—	2	—	244	—	45	—	1,837	—
Other ^f	0	—	0	—	32	—	15	—	0	—	13	—	9	—	70	—
Subtotal	51	5.3	278	3.8	5,685	36.1	3,238	14.2	19	8.1	3,570	4.2	480	21.8	13,321	10.0
Female adult or adolescent																
Injection drug use	6	—	2	—	325	—	105	—	0	—	254	—	43	—	735	—
Heterosexual contact ^e	13	—	54	—	2,253	—	495	—	7	—	490	—	115	—	3,428	—
Other ^f	0	—	1	—	55	—	19	—	0	—	7	—	6	—	87	—
Subtotal	19	1.9	57	0.7	2,633	14.9	619	2.8	7	3.0	751	0.9	164	7.0	4,250	3.0
Child (<13 yrs at diagnosis)																
Perinatal	2	—	0	—	19	—	3	—	1	—	0	—	1	—	26	—
Other ^g	0	—	0	—	4	—	3	—	0	—	0	—	0	—	7	—
Subtotal	2	0.4	0	0.0	23	0.3	6	0.0	1	0.9	0	0.0	1	0.0	33	0.1
Region of residence^h																
Northeast	0	0.0	66	1.7	1,299	20.3	835	10.1	2	9.2	608	1.6	167	17.6	2,977	5.3
Midwest	6	1.5	33	1.5	1,109	15.6	247	4.6	1	3.0	735	1.4	86	6.5	2,217	3.3
South	20	2.5	91	2.1	5,424	23.0	1,594	7.2	9	10.0	1,986	2.8	282	12.3	9,406	7.6
West	46	4.3	145	1.8	509	14.4	1,187	5.1	15	3.5	992	2.6	110	4.6	3,004	3.9
Total	72	3.0	335	1.8	8,341	20.5	3,863	6.6	27	4.7	4,321	2.2	645	9.3	17,604	5.4

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at time of stage 3 (AIDS) classification.

Table 4b. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas

	American Indian/ Alaska Native No.	Asian ^a No.	Black/African American No.	Hispanic/ Latino ^b No.	Native Hawaiian/ Other Pacific Islander No.	White No.	Multiple races No.	Total No.
Age at diagnosis (yr)								
<13	2	0	23	6	1	0	1	33
13–14	0	0	3	4	0	0	0	7
15–19	0	2	125	50	0	18	8	203
20–24	3	25	690	240	2	163	35	1,158
25–29	12	48	1,231	565	4	368	87	2,315
30–34	7	53	1,140	692	7	472	82	2,453
35–39	10	46	993	574	1	515	80	2,219
40–44	9	40	878	489	4	453	66	1,939
45–49	11	47	903	476	5	567	83	2,092
50–54	12	33	831	423	2	688	77	2,066
55–59	1	23	709	253	2	530	61	1,579
60–64	3	9	460	159	0	272	31	934
≥65	2	11	358	123	1	276	34	805
Transmission category^c								
Male adult or adolescent								
Male-to-male sexual contact	30	240	3,829	2,564	18	2,757	343	9,781
Injection drug use	8	6	417	261	0	239	37	968
Male-to-male sexual contact and injection drug use	9	9	207	178	1	317	45	766
Heterosexual contact ^d	4	24	1,201	357	2	244	45	1,877
Other ^e	0	0	32	15	0	13	9	70
Subtotal	51	280	5,685	3,375	21	3,570	480	13,462
Female adult or adolescent								
Injection drug use	6	2	325	109	0	254	43	740
Heterosexual contact ^d	13	54	2,256	542	7	491	115	3,478
Other ^e	0	1	55	22	0	7	6	90
Subtotal	19	57	2,636	673	7	752	164	4,308
Child (<13 yrs at diagnosis)								
Perinatal	2	0	19	3	1	0	1	26
Other ^f	0	0	4	3	0	0	0	7
Subtotal	2	0	23	6	1	0	1	33
Region of residence^g								
Northeast	0	66	1,299	835	2	608	167	2,977
Midwest	6	33	1,109	247	1	735	86	2,217
South	20	91	5,424	1,594	9	1,986	282	9,406
West	46	145	509	1,187	15	992	110	3,004
U.S. dependent areas	0	2	3	191	2	1	0	199
Total	72	337	8,344	4,054	29	4,322	645	17,803

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of stage 3 (AIDS) classification.

Table 5a. Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States

	2012		2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	27	0.6	21	0.5	17	0.4	11	0.3	9	0.2	11	0.3
15–19	1,567	14.3	1,383	12.7	1,413	13.1	1,496	13.9	1,445	13.4	1,467	13.6
20–24	6,315	54.7	6,252	53.5	6,513	55.5	6,446	55.4	6,130	53.3	5,581	49.2
25–29	5,419	50.1	5,671	51.8	6,200	55.6	6,615	58.0	6,879	59.0	6,705	56.3
30–34	4,358	41.6	4,204	39.4	4,438	41.1	4,468	41.1	4,612	41.9	4,621	41.7
35–39	3,185	32.8	3,062	31.3	3,251	32.7	3,309	32.6	3,255	31.3	3,363	31.7
40–44	3,446	33.0	3,061	29.5	2,913	28.5	2,605	26.0	2,480	25.3	2,245	23.0
45–49	3,294	30.7	3,019	28.7	2,821	27.3	2,559	24.8	2,313	22.3	2,204	21.2
50–54	2,387	21.5	2,185	19.7	2,202	19.9	2,256	20.6	2,144	20.0	2,011	19.1
55–59	1,362	13.5	1,436	14.0	1,347	12.9	1,338	12.6	1,318	12.3	1,320	12.3
60–64	743	8.7	771	8.9	704	7.9	695	7.6	731	7.8	747	7.8
≥65	608	3.2	642	3.3	628	3.1	626	3.0	615	2.8	595	2.6
Race/ethnicity												
American Indian/Alaska Native	132	14.6	115	12.5	145	15.6	138	14.7	187	19.7	167	17.4
Asian	656	10.5	646	10.0	784	11.7	804	11.6	814	11.4	819	11.1
Black/African American	12,813	86.5	12,488	83.1	12,814	84.2	12,932	83.9	12,683	81.4	12,235	77.6
Hispanic/Latino ^b	7,974	39.5	7,784	37.6	8,287	39.1	8,477	39.0	8,643	38.8	8,325	36.4
Native Hawaiian/Other Pacific Islander	45	21.4	37	17.1	35	15.8	66	29.2	33	14.3	44	18.7
White	9,688	11.6	9,321	11.2	9,236	11.0	8,961	10.7	8,641	10.3	8,564	10.2
Multiple races	1,403	76.4	1,316	69.1	1,146	58.0	1,046	51.1	930	43.8	716	32.5
Region of residence^c												
Northeast	5,690	25.0	5,425	23.7	5,362	23.3	5,033	21.8	4,773	20.6	4,647	20.0
Midwest	4,458	16.3	4,325	15.7	4,228	15.3	4,261	15.3	4,188	15.0	4,072	14.5
South	15,715	33.3	15,554	32.5	15,989	33.0	16,222	33.1	16,074	32.4	15,788	31.5
West	6,848	22.8	6,403	21.0	6,868	22.3	6,908	22.1	6,896	21.8	6,363	19.9
Subtotal	32,711	25.7	31,707	24.6	32,447	25.0	32,424	24.7	31,931	24.1	30,870	23.1
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	23	0.6	22	0.5	15	0.4	14	0.3	16	0.4	14	0.3
15–19	352	3.4	304	2.9	314	3.1	244	2.4	255	2.5	244	2.4
20–24	859	7.8	802	7.2	857	7.7	830	7.5	738	6.8	773	7.2
25–29	1,040	9.8	982	9.2	987	9.1	981	8.9	1,051	9.3	986	8.6
30–34	1,100	10.5	998	9.4	1,013	9.5	989	9.2	1,050	9.7	993	9.1
35–39	976	10.0	902	9.2	990	9.9	954	9.4	969	9.3	952	9.0
40–44	1,002	9.5	864	8.2	880	8.5	812	8.0	784	7.9	750	7.6
45–49	996	9.1	904	8.4	789	7.5	766	7.3	785	7.4	760	7.2
50–54	800	7.0	783	6.8	697	6.1	744	6.6	735	6.6	666	6.1
55–59	562	5.2	574	5.3	586	5.3	536	4.8	568	5.0	566	5.0
60–64	306	3.3	295	3.1	269	2.8	304	3.1	347	3.4	339	3.3
≥65	212	0.9	218	0.9	203	0.8	226	0.8	230	0.8	269	1.0
Race/ethnicity												
American Indian/Alaska Native	40	4.2	32	3.3	34	3.5	49	5.0	43	4.3	45	4.5
Asian	127	1.8	130	1.8	129	1.7	127	1.6	148	1.8	120	1.4
Black/African American	5,216	31.2	4,718	27.9	4,608	27.0	4,433	25.7	4,505	25.8	4,395	24.9
Hispanic/Latino ^b	1,206	6.1	1,192	5.9	1,244	6.0	1,153	5.4	1,170	5.3	1,117	5.0
Native Hawaiian/Other Pacific Islander	6	2.9	10	4.7	8	3.7	8	3.6	8	3.5	12	5.1
White	1,321	1.5	1,276	1.5	1,316	1.5	1,423	1.6	1,459	1.7	1,474	1.7
Multiple races	312	15.7	290	14.1	261	12.3	207	9.4	195	8.6	149	6.4
Region of residence^c												
Northeast	1,783	7.3	1,514	6.2	1,559	6.3	1,423	5.7	1,419	5.7	1,354	5.4
Midwest	978	3.4	956	3.3	857	3.0	956	3.3	954	3.3	943	3.2
South	4,544	9.1	4,337	8.6	4,227	8.3	4,131	8.0	4,147	7.9	4,122	7.8
West	923	3.0	841	2.7	957	3.1	890	2.8	1,008	3.1	893	2.7
Subtotal	8,228	6.2	7,648	5.7	7,600	5.6	7,400	5.4	7,528	5.4	7,312	5.2
Total	40,939	15.7	39,355	14.9	40,047	15.1	39,824	14.8	39,459	14.6	38,182	14.0

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

^b Hispanics/Latinos can be of any race.

^c Data are based on residence at time of diagnosis of HIV infection.

Table 5b. Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States and 6 dependent areas

	2012		2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	27	0.6	21	0.5	17	0.4	11	0.3	9	0.2	11	0.3
15–19	1,583	14.2	1,399	12.7	1,432	13.1	1,501	13.7	1,454	13.3	1,476	13.5
20–24	6,400	54.7	6,329	53.5	6,617	55.7	6,517	55.3	6,198	53.3	5,638	49.1
25–29	5,506	50.3	5,743	51.9	6,288	55.8	6,697	58.1	6,943	58.9	6,757	56.2
30–34	4,436	41.8	4,280	39.6	4,483	41.0	4,521	41.1	4,668	42.0	4,678	41.8
35–39	3,233	32.9	3,106	31.4	3,302	32.9	3,365	32.7	3,309	31.5	3,402	31.7
40–44	3,518	33.2	3,112	29.7	2,968	28.7	2,651	26.2	2,521	25.4	2,276	23.1
45–49	3,363	31.0	3,076	28.9	2,864	27.4	2,608	25.0	2,355	22.4	2,232	21.3
50–54	2,431	21.7	2,234	20.0	2,236	20.0	2,297	20.8	2,182	20.1	2,053	19.3
55–59	1,388	13.6	1,461	14.1	1,379	13.1	1,360	12.7	1,354	12.5	1,342	12.4
60–64	756	8.7	798	9.1	728	8.1	710	7.7	750	8.0	763	7.9
≥65	633	3.3	664	3.3	647	3.1	647	3.0	636	2.9	611	2.7
Race/ethnicity												
American Indian/Alaska Native	132	—	115	—	145	—	138	—	187	—	167	—
Asian	657	—	646	—	785	—	809	—	815	—	822	—
Black/African American	12,815	—	12,497	—	12,825	—	12,937	—	12,689	—	12,237	—
Hispanic/Latino ^b	8,528	—	8,286	—	8,781	—	8,923	—	9,075	—	8,686	—
Native Hawaiian/Other Pacific Islander	48	—	38	—	36	—	69	—	39	—	46	—
White	9,689	—	9,325	—	9,242	—	8,963	—	8,644	—	8,564	—
Multiple races	1,405	—	1,316	—	1,147	—	1,046	—	930	—	717	—
Region of residence^c												
Northeast	5,690	25.0	5,425	23.7	5,362	23.3	5,033	21.8	4,773	20.6	4,647	20.0
Midwest	4,458	16.3	4,325	15.7	4,228	15.3	4,261	15.3	4,188	15.0	4,072	14.5
South	15,715	33.3	15,554	32.5	15,989	33.0	16,222	33.1	16,074	32.4	15,788	31.5
West	6,848	22.8	6,403	21.0	6,868	22.3	6,908	22.1	6,896	21.8	6,363	19.9
U.S. dependent areas	563	35.2	516	32.4	514	32.6	461	29.6	448	29.2	369	24.4
Subtotal	33,274	25.8	32,223	24.7	32,961	25.1	32,885	24.8	32,379	24.2	31,239	23.1
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	24	0.6	23	0.6	15	0.4	14	0.3	16	0.4	14	0.3
15–19	357	3.4	307	2.9	322	3.1	247	2.4	258	2.5	247	2.4
20–24	877	7.8	815	7.2	869	7.7	841	7.5	744	6.8	778	7.1
25–29	1,054	9.9	994	9.2	994	9.1	992	8.9	1,058	9.3	998	8.6
30–34	1,123	10.6	1,012	9.4	1,030	9.5	996	9.1	1,059	9.7	1,000	9.1
35–39	999	10.1	925	9.3	1,014	10.0	965	9.4	987	9.4	963	9.0
40–44	1,025	9.6	879	8.3	904	8.6	827	8.0	798	7.9	756	7.6
45–49	1,026	9.2	931	8.6	807	7.6	781	7.3	800	7.5	774	7.2
50–54	824	7.1	807	6.9	710	6.1	759	6.6	744	6.6	676	6.1
55–59	575	5.3	592	5.4	599	5.4	547	4.8	583	5.1	576	5.0
60–64	316	3.4	304	3.2	273	2.8	305	3.0	353	3.4	345	3.3
≥65	227	0.9	224	0.9	210	0.8	235	0.9	233	0.8	274	1.0
Race/ethnicity												
American Indian/Alaska Native	40	—	32	—	34	—	49	—	43	—	45	—
Asian	127	—	130	—	129	—	127	—	148	—	120	—
Black/African American	5,218	—	4,726	—	4,613	—	4,437	—	4,505	—	4,397	—
Hispanic/Latino ^b	1,403	—	1,348	—	1,384	—	1,257	—	1,275	—	1,203	—
Native Hawaiian/Other Pacific Islander	6	—	10	—	9	—	8	—	8	—	12	—
White	1,321	—	1,277	—	1,317	—	1,423	—	1,459	—	1,475	—
Multiple races	312	—	290	—	261	—	208	—	195	—	149	—
Region of residence^c												
Northeast	1,783	7.3	1,514	6.2	1,559	6.3	1,423	5.7	1,419	5.7	1,354	5.4
Midwest	978	3.4	956	3.3	857	3.0	956	3.3	954	3.3	943	3.2
South	4,544	9.1	4,337	8.6	4,227	8.3	4,131	8.0	4,147	7.9	4,122	7.8
West	923	3.0	841	2.7	957	3.1	890	2.8	1,008	3.1	893	2.7
U.S. dependent areas	199	11.3	165	9.4	147	8.4	109	6.3	105	6.1	89	5.3
Subtotal	8,427	6.2	7,813	5.7	7,747	5.6	7,509	5.4	7,633	5.4	7,401	5.2
Total	41,701	15.8	40,036	15.0	40,708	15.1	40,394	14.9	40,012	14.6	38,640	14.0

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

^b Hispanics/Latinos can be of any race.

^c Data are based on residence at time of diagnosis of HIV infection.

Table 6a. Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States

	2012		2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	12	0.3	12	0.3	7	0.2	4	0.1	7	0.2	3	0.1
15–19	272	2.5	294	2.7	132	1.2	145	1.3	162	1.5	158	1.5
20–24	1,640	14.2	1,695	14.5	1,135	9.7	1,109	9.5	1,061	9.2	961	8.5
25–29	2,246	20.7	2,302	21.0	1,931	17.3	1,998	17.5	2,095	18.0	1,935	16.3
30–34	2,445	23.3	2,260	21.2	1,854	17.2	1,921	17.7	1,910	17.4	1,938	17.5
35–39	2,091	21.5	2,062	21.1	1,725	17.4	1,663	16.4	1,708	16.4	1,595	15.0
40–44	2,531	24.2	2,256	21.8	1,789	17.5	1,635	16.3	1,507	15.4	1,356	13.9
45–49	2,769	25.8	2,456	23.4	2,011	19.5	1,806	17.5	1,656	15.9	1,493	14.4
50–54	2,150	19.4	2,058	18.6	1,700	15.4	1,774	16.2	1,687	15.7	1,496	14.2
55–59	1,257	12.5	1,279	12.4	1,143	11.0	1,122	10.6	1,128	10.6	1,145	10.7
60–64	716	8.4	741	8.5	617	7.0	627	6.9	671	7.2	650	6.8
≥65	541	2.9	575	2.9	549	2.7	552	2.6	586	2.7	591	2.6
Race/ethnicity												
American Indian/Alaska Native	67	7.4	65	7.1	60	6.5	55	5.9	73	7.7	51	5.3
Asian	290	4.6	292	4.5	261	3.9	280	4.0	286	4.0	278	3.8
Black/African American	7,935	53.6	7,557	50.3	6,018	39.5	5,916	38.4	5,904	37.9	5,685	36.1
Hispanic/Latino ^b	4,262	21.1	4,142	20.0	3,434	16.2	3,462	15.9	3,492	15.7	3,238	14.2
Native Hawaiian/Other Pacific Islander	19	9.0	16	7.4	14	6.3	20	8.8	12	5.2	19	8.1
White	5,192	6.2	5,026	6.0	4,102	4.9	4,020	4.8	3,848	4.6	3,570	4.2
Multiple races	905	49.3	892	46.8	704	35.6	603	29.4	563	26.5	480	21.8
Region of residence^c												
Northeast	3,334	14.6	3,084	13.4	2,483	10.8	2,401	10.4	2,285	9.9	2,125	9.1
Midwest	2,457	9.0	2,381	8.6	1,927	7.0	1,955	7.0	1,896	6.8	1,690	6.0
South	9,245	19.6	9,081	19.0	7,353	15.2	7,082	14.4	7,082	14.3	6,919	13.8
West	3,634	12.1	3,444	11.3	2,830	9.2	2,918	9.3	2,915	9.2	2,587	8.1
Subtotal	18,670	14.6	17,990	14.0	14,593	11.2	14,356	10.9	14,178	10.7	13,321	10.0
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	16	0.4	17	0.4	8	0.2	4	0.1	7	0.2	4	0.1
15–19	88	0.8	107	1.0	55	0.5	46	0.4	53	0.5	44	0.4
20–24	270	2.4	306	2.7	218	2.0	216	2.0	217	2.0	186	1.7
25–29	517	4.9	486	4.6	411	3.8	412	3.7	394	3.5	372	3.2
30–34	802	7.7	668	6.3	558	5.2	551	5.1	501	4.6	492	4.5
35–39	867	8.9	755	7.7	674	6.8	640	6.3	660	6.3	603	5.7
40–44	937	8.9	817	7.8	697	6.7	625	6.1	573	5.8	558	5.6
45–49	911	8.3	857	8.0	670	6.4	648	6.2	542	5.1	575	5.4
50–54	741	6.4	709	6.2	597	5.2	564	5.0	527	4.7	530	4.9
55–59	512	4.8	503	4.6	436	3.9	392	3.5	418	3.7	414	3.7
60–64	295	3.2	289	3.1	230	2.4	246	2.5	249	2.4	274	2.6
≥65	187	0.8	186	0.7	187	0.7	202	0.8	196	0.7	198	0.7
Race/ethnicity												
American Indian/Alaska Native	23	2.4	19	2.0	21	2.2	36	3.7	24	2.4	19	1.9
Asian	59	0.8	51	0.7	59	0.8	53	0.7	60	0.7	57	0.7
Black/African American	3,990	23.9	3,604	21.3	2,988	17.5	2,802	16.2	2,632	15.1	2,633	14.9
Hispanic/Latino ^b	880	4.4	851	4.2	705	3.4	669	3.1	698	3.2	619	2.8
Native Hawaiian/Other Pacific Islander	3	1.4	5	2.3	3	1.4	2	0.9	3	1.3	7	3.0
White	892	1.0	840	1.0	734	0.8	769	0.9	726	0.8	751	0.9
Multiple races	296	14.9	330	16.0	231	10.9	215	9.8	194	8.6	164	7.0
Region of residence^c												
Northeast	1,377	5.6	1,229	5.0	1,023	4.1	903	3.6	873	3.5	847	3.4
Midwest	659	2.3	568	2.0	539	1.9	469	1.6	525	1.8	522	1.8
South	3,550	7.1	3,424	6.8	2,716	5.3	2,677	5.2	2,456	4.7	2,468	4.7
West	557	1.8	479	1.5	463	1.5	497	1.6	483	1.5	413	1.3
Subtotal	6,143	4.6	5,700	4.2	4,741	3.5	4,546	3.3	4,337	3.1	4,250	3.0
Total	24,813	9.5	23,690	9.0	19,334	7.3	18,902	7.0	18,515	6.8	17,571	6.4

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

^b Hispanics/Latinos can be of any race.

^c Data are based on residence at time of stage 3 (AIDS) classification.

Table 6b. Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States and 6 dependent areas

	2012		2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	12	0.3	13	0.3	7	0.2	4	0.1	7	0.2	3	0.1
15–19	273	2.5	296	2.7	134	1.2	145	1.3	164	1.5	158	1.4
20–24	1,655	14.2	1,715	14.5	1,150	9.7	1,121	9.5	1,074	9.2	967	8.4
25–29	2,274	20.8	2,326	21.0	1,946	17.3	2,018	17.5	2,106	17.9	1,941	16.1
30–34	2,471	23.3	2,298	21.3	1,873	17.1	1,939	17.6	1,934	17.4	1,956	17.5
35–39	2,133	21.7	2,097	21.2	1,761	17.5	1,687	16.4	1,742	16.6	1,611	15.0
40–44	2,584	24.4	2,296	21.9	1,825	17.7	1,662	16.4	1,533	15.5	1,373	13.9
45–49	2,826	26.0	2,496	23.5	2,054	19.6	1,835	17.6	1,690	16.1	1,505	14.3
50–54	2,187	19.5	2,105	18.8	1,733	15.5	1,812	16.4	1,718	15.8	1,527	14.4
55–59	1,283	12.6	1,310	12.6	1,167	11.1	1,140	10.7	1,148	10.6	1,159	10.7
60–64	725	8.4	762	8.7	636	7.1	634	6.9	682	7.2	660	6.8
≥65	562	2.9	591	3.0	560	2.7	562	2.6	603	2.7	602	2.6
Race/ethnicity												
American Indian/Alaska Native	67	—	65	—	60	—	55	—	73	—	51	—
Asian	291	—	292	—	262	—	281	—	287	—	280	—
Black/African American	7,943	—	7,559	—	6,024	—	5,922	—	5,906	—	5,685	—
Hispanic/Latino ^b	4,565	—	4,454	—	3,678	—	3,654	—	3,708	—	3,375	—
Native Hawaiian/Other Pacific Islander	20	—	16	—	15	—	22	—	15	—	21	—
White	5,194	—	5,027	—	4,103	—	4,022	—	3,849	—	3,570	—
Multiple races	905	—	892	—	704	—	603	—	563	—	480	—
Region of residence^c												
Northeast	3,334	14.6	3,084	13.4	2,483	10.8	2,401	10.4	2,285	9.9	2,125	9.1
Midwest	2,457	9.0	2,381	8.6	1,927	7.0	1,955	7.0	1,896	6.8	1,690	6.0
South	9,245	19.6	9,081	19.0	7,353	15.2	7,082	14.4	7,082	14.3	6,919	13.8
West	3,634	12.1	3,444	11.3	2,830	9.2	2,918	9.3	2,915	9.2	2,587	8.1
U.S. dependent areas	315	19.7	315	19.8	253	16.1	203	13.0	223	14.5	141	9.3
Subtotal	18,985	14.7	18,305	14.1	14,846	11.3	14,559	11.0	14,401	10.8	13,462	10.0
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	17	0.4	17	0.4	8	0.2	4	0.1	7	0.2	4	0.1
15–19	88	0.8	110	1.1	58	0.6	46	0.4	53	0.5	45	0.4
20–24	274	2.4	307	2.7	222	2.0	217	1.9	219	2.0	191	1.8
25–29	523	4.9	491	4.6	416	3.8	414	3.7	397	3.5	374	3.2
30–34	817	7.7	678	6.3	578	5.3	558	5.1	502	4.6	497	4.5
35–39	881	8.9	771	7.7	687	6.8	648	6.3	671	6.4	608	5.7
40–44	957	8.9	835	7.8	718	6.8	633	6.1	579	5.8	566	5.7
45–49	935	8.4	888	8.2	680	6.4	659	6.2	553	5.2	587	5.5
50–54	761	6.5	729	6.3	611	5.3	572	5.0	533	4.7	539	4.9
55–59	525	4.8	520	4.7	450	4.0	397	3.5	427	3.7	420	3.7
60–64	307	3.3	294	3.1	233	2.4	247	2.5	253	2.5	274	2.6
≥65	197	0.8	192	0.8	192	0.7	210	0.8	197	0.7	203	0.7
Race/ethnicity												
American Indian/Alaska Native	23	—	19	—	21	—	36	—	24	—	19	—
Asian	59	—	51	—	59	—	53	—	60	—	57	—
Black/African American	3,992	—	3,607	—	2,990	—	2,805	—	2,634	—	2,636	—
Hispanic/Latino ^b	1,017	—	980	—	814	—	725	—	749	—	673	—
Native Hawaiian/Other Pacific Islander	3	—	5	—	3	—	2	—	4	—	7	—
White	892	—	840	—	735	—	769	—	726	—	752	—
Multiple races	296	—	330	—	231	—	215	—	194	—	164	—
Region of residence^c												
Northeast	1,377	5.6	1,229	5.0	1,023	4.1	903	3.6	873	3.5	847	3.4
Midwest	659	2.3	568	2.0	539	1.9	469	1.6	525	1.8	522	1.8
South	3,550	7.1	3,424	6.8	2,716	5.3	2,677	5.2	2,456	4.7	2,468	4.7
West	557	1.8	479	1.5	463	1.5	497	1.6	483	1.5	413	1.3
U.S. dependent areas	139	7.9	132	7.5	112	6.4	59	3.4	54	3.2	58	3.4
Subtotal	6,282	4.6	5,832	4.3	4,853	3.5	4,605	3.3	4,391	3.1	4,308	3.1
Total	25,267	9.6	24,137	9.0	19,699	7.3	19,164	7.1	18,792	6.9	17,770	6.4

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

^b Hispanics/Latinos can be of any race.

^c Data are based on residence at time of stage 3 (AIDS) classification.

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	4	1	4	5	2	2	1	0	0	1	0	0
20–24	21	18	30	32	27	19	1	0	1	3	4	2
25–29	15	23	28	24	39	35	5	1	1	1	7	7
30–34	13	12	18	17	31	21	3	2	1	0	4	5
35–39	8	6	6	14	12	15	2	1	0	3	2	1
40–44	14	7	10	6	13	12	1	0	1	0	0	1
45–49	9	7	10	7	7	8	1	1	2	0	0	1
50–54	6	6	7	5	5	10	1	1	2	0	1	0
55–59	1	0	2	4	3	2	0	0	0	0	0	0
60–64	0	1	0	0	4	2	0	0	0	0	1	1
≥65	1	2	1	0	1	0	0	0	0	0	0	1
Region of residence^a												
Northeast	5	1	4	3	7	2	1	0	0	0	0	0
Midwest	7	6	9	9	15	13	2	1	3	0	2	4
South	29	20	27	34	37	34	1	1	1	2	6	10
West	51	55	76	65	85	76	10	5	4	6	12	5
Total	91	81	116	112	144	125	15	7	8	9	19	19
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	1	0	0	0	0	0	0	0	0
15–19	13	7	15	21	20	27	0	0	1	0	1	0
20–24	84	96	129	127	113	154	1	1	2	4	3	3
25–29	127	109	144	169	169	153	3	1	3	3	1	3
30–34	86	98	116	109	126	108	5	1	3	3	2	5
35–39	96	78	93	73	85	91	2	1	3	2	2	1
40–44	69	88	74	82	88	74	6	2	6	3	0	0
45–49	52	52	60	63	53	70	1	1	0	2	1	2
50–54	26	20	31	37	32	32	0	0	1	1	1	2
55–59	9	12	10	14	20	21	0	0	0	0	0	0
60–64	7	6	6	4	8	10	0	0	0	0	0	0
≥65	7	4	7	5	11	8	0	0	0	0	1	0
Region of residence^a												
Northeast	104	88	121	110	139	142	6	4	3	2	3	1
Midwest	40	48	55	83	71	85	2	0	6	2	4	1
South	115	140	137	159	154	169	2	1	3	5	1	2
West	316	292	373	354	361	351	7	3	8	9	6	14
Total	574	567	686	705	726	747	17	8	19	19	14	18

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	8	11	3	7	4	4	1	0	0	0	0	0
15–19	881	796	800	867	815	841	14	17	14	12	14	10
20–24	3,007	3,059	3,179	3,013	2,888	2,556	53	76	56	61	60	39
25–29	1,891	2,066	2,332	2,520	2,623	2,584	40	64	50	48	64	63
30–34	1,006	1,068	1,201	1,224	1,247	1,402	44	39	38	38	42	38
35–39	689	664	692	750	748	813	32	19	24	31	30	37
40–44	697	589	524	492	473	464	24	23	23	18	12	16
45–49	601	524	486	477	405	384	31	28	15	16	16	13
50–54	400	375	340	370	365	358	23	22	21	10	13	23
55–59	207	188	231	208	225	217	13	16	14	14	8	14
60–64	115	100	110	90	100	115	13	8	10	3	8	5
≥65	68	65	82	85	62	68	3	4	4	5	4	5
Region of residence^a												
Northeast	1,285	1,251	1,305	1,256	1,187	1,216	51	50	48	31	32	35
Midwest	1,627	1,605	1,624	1,585	1,633	1,544	52	51	40	36	58	42
South	5,884	5,903	6,250	6,403	6,219	6,218	141	174	137	149	142	138
West	775	748	800	859	917	828	46	39	43	39	40	49
Total	9,570	9,507	9,980	10,103	9,957	9,806	290	314	269	256	272	263
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	4	2	5	1	1	5	1	0	0	0	0	0
15–19	324	264	281	296	292	298	13	11	16	12	11	6
20–24	1,325	1,265	1,440	1,482	1,423	1,288	73	57	45	64	58	52
25–29	1,327	1,372	1,479	1,571	1,778	1,680	65	74	57	72	61	69
30–34	1,162	1,104	1,202	1,197	1,301	1,294	75	58	67	63	61	48
35–39	746	762	867	921	923	909	50	39	44	38	40	38
40–44	679	640	660	607	619	572	41	35	30	29	32	20
45–49	523	514	539	541	472	508	29	15	26	22	12	18
50–54	284	300	293	352	357	342	15	16	9	10	15	10
55–59	129	154	139	166	153	172	3	7	7	5	5	9
60–64	68	60	75	58	72	72	4	1	2	2	4	3
≥65	43	49	54	57	53	67	1	2	2	3	2	2
Region of residence^a												
Northeast	1,243	1,256	1,285	1,269	1,202	1,233	80	72	50	53	43	34
Midwest	503	485	505	486	465	481	27	24	15	27	25	21
South	2,528	2,572	2,793	3,019	3,206	3,153	113	102	110	109	102	95
West	2,341	2,175	2,451	2,475	2,570	2,340	151	118	129	129	131	126
Total	6,615	6,487	7,034	7,248	7,442	7,208	370	316	305	319	300	275

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	1	2	1	1	0	0	0	0	0	0
20–24	10	2	6	9	1	8	0	0	0	0	0	0
25–29	4	9	3	12	7	10	1	2	0	0	2	0
30–34	9	9	6	10	3	8	2	1	1	0	2	0
35–39	4	3	7	7	6	2	0	0	0	1	0	1
40–44	1	3	3	3	4	5	0	0	0	0	0	1
45–49	3	4	3	6	1	1	1	0	0	0	0	0
50–54	4	2	1	4	2	2	0	0	0	0	0	0
55–59	3	0	0	3	0	0	0	0	0	0	0	0
60–64	0	0	1	0	0	0	0	0	0	0	0	0
≥65	0	0	1	0	1	0	0	0	0	0	1	0
Region of residence^a												
Northeast	3	1	0	2	3	3	0	1	0	0	1	0
Midwest	1	2	1	1	2	0	1	0	0	0	0	0
South	7	2	7	18	4	8	0	1	0	1	0	1
West	28	28	24	35	17	26	3	1	1	1	4	1
Total	38	33	32	55	26	37	5	3	1	2	5	2
White												
Age at diagnosis (yr)												
13–14	2	1	3	0	0	1	0	0	0	0	0	0
15–19	149	135	143	153	165	177	10	11	9	16	16	12
20–24	979	973	992	969	916	981	92	106	75	100	88	76
25–29	1,189	1,127	1,288	1,291	1,257	1,303	115	133	144	147	141	150
30–34	1,115	1,029	1,015	1,034	1,013	952	118	104	114	116	113	106
35–39	822	790	827	756	710	785	91	72	80	95	75	93
40–44	1,052	943	818	721	635	528	81	74	79	47	64	54
45–49	1,150	1,044	949	770	744	646	80	48	62	49	51	52
50–54	837	770	815	817	747	713	49	40	49	56	37	34
55–59	475	515	461	422	462	450	24	24	22	31	30	24
60–64	229	298	236	249	240	251	7	12	10	11	12	16
≥65	206	231	206	195	201	195	6	8	3	4	9	9
Region of residence^a												
Northeast	1,284	1,210	1,186	1,046	999	916	91	69	63	73	56	71
Midwest	1,413	1,385	1,323	1,272	1,231	1,230	106	86	107	120	119	107
South	3,412	3,346	3,316	3,123	3,092	3,134	222	251	250	250	241	252
West	2,095	1,915	1,928	1,936	1,769	1,703	255	225	226	229	218	195
Total	8,203	7,856	7,753	7,377	7,091	6,982	674	631	646	671	635	625

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	2	0	0	0	0	0	0	0	0	0	0	0
15–19	78	70	69	47	43	37	4	6	5	3	3	0
20–24	321	295	233	229	199	138	22	23	20	11	12	9
25–29	220	223	202	222	186	155	12	14	20	17	12	10
30–34	146	141	126	114	111	92	19	14	6	17	12	3
35–39	111	98	95	83	64	54	10	8	8	3	7	7
40–44	100	73	70	51	45	38	8	3	10	4	2	3
45–49	76	81	64	47	43	35	11	6	5	4	5	3
50–54	53	42	49	40	34	33	4	6	4	2	4	1
55–59	33	32	25	21	26	14	7	1	2	1	1	1
60–64	10	16	5	14	16	8	4	0	0	1	1	0
≥65	12	10	9	11	7	4	0	1	0	0	0	0
Region of residence^a												
Northeast	259	282	212	213	180	127	17	14	16	13	12	8
Midwest	194	145	126	116	94	98	17	13	11	9	12	6
South	504	450	419	363	331	269	33	34	28	17	22	19
West	202	206	188	188	170	115	32	21	24	21	14	7
Total	1,160	1,083	945	880	774	608	99	83	79	62	59	39
Total												
Age at diagnosis (yr)												
13–14	16	14	11	9	5	9	3	0	0	0	0	0
15–19	1,449	1,275	1,312	1,392	1,339	1,383	42	44	45	44	44	28
20–24	5,746	5,708	6,010	5,860	5,567	5,144	242	264	200	243	226	180
25–29	4,773	4,929	5,475	5,809	6,058	5,921	240	289	275	287	288	301
30–34	3,537	3,462	3,683	3,705	3,833	3,877	265	218	228	236	235	206
35–39	2,476	2,401	2,587	2,603	2,548	2,669	187	141	159	174	156	178
40–44	2,612	2,343	2,159	1,961	1,878	1,693	160	137	148	100	110	96
45–49	2,416	2,226	2,111	1,910	1,725	1,651	154	100	110	93	85	90
50–54	1,609	1,514	1,536	1,625	1,542	1,489	92	85	87	79	71	70
55–59	856	900	867	838	889	877	46	48	44	51	45	50
60–64	428	481	433	416	440	458	29	22	22	18	25	25
≥65	336	361	361	353	337	341	10	15	9	11	17	17
Region of residence^a												
Northeast	4,182	4,088	4,114	3,899	3,717	3,639	245	211	180	173	146	149
Midwest	3,785	3,675	3,643	3,552	3,511	3,451	208	175	183	196	220	180
South	12,478	12,432	12,950	13,119	13,043	12,985	513	564	528	534	514	517
West	5,807	5,418	5,840	5,911	5,889	5,438	505	412	436	434	424	396
Total	26,252	25,614	26,546	26,481	26,159	25,513	1,471	1,361	1,327	1,336	1,304	1,241

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	4	1	4	5	2	2	1	0	0	1	0	0
20–24	21	18	30	32	27	19	1	0	1	3	4	2
25–29	15	23	28	24	39	35	5	1	1	1	7	7
30–34	13	12	18	17	31	21	3	2	1	0	4	5
35–39	8	6	6	14	12	15	2	1	0	3	2	1
40–44	14	7	10	6	13	12	1	0	1	0	0	1
45–49	9	7	10	7	7	8	1	1	2	0	0	1
50–54	6	6	7	5	5	10	1	1	2	0	1	0
55–59	1	0	2	4	3	2	0	0	0	0	0	0
60–64	0	1	0	0	4	2	0	0	0	0	1	1
≥65	1	2	1	0	1	0	0	0	0	0	0	1
Region of residence^a												
Northeast	5	1	4	3	7	2	1	0	0	0	0	0
Midwest	7	6	9	9	15	13	2	1	3	0	2	4
South	29	20	27	34	37	34	1	1	1	2	6	10
West	51	55	76	65	85	76	10	5	4	6	12	5
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	91	81	116	112	144	125	15	7	8	9	19	19
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	1	0	0	0	0	0	0	0	0
15–19	13	7	15	21	20	27	0	0	1	0	1	0
20–24	84	96	129	127	113	154	1	1	2	4	3	3
25–29	127	109	144	171	169	153	3	1	3	3	1	3
30–34	86	98	116	110	126	110	5	1	3	3	2	5
35–39	97	78	93	73	86	92	2	1	3	2	2	1
40–44	69	88	74	82	88	74	6	2	6	3	0	0
45–49	52	52	60	63	53	70	1	1	0	2	1	2
50–54	26	20	32	37	32	32	0	0	1	1	1	2
55–59	9	12	10	14	20	21	0	0	0	0	0	0
60–64	7	6	6	4	8	10	0	0	0	0	0	0
≥65	7	4	7	5	11	8	0	0	0	0	1	0
Region of residence^a												
Northeast	104	88	121	110	139	142	6	4	3	2	3	1
Midwest	40	48	55	83	71	85	2	0	6	2	4	1
South	115	140	137	159	154	169	2	1	3	5	1	2
West	316	292	373	354	361	351	7	3	8	9	6	14
U.S. dependent areas	1	0	1	4	1	3	0	0	0	0	0	0
Total	575	567	687	709	727	750	17	8	19	19	14	18

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	8	11	3	7	4	4	1	0	0	0	0	0
15–19	881	796	800	867	815	841	14	17	14	12	14	10
20–24	3,007	3,060	3,179	3,014	2,889	2,556	53	76	56	61	60	39
25–29	1,891	2,067	2,332	2,521	2,623	2,584	40	64	50	48	64	63
30–34	1,006	1,068	1,202	1,224	1,248	1,403	44	39	38	38	42	38
35–39	689	665	693	751	748	813	32	19	24	31	30	37
40–44	698	590	524	493	474	465	24	23	23	18	12	16
45–49	601	524	487	478	405	384	31	28	15	16	16	13
50–54	400	375	340	370	365	358	23	22	21	10	13	23
55–59	207	188	231	208	225	217	13	16	14	14	8	14
60–64	115	100	111	90	100	115	13	8	10	3	8	5
≥65	68	65	82	85	62	68	3	4	4	5	4	5
Region of residence^a												
Northeast	1,285	1,251	1,305	1,256	1,187	1,216	51	50	48	31	32	35
Midwest	1,627	1,605	1,624	1,585	1,633	1,544	52	51	40	36	58	42
South	5,884	5,903	6,250	6,403	6,219	6,218	141	174	137	149	142	138
West	775	748	800	859	917	828	46	39	43	39	40	49
U.S. dependent areas	1	4	4	5	3	1	0	0	0	0	0	0
Total	9,571	9,511	9,984	10,108	9,960	9,807	290	314	269	256	272	263
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	4	2	5	1	1	5	1	0	0	0	0	0
15–19	336	278	298	299	300	306	13	11	16	12	11	6
20–24	1,398	1,331	1,529	1,540	1,483	1,336	76	59	47	68	58	52
25–29	1,392	1,429	1,546	1,638	1,830	1,723	70	75	58	74	63	72
30–34	1,208	1,154	1,234	1,230	1,343	1,333	80	64	67	64	63	50
35–39	768	784	901	956	958	930	55	40	46	42	43	40
40–44	707	670	693	636	639	588	43	39	31	33	34	20
45–49	548	532	558	567	490	523	31	17	26	23	13	21
50–54	298	315	306	367	379	364	19	20	9	11	15	10
55–59	136	157	146	174	168	182	4	7	7	5	6	9
60–64	73	70	80	66	75	76	4	1	2	2	4	3
≥65	48	53	59	64	55	70	1	2	3	5	2	2
Region of residence^a												
Northeast	1,243	1,256	1,285	1,269	1,202	1,233	80	72	50	53	43	34
Midwest	503	485	505	486	465	481	27	24	15	27	25	21
South	2,528	2,572	2,793	3,019	3,206	3,153	113	102	110	109	102	95
West	2,341	2,175	2,451	2,475	2,570	2,340	151	118	129	129	131	126
U.S. dependent areas	301	289	323	289	279	228	27	20	9	19	10	11
Total	6,916	6,776	7,357	7,537	7,721	7,436	397	336	313	338	311	286

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	1	1	2	1	1	0	0	0	0	0	0
20–24	10	2	6	10	3	8	0	0	0	0	0	0
25–29	5	9	3	13	7	10	1	2	0	0	3	0
30–34	10	10	6	10	5	8	2	1	1	0	2	0
35–39	4	3	7	7	6	2	0	0	0	1	0	1
40–44	1	3	4	3	4	5	0	0	0	0	0	1
45–49	3	4	3	6	1	1	1	0	0	0	0	0
50–54	4	2	1	5	2	3	0	0	0	0	0	0
55–59	3	0	0	3	0	1	0	0	0	0	0	0
60–64	0	0	1	0	0	0	0	0	0	0	0	0
≥65	0	0	1	0	1	0	0	0	0	0	1	0
Region of residence^a												
Northeast	3	1	0	2	3	3	0	1	0	0	1	0
Midwest	1	2	1	1	2	0	1	0	0	0	0	0
South	7	2	7	18	4	8	0	1	0	1	0	1
West	28	28	24	35	17	26	3	1	1	1	4	1
U.S. dependent areas	3	1	1	2	4	2	0	0	0	0	1	0
Total	41	34	33	58	29	39	5	3	1	2	6	2
White												
Age at diagnosis (yr)												
13–14	2	1	3	0	0	1	0	0	0	0	0	0
15–19	149	135	143	153	165	177	10	11	9	16	16	12
20–24	979	973	993	969	917	981	92	106	75	100	88	76
25–29	1,189	1,127	1,289	1,291	1,257	1,303	115	133	144	147	141	150
30–34	1,115	1,031	1,016	1,034	1,014	952	118	104	114	116	113	106
35–39	822	790	827	756	710	785	91	72	80	95	75	93
40–44	1,053	943	820	721	635	528	81	74	79	47	64	54
45–49	1,150	1,044	949	770	744	646	80	48	62	49	51	52
50–54	837	770	815	818	747	713	49	40	49	56	37	34
55–59	475	515	462	422	462	450	24	24	22	31	30	24
60–64	229	298	236	249	240	251	7	12	10	11	12	16
≥65	206	231	206	195	201	195	6	8	3	4	9	9
Region of residence^a												
Northeast	1,284	1,210	1,186	1,046	999	916	91	69	63	73	56	71
Midwest	1,413	1,385	1,323	1,272	1,231	1,230	106	86	107	120	119	107
South	3,412	3,346	3,316	3,123	3,092	3,134	222	251	250	250	241	252
West	2,095	1,915	1,928	1,936	1,769	1,703	255	225	226	229	218	195
U.S. dependent areas	1	3	6	1	2	0	0	0	0	0	0	0
Total	8,204	7,859	7,758	7,378	7,093	6,982	674	631	646	671	635	625

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	2	0	0	0	0	0	0	0	0	0	0	0
15–19	79	70	70	47	43	37	4	6	5	3	3	0
20–24	321	295	233	229	199	138	22	23	20	11	12	9
25–29	220	223	202	222	186	155	12	14	20	17	12	10
30–34	147	141	126	114	111	92	19	14	6	17	12	3
35–39	111	98	95	83	64	55	10	8	8	3	7	7
40–44	100	73	70	51	45	38	8	3	10	4	2	3
45–49	76	81	64	47	43	35	11	6	5	4	5	3
50–54	53	42	49	40	34	33	4	6	4	2	4	1
55–59	33	32	25	21	26	14	7	1	2	1	1	1
60–64	10	16	5	14	16	8	4	0	0	1	1	0
≥65	12	10	9	11	7	4	0	1	0	0	0	0
Region of residence^a												
Northeast	259	282	212	213	180	127	17	14	16	13	12	8
Midwest	194	145	126	116	94	98	17	13	11	9	12	6
South	504	450	419	363	331	269	33	34	28	17	22	19
West	202	206	188	188	170	115	32	21	24	21	14	7
U.S. dependent areas	2	0	1	0	0	1	0	0	0	0	0	0
Total	1,162	1,083	946	880	774	609	99	83	79	62	59	39
Total												
Age at diagnosis (yr)												
13–14	16	14	11	9	5	9	3	0	0	0	0	0
15–19	1,463	1,289	1,331	1,395	1,347	1,391	42	44	45	44	44	28
20–24	5,819	5,775	6,100	5,920	5,632	5,192	245	266	203	246	226	180
25–29	4,838	4,988	5,544	5,880	6,110	5,964	246	290	276	289	291	304
30–34	3,585	3,515	3,717	3,739	3,879	3,918	269	224	229	238	237	208
35–39	2,498	2,424	2,622	2,640	2,583	2,692	192	141	161	178	159	181
40–44	2,641	2,375	2,195	1,992	1,899	1,709	162	141	149	104	112	96
45–49	2,441	2,244	2,131	1,937	1,743	1,666	156	102	110	94	87	92
50–54	1,623	1,529	1,550	1,641	1,564	1,513	96	89	87	80	71	70
55–59	862	904	876	846	904	887	47	48	44	51	46	50
60–64	433	491	438	423	444	462	29	22	22	18	25	25
≥65	341	365	366	360	338	344	10	15	10	13	17	17
Region of residence^a												
Northeast	4,182	4,088	4,114	3,899	3,717	3,639	245	211	180	173	146	149
Midwest	3,785	3,675	3,643	3,552	3,511	3,451	208	175	183	196	220	180
South	12,478	12,432	12,950	13,119	13,043	12,985	513	564	528	534	514	517
West	5,807	5,418	5,840	5,911	5,889	5,438	505	412	436	434	424	396
U.S. dependent areas	309	296	336	300	289	235	27	21	9	19	11	11
Total	26,561	25,910	26,882	26,781	26,448	25,748	1,497	1,382	1,335	1,355	1,315	1,252

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	1
20–24	2	2	1	0	3	0	1	1	0	1	1	1
25–29	2	1	2	2	4	6	0	0	2	2	2	1
30–34	1	3	0	2	0	4	3	2	2	2	1	2
35–39	0	0	0	1	1	0	1	0	1	1	2	2
40–44	5	3	3	0	2	2	2	3	2	2	1	1
45–49	1	3	2	0	2	0	3	1	1	2	1	2
50–54	0	1	3	1	0	2	0	2	0	0	4	3
55–59	2	1	0	1	2	0	2	0	1	1	0	1
60–64	0	0	0	0	0	1	1	1	1	1	0	0
≥65	0	1	0	0	0	0	1	0	0	0	0	1
Region of residence^a												
Northeast	1	0	0	0	0	0	0	1	0	0	0	0
Midwest	2	1	1	0	0	1	4	3	2	0	1	0
South	1	3	4	2	3	3	1	2	3	3	0	4
West	10	11	6	5	12	12	8	6	5	9	11	10
Total	13	15	11	7	15	16	13	11	10	12	12	14
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	1	0	0	0	0	0	0	0	0	0
20–24	0	2	0	0	0	0	1	0	0	0	1	0
25–29	1	2	2	1	1	2	2	0	0	1	2	2
30–34	2	3	3	8	1	1	0	1	0	1	1	1
35–39	6	3	4	1	3	3	2	1	2	1	1	1
40–44	5	5	3	3	1	2	0	0	1	1	1	0
45–49	1	3	2	2	3	3	1	1	0	0	1	1
50–54	1	1	2	2	3	2	0	1	0	0	0	0
55–59	1	1	1	0	1	1	0	2	2	0	0	0
60–64	0	1	1	1	0	0	1	0	1	1	0	0
≥65	0	0	2	1	1	0	0	0	0	0	0	0
Region of residence^a												
Northeast	4	7	6	7	4	5	2	1	2	1	1	1
Midwest	0	2	2	0	1	0	1	2	1	1	0	0
South	4	6	8	3	3	4	1	2	1	2	2	1
West	10	6	4	9	7	5	3	3	2	3	3	3
Total	18	22	20	19	15	13	7	7	7	6	7	6

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	1	0	0	2	1	0	1	0	0
15–19	9	7	6	5	5	6	14	9	10	6	7	9
20–24	32	29	31	33	24	24	45	27	28	27	20	26
25–29	43	40	37	34	39	44	41	30	38	42	40	38
30–34	56	42	42	40	38	52	56	40	37	34	38	40
35–39	52	52	38	39	52	48	61	37	37	34	30	44
40–44	66	51	48	50	41	37	62	45	38	34	25	41
45–49	92	94	67	47	48	51	72	57	52	44	31	43
50–54	115	95	67	68	61	49	83	56	49	41	48	39
55–59	88	83	78	63	45	56	52	60	46	35	39	33
60–64	50	45	43	34	37	34	28	23	21	27	27	27
≥65	37	29	40	32	30	31	19	11	17	14	12	17
Region of residence^a												
Northeast	202	184	157	128	123	153	150	91	100	93	71	94
Midwest	67	61	47	48	53	56	70	62	50	47	48	60
South	324	280	262	227	195	192	275	215	187	163	165	170
West	46	41	32	42	47	30	40	28	38	36	33	32
Total	639	566	497	445	418	431	535	396	374	339	317	356
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	3	4	3	1	3	4	4	6	7	5	5	4
20–24	12	20	17	26	20	19	19	14	20	25	10	16
25–29	34	34	33	37	34	37	20	23	15	10	28	16
30–34	55	49	41	46	51	55	30	22	23	17	23	24
35–39	56	43	37	42	39	44	25	18	21	16	12	18
40–44	57	45	51	39	26	42	18	21	28	17	18	17
45–49	52	58	47	37	38	37	25	18	16	15	16	14
50–54	47	31	34	36	40	38	16	18	17	13	15	13
55–59	25	37	27	30	24	24	13	9	15	9	12	7
60–64	23	9	13	9	12	13	7	5	7	3	5	3
≥65	14	11	8	13	15	10	3	5	7	4	6	4
Region of residence^a												
Northeast	158	134	103	107	104	115	90	69	68	47	49	47
Midwest	20	18	11	19	12	13	9	12	10	7	11	8
South	115	97	90	98	89	99	42	42	49	45	45	39
West	86	94	105	90	95	95	37	36	47	36	46	40
Total	378	342	308	314	300	322	179	159	175	134	150	135

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	1	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	1	0	0	0	0	0	0	0	0
40–44	0	0	0	1	0	0	0	0	0	0	0	1
45–49	0	1	0	0	0	0	0	0	0	0	0	0
50–54	0	0	0	0	0	1	0	0	0	0	2	0
55–59	0	0	0	1	0	0	0	0	0	0	0	0
60–64	0	0	1	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	1	1	0	0	0	0	0	0	0	1
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	1	0	0	0	0	0	0	0	0
West	0	1	0	1	0	1	0	0	0	1	2	0
Total	0	1	1	3	0	1	0	0	1	1	2	1
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	1	0	0
15–19	7	2	2	1	3	3	10	9	11	8	5	7
20–24	32	26	26	46	30	44	27	36	39	49	40	43
25–29	37	36	40	81	76	87	52	47	55	90	90	89
30–34	46	46	54	77	66	94	50	58	62	84	64	90
35–39	26	36	48	53	69	74	43	34	44	53	62	75
40–44	45	43	60	54	46	49	47	46	37	61	45	51
45–49	54	58	52	64	48	61	44	47	39	46	41	36
50–54	57	46	52	55	50	40	37	41	26	41	39	38
55–59	21	38	28	32	28	39	30	23	19	24	21	29
60–64	15	18	21	20	19	22	11	13	5	12	12	10
≥65	7	13	12	10	16	15	3	5	6	6	9	4
Region of residence^a												
Northeast	67	64	65	74	84	101	75	69	57	74	82	88
Midwest	46	49	51	136	82	94	44	61	40	132	81	90
South	134	145	156	156	163	216	165	158	168	191	180	209
West	100	104	124	125	120	116	71	70	77	76	84	85
Total	347	362	396	492	450	527	354	358	343	473	427	471

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	1	1	0	4	1	2	2	1	1
20–24	3	1	1	3	2	0	4	3	2	2	2	4
25–29	3	4	7	6	4	2	7	5	2	3	3	2
30–34	4	5	7	5	0	4	6	4	6	9	2	3
35–39	4	4	4	2	4	4	7	5	7	2	7	4
40–44	5	10	4	2	4	4	8	8	6	2	4	4
45–49	5	6	4	3	3	4	9	5	5	4	7	2
50–54	11	8	4	4	6	1	5	6	7	3	3	4
55–59	6	3	3	3	3	4	5	4	2	8	4	1
60–64	4	3	2	1	1	2	2	3	2	1	1	0
≥65	2	2	2	4	0	1	2	1	2	1	1	0
Region of residence^a												
Northeast	19	11	10	8	7	7	21	14	13	6	8	8
Midwest	4	2	8	7	3	3	7	8	2	6	4	3
South	11	23	9	13	11	7	26	18	20	15	15	9
West	11	10	11	5	7	8	5	8	8	8	9	6
Total	45	45	37	33	28	24	58	47	43	36	36	25
Total												
Age at diagnosis (yr)												
13–14	0	0	0	1	0	0	2	1	0	2	0	0
15–19	20	13	12	8	12	13	31	25	30	20	18	22
20–24	81	79	77	109	79	88	97	82	89	104	74	90
25–29	120	118	121	160	158	178	122	105	113	148	165	149
30–34	163	149	147	177	156	209	146	127	131	146	129	160
35–39	143	138	131	137	168	172	138	95	112	107	113	144
40–44	181	157	168	148	120	134	138	122	112	116	93	114
45–49	205	223	172	152	140	155	153	131	113	111	96	97
50–54	231	181	162	167	159	132	140	124	100	98	111	96
55–59	143	164	137	130	103	123	102	98	84	78	77	71
60–64	92	76	81	65	69	72	49	46	37	45	45	40
≥65	59	56	63	59	62	57	27	22	31	26	28	26
Region of residence^a												
Northeast	451	399	342	325	323	381	338	244	240	220	212	239
Midwest	139	133	120	210	151	168	134	147	106	193	144	161
South	588	555	530	500	465	521	509	437	428	420	406	433
West	262	267	281	278	287	265	165	149	178	169	188	175
Total	1,440	1,353	1,272	1,313	1,226	1,335	1,146	978	952	1,001	950	1,009

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	1
20–24	2	2	1	0	3	0	1	1	0	1	1	1
25–29	2	1	2	2	4	6	0	0	2	2	2	1
30–34	1	3	0	2	0	4	3	2	2	2	1	2
35–39	0	0	0	1	1	0	1	0	1	1	2	2
40–44	5	3	3	0	2	2	2	3	2	2	1	1
45–49	1	3	2	0	2	0	3	1	1	2	1	2
50–54	0	1	3	1	0	2	0	2	0	0	4	3
55–59	2	1	0	1	2	0	2	0	1	1	0	1
60–64	0	0	0	0	0	1	1	1	1	1	0	0
≥65	0	1	0	0	0	0	1	0	0	0	0	1
Region of residence^a												
Northeast	1	0	0	0	0	0	0	1	0	0	0	0
Midwest	2	1	1	0	0	1	4	3	2	0	1	0
South	1	3	4	2	3	3	1	2	3	3	0	4
West	10	11	6	5	12	12	8	6	5	9	11	10
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	13	15	11	7	15	16	13	11	10	12	12	14
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	1	0	0	0	0	0	0	0	0	0
20–24	0	2	0	0	0	0	1	0	0	0	1	0
25–29	1	2	2	1	1	2	2	0	0	1	2	2
30–34	2	3	3	8	1	1	0	1	0	1	1	1
35–39	6	3	4	2	3	3	2	1	2	1	1	1
40–44	5	5	3	3	1	2	0	0	1	1	1	0
45–49	1	3	2	2	3	3	1	1	0	0	1	1
50–54	1	1	2	2	3	2	0	1	0	0	0	0
55–59	1	1	1	0	1	1	0	2	2	0	0	0
60–64	0	1	1	1	0	0	1	0	1	1	0	0
≥65	0	0	2	1	1	0	0	0	0	0	0	0
Region of residence^a												
Northeast	4	7	6	7	4	5	2	1	2	1	1	1
Midwest	0	2	2	0	1	0	1	2	1	1	0	0
South	4	6	8	3	3	4	1	2	1	2	2	1
West	10	6	4	9	7	5	3	3	2	3	3	3
U.S. dependent areas	0	0	0	1	0	0	0	0	0	0	0	0
Total	18	22	20	20	15	13	7	7	7	6	7	6

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	1	0	0	2	1	0	1	0	0
15–19	9	7	6	5	5	6	14	9	10	6	7	9
20–24	32	29	31	33	24	24	45	27	28	27	20	26
25–29	43	40	37	34	39	44	41	30	38	42	40	38
30–34	56	42	42	40	38	52	56	40	37	34	38	40
35–39	52	52	38	39	52	48	61	37	37	34	30	44
40–44	66	51	48	50	41	37	62	45	38	34	25	41
45–49	93	94	67	47	48	51	72	57	52	44	31	43
50–54	115	95	67	68	61	49	83	56	49	41	48	39
55–59	88	83	79	63	45	56	52	60	46	35	39	33
60–64	50	45	45	34	37	34	28	23	21	27	27	27
≥65	37	30	40	32	30	31	19	12	17	14	12	17
Region of residence^a												
Northeast	202	184	157	128	123	153	150	91	100	93	71	94
Midwest	67	61	47	48	53	56	70	62	50	47	48	60
South	324	280	262	227	195	192	275	215	187	163	165	170
West	46	41	32	42	47	30	40	28	38	36	33	32
U.S. dependent areas	0	1	2	0	0	0	0	1	0	0	0	0
Total	639	567	500	445	419	431	535	397	374	339	317	356
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	4	4	3	2	4	4	4	6	7	5	5	4
20–24	17	22	20	28	22	20	23	14	21	27	11	16
25–29	42	39	41	39	36	38	21	25	15	10	30	16
30–34	67	57	44	53	53	59	33	24	25	18	24	25
35–39	64	54	44	47	45	46	28	25	25	18	14	18
40–44	73	53	57	45	30	45	19	23	31	18	19	17
45–49	69	73	59	43	43	40	29	23	17	15	17	16
50–54	55	43	40	45	43	49	18	21	18	14	16	14
55–59	31	49	37	38	32	28	15	10	16	9	12	8
60–64	25	15	17	13	16	17	9	7	7	3	6	4
≥65	19	15	10	15	19	15	3	6	8	4	6	4
Region of residence^a												
Northeast	158	134	103	107	104	115	90	69	68	47	49	47
Midwest	20	18	11	19	12	13	9	12	10	7	11	8
South	115	97	90	98	89	99	42	42	49	45	45	39
West	86	94	105	90	95	95	37	36	47	36	46	40
U.S. dependent areas	88	81	64	53	43	38	23	25	15	7	11	6
Total	467	423	372	367	343	360	201	184	189	141	161	141

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	1	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	1	0	0	0	0	0	0	0	0
40–44	0	0	0	1	0	0	0	0	0	0	0	1
45–49	0	1	0	0	0	0	0	0	0	0	0	0
50–54	0	0	0	1	0	1	0	0	0	0	2	0
55–59	0	0	0	1	1	0	0	0	0	0	0	0
60–64	0	0	1	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	1	1	0	0	0	0	0	0	0	1
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	1	0	0	0	0	0	0	0	0
West	0	1	0	1	0	1	0	0	0	1	2	0
U.S. dependent areas	0	0	0	0	1	0	0	0	0	0	0	0
Total	0	1	1	4	1	1	0	0	1	1	2	1
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	1	0	0
15–19	7	2	2	1	3	3	10	9	11	8	5	7
20–24	32	26	26	46	30	44	27	36	39	49	40	43
25–29	37	36	40	81	76	87	52	47	55	90	90	89
30–34	46	46	54	77	66	94	50	58	62	84	64	90
35–39	26	36	48	53	69	74	43	34	44	53	62	75
40–44	45	43	60	54	46	49	47	46	37	61	45	51
45–49	54	59	52	64	48	61	44	47	39	46	41	36
50–54	57	46	52	56	50	40	37	41	26	41	39	38
55–59	21	38	28	32	28	39	30	23	19	24	21	29
60–64	15	18	21	20	19	22	11	13	5	12	12	10
≥65	7	13	12	10	16	15	3	5	6	6	9	4
Region of residence^a												
Northeast	67	64	65	74	84	101	75	69	57	74	82	88
Midwest	46	49	51	136	82	94	44	61	40	132	81	90
South	134	145	156	156	163	216	165	158	168	191	180	209
West	100	104	124	125	120	116	71	70	77	76	84	85
U.S. dependent areas	0	1	0	1	0	0	0	0	0	0	0	0
Total	347	363	396	493	450	527	354	358	343	473	427	472

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	1	1	0	4	1	2	2	1	1
20–24	3	1	1	3	2	0	4	3	2	2	2	4
25–29	3	4	7	6	4	2	7	5	2	3	3	2
30–34	4	5	7	5	0	4	6	4	6	9	2	3
35–39	4	4	4	2	4	4	7	5	7	2	7	4
40–44	5	10	4	2	4	4	8	8	6	2	4	4
45–49	5	6	4	3	3	4	9	5	5	4	7	2
50–54	11	8	4	4	6	1	5	6	7	3	3	4
55–59	6	3	3	3	3	4	5	4	2	8	4	1
60–64	4	3	2	1	1	2	2	3	2	1	1	0
≥65	2	2	2	4	0	1	2	1	2	1	1	0
Region of residence^a												
Northeast	19	11	10	8	7	7	21	14	13	6	8	8
Midwest	4	2	8	7	3	3	7	8	2	6	4	3
South	11	23	9	13	11	7	26	18	20	15	15	9
West	11	10	11	5	7	8	5	8	8	8	9	6
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	45	45	37	33	28	25	58	47	43	36	36	25
Total												
Age at diagnosis (yr)												
13–14	0	0	0	1	0	0	2	1	0	2	0	0
15–19	21	13	12	9	13	13	31	25	30	20	18	22
20–24	86	81	80	110	82	89	101	82	90	105	75	90
25–29	128	122	129	163	160	179	123	107	113	148	167	149
30–34	174	156	151	185	158	214	149	129	133	147	130	160
35–39	151	149	138	143	174	174	141	101	116	109	116	144
40–44	198	165	174	154	125	137	139	124	115	117	94	114
45–49	222	238	184	158	146	158	157	136	114	111	97	99
50–54	238	193	168	177	162	143	143	127	101	99	112	97
55–59	150	176	148	138	112	127	104	100	85	78	78	72
60–64	94	81	87	69	73	76	51	49	37	45	46	41
≥65	65	60	66	62	66	61	27	24	32	26	28	27
Region of residence^a												
Northeast	451	399	342	325	323	381	338	244	240	220	212	239
Midwest	139	133	120	210	151	168	134	147	106	193	144	161
South	588	555	530	500	465	521	509	437	428	420	406	433
West	262	267	281	278	287	265	165	149	178	169	188	175
U.S. dependent areas	88	83	66	55	44	38	23	25	15	7	11	7
Total	1,528	1,436	1,338	1,368	1,270	1,373	1,169	1,003	967	1,008	962	1,016

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	0	1	3	1	0	0
20–24	1	1	0	1	0	0	3	3	1	2	1	2
25–29	0	2	0	0	0	0	2	1	6	7	5	5
30–34	2	3	3	1	1	2	6	2	1	7	3	2
35–39	0	1	1	1	2	3	4	3	3	5	7	4
40–44	1	0	1	0	1	0	4	2	2	5	6	5
45–49	4	3	3	3	1	0	4	2	1	3	3	5
50–54	0	1	0	2	1	0	1	6	5	4	1	5
55–59	1	0	1	1	0	0	1	1	3	4	2	2
60–64	2	0	0	0	0	0	2	0	0	0	2	2
≥65	0	0	0	0	2	0	1	2	0	1	1	0
Region of residence^a												
Northeast	1	3	2	2	0	0	2	0	0	1	4	0
Midwest	2	5	1	1	1	0	7	5	3	7	1	3
South	3	1	1	3	3	3	6	5	8	16	9	6
West	7	2	7	4	5	3	12	11	13	13	17	22
Total	13	11	10	10	9	7	27	21	24	37	31	31
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	1	0	0	1	0
15–19	0	0	1	0	0	0	6	2	1	3	0	1
20–24	0	1	1	0	3	2	10	8	9	12	10	8
25–29	2	5	7	6	3	2	24	20	19	16	17	16
30–34	6	6	13	4	11	4	21	23	19	22	32	9
35–39	8	5	7	19	12	10	21	23	23	19	26	25
40–44	9	9	6	9	5	2	14	16	20	15	15	13
45–49	6	10	6	8	7	6	8	13	9	11	11	12
50–54	7	6	8	6	4	3	7	6	8	7	10	12
55–59	1	4	2	5	3	3	4	7	7	5	7	8
60–64	6	2	1	0	4	5	6	2	4	7	4	7
≥65	2	1	5	4	6	3	0	3	1	5	5	4
Region of residence^a												
Northeast	13	10	17	10	8	10	22	21	22	20	34	16
Midwest	6	6	9	7	10	4	8	18	13	16	14	21
South	13	17	16	24	24	12	34	38	35	44	43	34
West	14	16	15	19	16	14	56	45	52	40	48	42
Total	46	49	57	60	57	40	119	123	121	121	139	113

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	1	1	2	1	0	0	13	8	5	8	6	5
15–19	35	34	30	35	40	26	213	189	184	146	147	141
20–24	172	140	163	173	163	122	489	462	474	477	413	418
25–29	179	195	211	251	251	193	598	568	561	537	568	539
30–34	240	217	215	214	235	197	648	567	539	529	556	545
35–39	235	225	216	229	224	202	553	515	553	549	562	506
40–44	302	241	268	251	224	182	548	485	487	435	436	423
45–49	350	302	252	252	222	191	562	493	437	401	445	396
50–54	306	266	257	262	232	202	447	416	369	397	391	344
55–59	218	206	201	213	183	177	307	319	327	288	310	312
60–64	124	127	111	128	126	116	170	144	151	174	196	204
≥65	128	128	123	104	121	106	110	125	125	134	126	173
Region of residence^a												
Northeast	482	411	424	375	325	273	876	694	777	717	690	675
Midwest	186	206	168	189	191	177	563	531	480	502	522	513
South	1,560	1,378	1,362	1,452	1,415	1,204	2,961	2,842	2,712	2,586	2,629	2,584
West	63	86	95	96	92	62	259	224	243	270	314	234
Total	2,290	2,081	2,048	2,112	2,023	1,716	4,659	4,291	4,212	4,074	4,155	4,007
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	2	1	0	2	1
15–19	6	7	3	6	5	8	46	42	43	37	30	32
20–24	39	34	36	32	51	23	105	93	127	115	100	114
25–29	53	78	60	52	69	62	143	147	131	130	135	132
30–34	98	105	97	83	88	71	131	131	154	131	156	120
35–39	77	98	103	99	86	75	132	126	152	141	124	129
40–44	89	84	98	81	79	79	129	118	121	120	122	98
45–49	76	72	83	68	77	55	118	121	111	109	101	119
50–54	66	62	68	62	54	47	84	117	90	107	100	91
55–59	43	50	42	44	37	34	62	62	73	58	68	64
60–64	26	21	23	27	28	31	29	40	37	39	42	40
≥65	33	22	21	35	23	27	41	29	24	29	38	37
Region of residence^a												
Northeast	181	165	157	145	146	114	323	332	308	278	304	249
Midwest	36	41	34	38	38	23	64	62	70	49	57	59
South	290	317	342	314	305	278	395	406	414	465	437	448
West	98	110	100	90	106	98	240	228	272	224	219	222
Total	606	633	633	587	596	513	1,021	1,027	1,064	1,016	1,017	978

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	1	1	0	0
20–24	0	0	0	0	0	0	0	4	1	2	1	0
25–29	0	0	0	1	0	1	1	0	0	0	0	3
30–34	0	0	0	0	0	1	3	1	1	1	1	3
35–39	0	0	0	2	1	0	1	0	1	0	2	3
40–44	0	0	1	0	0	0	0	0	1	1	0	0
45–49	0	0	0	1	1	1	0	1	0	0	0	1
50–54	0	0	0	1	0	0	1	3	1	1	2	0
55–59	0	0	0	0	0	0	0	0	1	1	0	1
60–64	1	0	0	0	0	0	0	1	1	0	0	0
≥65	1	0	0	0	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	1	0	0	1	1	0	1	0	0	2
Midwest	0	0	0	0	1	0	0	0	0	2	0	0
South	0	0	0	1	1	1	1	5	1	2	1	4
West	2	0	0	4	0	2	4	5	6	3	5	5
Total	2	0	1	6	2	4	6	10	8	7	6	11
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	2	3	3	0	0	2
15–19	3	3	3	2	3	1	33	19	29	22	34	31
20–24	21	15	15	15	31	16	112	103	118	95	108	111
25–29	41	39	40	36	40	40	122	110	125	118	140	117
30–34	35	31	43	38	45	44	112	114	134	124	150	137
35–39	40	43	30	36	46	47	100	112	119	107	113	123
40–44	74	75	56	48	50	50	139	97	105	105	97	88
45–49	71	67	63	64	46	47	119	113	102	113	110	117
50–54	62	57	74	43	74	60	100	88	111	111	107	105
55–59	47	53	41	48	51	49	69	71	80	90	91	99
60–64	26	32	28	37	34	34	32	52	29	34	54	44
≥65	29	45	38	47	42	32	23	27	16	27	23	26
Region of residence^a												
Northeast	94	90	93	79	83	65	143	151	152	128	136	132
Midwest	71	62	52	47	49	50	165	151	152	161	167	158
South	209	227	208	227	259	232	490	456	502	505	528	543
West	76	80	79	59	69	73	163	152	164	152	195	166
Total	449	459	432	412	461	420	962	910	970	945	1,026	998

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	2	0	0	0	1	1
15–19	2	2	1	1	0	1	14	16	11	9	7	4
20–24	7	8	5	9	7	2	36	31	33	17	23	19
25–29	8	12	7	11	10	4	25	29	31	22	19	19
30–34	9	11	6	9	6	6	32	31	34	29	20	14
35–39	17	8	16	8	11	4	26	28	26	25	20	18
40–44	17	13	8	5	12	6	30	22	31	13	14	8
45–49	10	16	19	5	8	6	30	28	15	18	18	12
50–54	10	11	8	9	6	6	18	24	14	20	14	14
55–59	6	9	9	6	5	4	17	15	10	11	12	9
60–64	8	7	2	2	3	3	17	10	10	5	4	2
≥65	2	6	3	7	2	4	8	7	4	4	7	3
Region of residence^a												
Northeast	34	43	28	19	24	11	74	66	52	51	32	32
Midwest	12	8	8	8	7	8	28	32	26	17	34	18
South	40	45	35	36	33	22	130	120	117	87	80	51
West	10	8	12	7	4	4	21	21	22	17	12	20
Total	96	104	83	70	68	45	254	240	217	171	158	121
Total												
Age at diagnosis (yr)												
13–14	1	1	2	1	0	0	17	13	9	8	10	9
15–19	48	46	38	44	48	36	311	268	272	218	217	210
20–24	241	199	219	229	255	166	755	704	764	720	655	672
25–29	283	331	325	356	373	301	914	874	872	830	884	830
30–34	390	373	377	349	387	325	952	869	881	841	918	829
35–39	377	380	373	393	382	342	838	806	877	845	854	807
40–44	491	422	437	395	371	320	863	740	767	695	691	635
45–49	517	469	427	401	362	306	841	772	675	655	688	663
50–54	451	403	415	384	370	318	657	659	596	645	623	569
55–59	315	322	297	317	278	267	459	475	500	457	489	494
60–64	192	189	165	194	195	189	256	248	231	258	301	299
≥65	196	202	190	196	195	173	183	193	170	199	200	242
Region of residence^a												
Northeast	805	722	722	632	587	474	1,441	1,265	1,312	1,195	1,200	1,107
Midwest	313	328	272	291	297	262	836	800	744	753	794	772
South	2,114	1,986	1,963	2,056	2,040	1,752	4,017	3,871	3,788	3,704	3,727	3,670
West	270	302	308	279	293	257	753	686	771	719	810	710
Total	3,502	3,337	3,265	3,258	3,216	2,744	7,047	6,621	6,614	6,370	6,531	6,259

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	0	1	3	1	0	0
20–24	1	1	0	1	0	0	3	3	1	2	1	2
25–29	0	2	0	0	0	0	2	1	6	7	5	5
30–34	2	3	3	1	1	2	6	2	1	7	3	2
35–39	0	1	1	1	2	3	4	3	3	5	7	4
40–44	1	0	1	0	1	0	4	2	2	5	6	5
45–49	4	3	3	3	1	0	4	2	1	3	3	5
50–54	0	1	0	2	1	0	1	6	5	4	1	5
55–59	1	0	1	1	0	0	1	1	3	4	2	2
60–64	2	0	0	0	0	0	2	0	0	0	2	2
≥65	0	0	0	0	2	0	1	2	0	1	1	0
Region of residence^a												
Northeast	1	3	2	2	0	0	2	0	0	1	4	0
Midwest	2	5	1	1	1	0	7	5	3	7	1	3
South	3	1	1	3	3	3	6	5	8	16	9	6
West	7	2	7	4	5	3	12	11	13	13	17	22
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	13	11	10	10	9	7	27	21	24	37	31	31
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	1	0	0	1	0
15–19	0	0	1	0	0	0	6	2	1	3	0	1
20–24	0	1	1	0	3	2	10	8	9	12	10	8
25–29	2	5	7	6	3	2	24	20	19	16	17	16
30–34	6	6	13	4	11	4	21	23	19	22	32	9
35–39	8	5	7	19	12	10	21	23	23	19	26	25
40–44	9	9	6	9	5	2	14	16	20	15	15	13
45–49	6	10	6	8	7	6	8	13	9	11	11	12
50–54	7	6	8	6	4	3	7	6	8	7	10	12
55–59	1	4	2	5	3	3	4	7	7	5	7	8
60–64	6	2	1	0	4	5	6	2	4	7	4	7
≥65	2	1	5	4	6	3	0	3	1	5	5	4
Region of residence^a												
Northeast	13	10	17	10	8	10	22	21	22	20	34	16
Midwest	6	6	9	7	10	4	8	18	13	16	14	21
South	13	17	16	24	24	12	34	38	35	44	43	34
West	14	16	15	19	16	14	56	45	52	40	48	42
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	46	49	57	60	58	40	119	123	121	121	139	113

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	1	1	2	1	0	0	13	8	5	8	6	5
15–19	35	34	30	35	40	26	213	189	184	146	147	141
20–24	172	140	163	173	163	122	489	463	474	477	413	418
25–29	179	196	211	251	251	193	598	569	561	539	568	539
30–34	240	217	215	214	235	198	649	567	540	529	556	546
35–39	235	226	216	229	224	202	553	515	554	549	562	506
40–44	302	241	268	251	224	182	549	485	487	435	436	423
45–49	350	302	252	252	223	191	562	495	438	401	445	397
50–54	306	267	259	262	232	202	447	416	370	397	391	344
55–59	218	206	201	213	183	177	307	320	328	288	310	312
60–64	124	128	111	128	128	116	170	145	151	174	196	204
≥65	128	128	124	104	121	106	110	125	125	136	126	173
Region of residence^a												
Northeast	482	411	424	375	325	273	876	694	777	717	690	675
Midwest	186	206	168	189	191	177	563	531	480	502	522	513
South	1,560	1,378	1,362	1,452	1,415	1,204	2,961	2,842	2,712	2,586	2,629	2,584
West	63	86	95	96	92	62	259	224	243	270	314	234
U.S. dependent areas	1	4	5	0	3	1	2	7	5	4	0	2
Total	2,291	2,085	2,053	2,112	2,025	1,717	4,660	4,298	4,217	4,078	4,155	4,008
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	3	1	0	2	1
15–19	8	9	3	7	5	9	51	45	51	40	33	34
20–24	43	40	44	38	52	31	119	105	137	124	105	119
25–29	61	84	71	58	75	67	156	156	138	139	140	144
30–34	112	114	104	93	95	80	150	143	167	137	164	126
35–39	89	108	110	108	95	87	152	142	171	150	139	140
40–44	113	92	108	86	93	91	150	131	142	134	135	104
45–49	100	93	94	83	93	63	144	141	127	124	115	130
50–54	84	79	79	75	66	55	106	138	101	121	108	100
55–59	55	59	54	50	48	41	73	77	84	69	83	73
60–64	32	32	36	30	38	39	37	44	41	40	47	45
≥65	47	35	29	45	37	35	56	33	29	36	41	42
Region of residence^a												
Northeast	181	165	157	145	146	114	323	332	308	278	304	249
Midwest	36	41	34	38	38	23	64	62	70	49	57	59
South	290	317	342	314	305	278	395	406	414	465	437	448
West	98	110	100	90	106	98	240	228	272	224	219	222
U.S. dependent areas	139	112	99	85	100	84	175	131	125	97	94	80
Total	744	746	732	673	697	597	1,196	1,159	1,189	1,113	1,111	1,058

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	1	1	0	0
20–24	0	0	0	0	0	0	0	4	2	2	1	0
25–29	0	0	0	1	0	1	1	0	0	0	0	3
30–34	0	0	0	0	0	1	3	1	1	1	1	3
35–39	0	0	0	2	1	0	1	0	1	0	2	3
40–44	0	0	1	0	0	0	0	0	1	1	0	0
45–49	0	0	0	1	1	1	0	1	0	0	0	1
50–54	0	0	0	2	0	0	1	3	1	1	2	0
55–59	0	0	0	0	0	0	0	0	1	1	0	1
60–64	1	0	0	0	0	0	0	1	1	0	0	0
≥65	1	0	0	0	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	1	0	0	1	1	0	1	0	0	2
Midwest	0	0	0	0	1	0	0	0	0	2	0	0
South	0	0	0	1	1	1	1	5	1	2	1	4
West	2	0	0	4	0	2	4	5	6	3	5	5
U.S. dependent areas	0	0	0	0	0	0	0	0	1	0	0	0
Total	2	0	1	6	3	4	6	10	8	7	6	11
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	2	3	3	0	0	2
15–19	3	3	3	2	3	1	33	19	29	22	34	32
20–24	21	15	15	15	31	16	112	103	118	95	108	111
25–29	41	39	40	36	40	40	122	110	125	118	140	117
30–34	35	31	43	38	45	44	112	114	134	124	150	137
35–39	40	43	30	36	46	47	100	112	119	107	113	123
40–44	74	75	56	48	50	50	139	97	105	105	97	88
45–49	71	67	63	64	46	47	119	113	102	113	110	117
50–54	62	57	74	43	74	60	100	88	111	111	107	105
55–59	47	53	41	48	51	49	69	71	80	90	91	99
60–64	26	32	28	37	34	34	32	53	29	34	54	44
≥65	29	45	38	47	43	32	23	27	17	27	23	26
Region of residence^a												
Northeast	94	90	93	79	83	65	143	151	152	128	136	132
Midwest	71	62	52	47	49	50	165	151	152	161	167	158
South	209	227	208	227	259	232	490	456	502	505	528	543
West	76	80	79	59	69	73	163	152	164	152	195	166
U.S. dependent areas	0	0	0	1	1	0	0	1	1	0	0	1
Total	449	459	432	413	462	420	962	911	971	945	1,026	999

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	2	0	0	0	1	1
15–19	2	2	1	1	0	1	14	16	11	9	7	4
20–24	7	8	5	9	7	2	36	31	33	18	23	19
25–29	8	12	7	11	10	4	25	29	31	22	19	19
30–34	9	11	6	9	6	6	32	31	34	29	20	14
35–39	17	8	16	8	11	4	26	28	26	25	20	18
40–44	17	13	8	5	12	6	30	22	31	13	14	8
45–49	10	16	19	5	8	6	30	28	15	18	18	12
50–54	10	11	8	9	6	6	18	24	14	20	14	14
55–59	6	9	9	6	5	4	17	15	10	11	12	9
60–64	8	7	2	2	3	3	17	10	10	5	4	2
≥65	2	6	3	7	2	4	8	7	4	4	7	3
Region of residence^a												
Northeast	34	43	28	19	24	11	74	66	52	51	32	32
Midwest	12	8	8	8	7	8	28	32	26	17	34	18
South	40	45	35	36	33	22	130	120	117	87	80	51
West	10	8	12	7	4	4	21	21	22	17	12	20
U.S. dependent areas	0	0	0	0	0	0	0	0	0	1	0	0
Total	96	104	83	70	68	45	254	240	217	172	158	121
Total												
Age at diagnosis (yr)												
13–14	1	1	2	1	0	0	18	14	9	8	10	9
15–19	49	48	38	45	48	37	316	271	280	221	220	212
20–24	245	205	227	236	256	173	769	717	774	729	660	677
25–29	291	338	336	362	379	306	927	884	879	841	889	842
30–34	404	383	385	358	393	335	972	881	896	847	926	836
35–39	389	391	380	402	392	353	858	823	897	854	870	818
40–44	515	429	448	400	384	332	885	753	788	709	703	641
45–49	542	490	437	415	379	314	867	794	692	670	702	675
50–54	470	421	429	398	383	325	679	680	608	659	631	578
55–59	328	331	309	323	290	275	470	492	512	468	504	503
60–64	198	201	178	197	207	197	264	254	235	259	306	304
≥65	210	216	199	205	210	182	198	197	176	207	203	246
Region of residence^a												
Northeast	805	722	722	632	587	474	1,441	1,265	1,312	1,195	1,200	1,107
Midwest	313	328	272	291	297	262	836	800	744	753	794	772
South	2,114	1,986	1,963	2,056	2,040	1,752	4,017	3,871	3,788	3,704	3,727	3,670
West	270	302	308	279	293	257	753	686	771	719	810	710
U.S. dependent areas	139	117	104	86	104	85	176	140	132	102	94	82
Total	3,641	3,454	3,369	3,344	3,321	2,829	7,223	6,761	6,746	6,472	6,625	6,341

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	1	0	0	0	0	0	1	0	0
20–24	3	4	2	6	3	1	2	0	0	2	3	2
25–29	5	5	5	5	12	7	2	0	0	1	2	2
30–34	12	9	8	6	11	3	2	2	0	0	0	0
35–39	2	2	4	5	9	7	1	0	0	1	0	0
40–44	8	10	9	4	7	5	2	1	0	0	1	2
45–49	3	4	5	3	6	4	2	0	2	2	0	1
50–54	6	7	6	3	3	3	0	1	2	0	0	1
55–59	1	0	2	2	3	0	0	2	0	0	0	0
60–64	0	0	0	1	1	1	0	0	0	0	0	1
≥65	1	1	1	1	2	0	0	0	0	0	0	0
Region of residence^a												
Northeast	2	1	1	0	3	0	0	1	0	0	0	0
Midwest	3	3	2	3	9	4	1	0	1	0	1	0
South	12	8	9	16	15	8	0	0	1	1	1	6
West	25	29	29	18	28	19	9	5	2	6	4	3
Total	42	41	40	36	56	30	11	7	4	8	7	9
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	1	0	3	2	2	0	0	0	0	0	0
20–24	9	20	16	14	16	22	1	0	0	0	0	0
25–29	30	36	25	37	50	37	2	1	2	0	0	0
30–34	31	38	33	35	41	38	0	1	0	1	0	1
35–39	43	33	40	25	24	31	2	2	3	0	2	1
40–44	39	51	38	46	37	30	4	4	6	2	0	2
45–49	38	32	37	31	30	33	1	0	0	1	0	1
50–54	19	20	12	29	20	21	1	0	0	1	2	2
55–59	11	8	4	13	9	15	0	0	0	0	0	0
60–64	6	3	3	1	2	5	1	0	0	0	0	0
≥65	4	4	5	4	8	5	0	0	0	0	1	0
Region of residence^a												
Northeast	33	35	41	50	42	49	2	2	0	1	1	0
Midwest	17	23	26	29	24	21	1	2	3	3	0	0
South	48	52	46	34	56	62	3	0	2	0	1	1
West	133	135	100	127	117	107	6	2	6	3	2	8
Total	231	245	213	239	239	238	12	7	12	7	5	9

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	2	2	0	0	0	1	0	0	0	0	0	0
15–19	147	156	82	83	86	85	4	1	3	2	2	1
20–24	849	920	590	572	544	508	22	24	13	10	12	13
25–29	917	990	841	864	957	875	28	35	21	27	22	29
30–34	730	690	582	628	602	682	45	31	25	20	34	27
35–39	521	487	413	426	447	418	38	27	14	22	25	25
40–44	565	467	378	346	327	328	40	40	25	22	20	21
45–49	534	482	369	359	317	299	66	47	31	27	28	21
50–54	350	364	287	313	304	278	58	42	29	31	28	27
55–59	202	196	192	166	185	190	24	38	25	23	19	25
60–64	96	104	91	81	90	99	17	17	11	14	22	12
≥65	64	63	60	74	61	66	6	4	6	10	9	8
Region of residence^a												
Northeast	646	668	492	491	487	469	62	44	27	28	30	29
Midwest	790	800	630	621	658	589	56	48	34	35	33	33
South	3,128	3,088	2,458	2,490	2,446	2,481	185	177	113	125	126	119
West	411	365	303	310	329	291	45	36	29	20	31	26
Total	4,976	4,922	3,883	3,911	3,920	3,829	348	305	204	208	220	207
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	1	0	0	1	1	1	0	0	0	0	0
15–19	44	49	16	16	22	36	2	4	1	1	1	1
20–24	346	284	232	226	230	177	22	15	10	10	14	9
25–29	514	507	424	425	470	429	23	29	27	38	16	31
30–34	574	515	457	464	481	494	42	42	33	31	29	23
35–39	431	490	418	415	444	355	46	41	21	31	28	31
40–44	413	416	320	319	302	292	43	31	23	25	27	15
45–49	382	376	315	307	280	274	43	28	18	28	21	20
50–54	205	236	181	215	225	224	30	22	13	18	19	15
55–59	122	108	104	109	115	117	9	7	12	12	5	17
60–64	60	46	54	52	54	55	6	5	6	6	5	8
≥65	33	44	41	33	56	45	1	3	4	2	4	4
Region of residence^a												
Northeast	563	568	455	454	424	411	64	43	30	33	27	32
Midwest	239	234	202	209	192	160	20	18	13	19	11	13
South	1,188	1,208	1,022	1,012	1,113	1,055	80	86	59	68	61	49
West	1,133	1,062	884	905	951	873	101	80	66	82	69	80
Total	3,124	3,071	2,562	2,580	2,681	2,498	265	226	168	202	168	173

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	2	0	0	2	1	2	0	0	0	1	0	0
25–29	3	5	0	3	2	3	0	0	0	0	1	0
30–34	2	2	3	0	1	3	0	0	1	1	0	0
35–39	2	2	3	2	4	0	0	0	0	0	0	0
40–44	1	2	1	1	0	3	0	0	0	0	0	1
45–49	3	1	2	3	0	4	1	0	0	0	0	0
50–54	3	2	1	3	0	1	0	0	0	0	0	0
55–59	1	0	0	0	0	0	0	0	0	0	0	0
60–64	0	0	1	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	1	0	0	1	0	0	0	0	0	1	1	0
Midwest	1	0	1	0	0	0	0	0	0	0	0	0
South	2	0	2	3	0	6	0	0	0	0	0	1
West	13	14	8	10	8	10	1	0	1	1	0	0
Total	17	14	11	14	8	16	1	0	1	2	1	1
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	22	18	6	11	10	13	1	0	1	2	1	0
20–24	158	177	112	107	91	114	20	16	18	14	13	6
25–29	362	333	264	277	251	243	41	39	30	29	30	40
30–34	456	403	327	336	327	297	62	57	38	49	43	49
35–39	415	426	329	325	283	303	63	51	38	54	51	50
40–44	619	591	412	364	338	272	84	64	51	44	46	30
45–49	730	667	561	477	442	360	111	70	58	46	47	43
50–54	624	607	519	560	522	460	61	60	59	54	53	35
55–59	335	386	315	334	354	336	31	33	26	30	31	36
60–64	211	228	179	188	208	168	10	18	13	17	14	17
≥65	165	167	166	187	173	191	10	10	5	7	7	11
Region of residence^a												
Northeast	598	541	443	439	413	372	64	35	39	32	37	25
Midwest	763	739	602	602	564	490	58	67	52	60	49	54
South	1,691	1,731	1,369	1,266	1,220	1,244	180	164	120	128	116	120
West	1,043	991	775	859	800	651	191	150	124	127	133	118
Total	4,095	4,002	3,189	3,166	2,997	2,757	494	416	336	347	335	317

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact and injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	1	0	0	0	0	0	0	0	0	0	0	0
15–19	5	25	6	3	5	3	0	1	0	1	2	0
20–24	79	113	58	45	36	21	8	4	2	5	5	1
25–29	104	91	94	88	65	62	4	8	11	8	7	2
30–34	104	86	60	53	62	59	15	9	12	8	9	3
35–39	74	86	54	58	49	43	9	10	8	2	8	10
40–44	81	60	61	44	27	33	14	9	7	8	6	3
45–49	78	79	62	50	48	36	18	15	10	6	5	7
50–54	57	49	47	41	50	30	6	9	8	10	10	5
55–59	46	32	31	25	32	27	6	6	9	5	4	6
60–64	14	20	11	14	13	15	3	3	5	5	4	5
≥65	9	11	14	11	11	15	1	2	1	1	2	3
Region of residence^a												
Northeast	162	134	94	109	99	79	17	12	12	9	9	6
Midwest	80	89	78	64	46	53	11	11	9	7	11	7
South	298	299	230	180	156	152	36	33	27	21	27	22
West	111	128	96	80	95	60	21	21	23	21	13	11
Total	650	650	498	433	396	343	85	77	71	59	61	45
Total												
Age at diagnosis (yr)												
13–14	3	3	0	0	1	2	1	0	0	0	0	0
15–19	221	249	110	117	125	139	8	6	5	7	6	2
20–24	1,445	1,517	1,009	972	920	844	74	59	44	41	46	31
25–29	1,935	1,968	1,654	1,699	1,806	1,655	100	112	90	103	78	104
30–34	1,908	1,742	1,469	1,522	1,523	1,575	166	141	109	111	115	102
35–39	1,488	1,525	1,259	1,256	1,259	1,158	159	131	84	111	114	117
40–44	1,726	1,597	1,218	1,124	1,038	962	186	148	112	101	100	74
45–49	1,768	1,641	1,351	1,230	1,123	1,010	241	160	119	110	100	93
50–54	1,264	1,284	1,053	1,164	1,124	1,017	156	134	111	116	111	84
55–59	717	730	648	650	698	685	70	86	72	70	58	85
60–64	387	400	338	338	368	342	36	42	35	42	46	43
≥65	275	289	286	309	310	322	18	19	16	20	23	27
Region of residence^a												
Northeast	2,005	1,947	1,526	1,544	1,468	1,378	211	137	109	104	106	92
Midwest	1,892	1,888	1,540	1,527	1,491	1,316	148	146	112	124	106	107
South	6,367	6,385	5,136	5,000	5,007	5,008	483	460	323	344	333	316
West	2,869	2,724	2,195	2,309	2,329	2,010	374	294	252	260	252	246
Total	13,134	12,944	10,396	10,380	10,296	9,712	1,216	1,037	795	832	797	761

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	1	0	0	0	0	0	1	0	0
20–24	3	4	2	6	3	1	2	0	0	2	3	2
25–29	5	5	5	5	12	7	2	0	0	1	2	2
30–34	12	9	8	6	11	3	2	2	0	0	0	0
35–39	2	2	4	5	9	7	1	0	0	1	0	0
40–44	8	10	9	4	7	5	2	1	0	0	1	2
45–49	3	4	5	3	6	4	2	0	2	2	0	1
50–54	6	7	6	3	3	3	0	1	2	0	0	1
55–59	1	0	2	2	3	0	0	2	0	0	0	0
60–64	0	0	0	1	1	1	0	0	0	0	0	1
≥65	1	1	1	1	2	0	0	0	0	0	0	0
Region of residence^a												
Northeast	2	1	1	0	3	0	0	1	0	0	0	0
Midwest	3	3	2	3	9	4	1	0	1	0	1	0
South	12	8	9	16	15	8	0	0	1	1	1	6
West	25	29	29	18	28	19	9	5	2	6	4	3
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	42	41	40	36	56	30	11	7	4	8	7	9
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	1	0	3	2	2	0	0	0	0	0	0
20–24	9	20	16	14	16	22	1	0	0	0	0	0
25–29	30	36	25	38	50	37	2	1	2	0	0	0
30–34	31	38	33	35	41	40	0	1	0	1	0	1
35–39	44	33	40	25	24	31	2	2	3	0	2	1
40–44	39	51	38	46	37	30	4	4	6	2	0	2
45–49	38	32	37	31	30	33	1	0	0	1	0	1
50–54	19	20	13	29	20	21	1	0	0	1	2	2
55–59	11	8	4	13	9	15	0	0	0	0	0	0
60–64	6	3	3	1	2	5	1	0	0	0	0	0
≥65	4	4	5	4	8	5	0	0	0	0	1	0
Region of residence^a												
Northeast	33	35	41	50	42	49	2	2	0	1	1	0
Midwest	17	23	26	29	24	21	1	2	3	3	0	0
South	48	52	46	34	56	62	3	0	2	0	1	1
West	133	135	100	127	117	107	6	2	6	3	2	8
U.S. dependent areas	1	0	1	1	0	2	0	0	0	0	0	0
Total	232	245	214	240	239	240	12	7	12	7	5	9

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	2	2	0	0	0	1	0	0	0	0	0	0
15–19	147	156	82	83	86	85	4	1	3	2	2	1
20–24	849	920	590	573	544	508	22	24	13	10	12	13
25–29	918	990	841	864	957	875	28	35	21	27	22	29
30–34	730	690	582	628	602	682	45	31	25	20	34	27
35–39	522	487	413	428	447	418	38	27	14	23	25	25
40–44	566	467	379	346	327	328	40	40	25	22	20	21
45–49	534	482	370	360	317	299	66	47	31	27	28	21
50–54	350	364	287	313	304	278	58	42	29	31	28	27
55–59	202	196	192	166	185	190	24	38	25	23	19	25
60–64	96	104	91	81	90	99	17	17	11	14	22	12
≥65	64	63	60	74	61	66	6	4	6	10	9	8
Region of residence^a												
Northeast	646	668	492	491	487	469	62	44	27	28	30	29
Midwest	790	800	630	621	658	589	56	48	34	35	33	33
South	3,128	3,088	2,458	2,490	2,446	2,481	185	177	113	125	126	119
West	411	365	303	310	329	291	45	36	29	20	31	26
U.S. dependent areas	3	0	2	4	0	0	0	0	0	0	0	0
Total	4,979	4,922	3,885	3,915	3,920	3,829	348	305	204	208	220	207
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	1	0	0	1	1	1	0	0	0	0	0
15–19	44	50	18	16	24	36	2	4	1	1	1	1
20–24	357	298	246	235	239	178	22	18	10	10	14	9
25–29	535	526	434	440	478	435	25	29	27	38	16	31
30–34	584	539	471	474	493	503	43	44	33	32	31	25
35–39	442	504	429	425	464	361	53	44	23	32	31	32
40–44	432	436	332	332	311	301	46	34	27	27	33	15
45–49	402	389	329	316	292	280	46	29	20	28	23	20
50–54	216	253	188	225	236	240	31	25	15	24	21	16
55–59	127	111	107	115	118	124	11	7	12	15	8	18
60–64	62	52	60	53	56	57	6	5	6	7	6	8
≥65	37	48	45	35	57	48	3	3	4	3	4	4
Region of residence^a												
Northeast	563	568	455	454	424	411	64	43	30	33	27	32
Midwest	239	234	202	209	192	160	20	18	13	19	11	13
South	1,188	1,208	1,022	1,012	1,113	1,055	80	86	59	68	61	49
West	1,133	1,062	884	905	951	873	101	80	66	82	69	80
U.S. dependent areas	114	135	98	86	88	65	21	14	10	14	19	5
Total	3,237	3,206	2,659	2,666	2,769	2,564	286	240	178	216	188	178

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	2	0	0	2	2	2	0	0	0	1	0	0
25–29	3	5	0	4	2	3	0	0	0	0	1	0
30–34	3	2	3	0	2	3	0	0	1	1	0	0
35–39	2	2	3	2	4	0	0	0	0	0	0	0
40–44	1	2	2	1	0	3	0	0	0	0	0	1
45–49	3	1	2	3	0	4	1	0	0	0	0	0
50–54	3	2	1	4	0	2	0	0	0	0	0	0
55–59	1	0	0	0	0	1	0	0	0	0	0	0
60–64	0	0	1	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	1	0	0	1	0	0	0	0	0	1	1	0
Midwest	1	0	1	0	0	0	0	0	0	0	0	0
South	2	0	2	3	0	6	0	0	0	0	0	1
West	13	14	8	10	8	10	1	0	1	1	0	0
U.S. dependent areas	1	0	1	1	2	2	0	0	0	0	0	0
Total	18	14	12	15	10	18	1	0	1	2	1	1
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	22	18	6	11	10	13	1	0	1	2	1	0
20–24	158	177	112	107	91	114	20	16	18	14	13	6
25–29	362	333	264	277	251	243	41	39	30	29	30	40
30–34	456	403	327	336	328	297	62	57	38	49	43	49
35–39	415	426	329	325	283	303	63	51	38	54	51	50
40–44	620	591	412	364	338	272	84	64	51	44	46	30
45–49	730	667	561	477	442	360	111	70	58	46	47	43
50–54	624	607	519	561	522	460	61	60	59	54	53	35
55–59	335	386	316	334	354	336	31	33	26	30	31	36
60–64	212	228	179	188	208	168	10	18	13	17	14	17
≥65	165	167	166	187	173	191	10	10	5	7	7	11
Region of residence^a												
Northeast	598	541	443	439	413	372	64	35	39	32	37	25
Midwest	763	739	602	602	564	490	58	67	52	60	49	54
South	1,691	1,731	1,369	1,266	1,220	1,244	180	164	120	128	116	120
West	1,043	991	775	859	800	651	191	150	124	127	133	118
U.S. dependent areas	2	0	1	1	1	0	0	0	0	0	0	0
Total	4,097	4,002	3,190	3,167	2,998	2,757	494	416	336	347	335	317

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	1	0	0	0	0	0	0	0	0	0	0	0
15–19	5	25	6	3	5	3	0	1	0	1	2	0
20–24	79	113	58	45	36	21	8	4	2	5	5	1
25–29	104	91	94	88	65	62	4	8	11	8	7	2
30–34	104	86	60	53	62	59	15	9	12	8	9	3
35–39	74	86	54	58	49	43	9	10	8	2	8	10
40–44	81	60	61	44	27	33	14	9	7	8	6	3
45–49	78	79	62	50	48	36	18	15	10	6	5	7
50–54	57	49	47	41	50	30	6	9	8	10	10	5
55–59	46	32	31	25	32	27	6	6	9	5	4	6
60–64	14	20	11	14	13	15	3	3	5	5	4	5
≥65	9	11	14	11	11	15	1	2	1	1	2	3
Region of residence^a												
Northeast	162	134	94	109	99	79	17	12	12	9	9	6
Midwest	80	89	78	64	46	53	11	11	9	7	11	7
South	298	299	230	180	156	152	36	33	27	21	27	22
West	111	128	96	80	95	60	21	21	23	21	13	11
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	650	650	498	433	396	343	85	77	71	59	61	45
Total												
Age at diagnosis (yr)												
13–14	3	3	0	0	1	2	1	0	0	0	0	0
15–19	221	250	112	117	127	139	8	6	5	7	6	2
20–24	1,456	1,531	1,023	982	930	845	74	62	44	41	46	31
25–29	1,957	1,987	1,664	1,716	1,814	1,661	102	112	90	103	78	104
30–34	1,919	1,766	1,483	1,532	1,537	1,586	167	143	109	112	117	104
35–39	1,501	1,539	1,270	1,268	1,279	1,164	166	134	86	111	117	118
40–44	1,746	1,617	1,232	1,137	1,047	971	189	151	116	103	106	74
45–49	1,788	1,654	1,366	1,240	1,135	1,016	244	161	121	110	102	93
50–54	1,275	1,301	1,061	1,175	1,135	1,034	157	136	113	122	113	85
55–59	722	733	652	656	701	693	72	86	72	73	61	86
60–64	390	407	345	339	370	344	36	42	35	43	47	43
≥65	280	293	290	311	311	325	20	19	16	21	23	27
Region of residence^a												
Northeast	2,005	1,947	1,526	1,544	1,468	1,378	211	137	109	104	106	92
Midwest	1,892	1,888	1,540	1,527	1,491	1,316	148	146	112	124	106	107
South	6,367	6,385	5,136	5,000	5,007	5,008	483	460	323	344	333	316
West	2,869	2,724	2,195	2,309	2,329	2,010	374	294	252	260	252	246
U.S. dependent areas	121	135	102	93	91	69	21	15	10	14	19	5
Total	13,255	13,078	10,498	10,472	10,387	9,781	1,237	1,052	806	846	817	766

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	1	0
25–29	2	0	2	0	0	2	0	1	0	1	1	1
30–34	1	1	1	2	0	3	2	1	1	1	1	0
35–39	0	0	0	0	0	0	2	1	3	2	0	1
40–44	1	1	4	1	1	2	0	0	2	1	1	0
45–49	2	2	1	0	3	0	1	1	0	1	1	1
50–54	1	1	2	2	0	1	0	0	1	2	0	2
55–59	1	0	1	1	1	0	5	0	0	1	2	1
60–64	0	0	0	0	0	0	1	1	1	1	0	0
≥65	0	1	0	0	0	0	1	0	0	0	0	1
Region of residence^a												
Northeast	1	0	0	1	0	0	1	0	0	0	0	0
Midwest	2	0	1	0	0	1	4	0	0	2	2	0
South	1	2	4	0	0	0	3	2	3	5	1	2
West	3	4	6	5	4	7	3	4	5	4	5	5
Total	7	7	11	6	5	8	11	6	8	10	7	6
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	1	1	0	0	0	0	0	0
30–34	2	1	1	4	2	1	0	1	0	0	1	1
35–39	5	1	2	2	1	0	2	0	1	0	0	1
40–44	4	1	2	2	1	1	1	1	0	1	0	0
45–49	1	2	0	1	2	1	1	0	1	0	0	0
50–54	1	0	1	2	1	1	0	1	0	0	0	0
55–59	0	1	0	0	1	0	0	0	0	1	0	0
60–64	0	1	0	1	1	0	0	0	0	1	0	0
≥65	0	0	1	1	1	1	0	0	0	1	0	0
Region of residence^a												
Northeast	3	2	3	5	5	2	3	0	0	1	1	1
Midwest	0	0	1	0	2	1	0	0	0	0	1	0
South	4	3	5	2	2	2	0	1	1	0	0	1
West	7	2	1	6	4	1	1	2	2	2	1	1
Total	14	8	9	13	13	6	4	3	3	3	3	2

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	2	1	1	1	1	2	2	2	1	1	2
20–24	9	7	5	4	2	7	12	8	7	10	4	8
25–29	23	19	11	20	11	13	25	23	17	18	16	17
30–34	37	35	20	19	20	21	45	40	22	24	25	24
35–39	50	41	41	33	40	35	70	53	31	33	37	38
40–44	85	50	43	38	37	30	93	59	59	40	40	40
45–49	111	111	80	57	51	52	110	81	77	51	42	42
50–54	162	138	90	91	64	53	109	84	77	57	56	57
55–59	138	108	89	86	67	85	76	83	59	42	51	41
60–64	69	73	64	59	53	63	34	35	20	35	34	41
≥65	52	49	51	41	41	57	24	20	17	15	22	16
Region of residence^a												
Northeast	209	192	137	124	111	128	162	110	107	94	78	77
Midwest	79	65	38	52	48	49	78	69	61	31	46	44
South	416	336	291	253	204	213	324	279	198	174	182	180
West	37	39	28	20	24	27	37	30	24	26	23	25
Total	741	633	494	450	388	417	601	488	390	325	328	325
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	1	0	2	1	0	0	1
20–24	4	8	2	8	5	3	5	6	5	6	3	2
25–29	19	14	15	13	15	12	12	11	12	7	5	8
30–34	42	34	24	27	25	28	17	20	14	14	12	9
35–39	45	34	45	35	32	25	24	20	17	17	21	15
40–44	49	48	43	37	26	24	31	28	19	19	15	17
45–49	76	69	43	34	32	37	36	30	22	22	20	15
50–54	64	52	48	35	30	38	27	23	25	16	16	17
55–59	35	37	40	26	31	30	18	13	16	10	10	6
60–64	29	22	14	16	21	23	12	12	6	8	6	9
≥65	13	12	13	16	21	14	3	8	4	7	9	6
Region of residence^a												
Northeast	181	166	123	100	97	94	96	96	66	67	52	51
Midwest	18	15	12	20	11	12	12	6	6	6	8	6
South	109	83	85	68	76	65	44	48	41	38	32	30
West	67	65	65	61	55	63	32	24	27	16	25	17
Total	376	330	286	248	238	234	184	174	141	127	117	105

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	0	1	0	0	0	0	0	0	0
40–44	0	0	0	0	0	0	0	0	0	0	0	0
45–49	0	1	0	0	0	0	0	0	0	0	0	0
50–54	0	0	0	0	0	0	0	0	0	0	0	0
55–59	0	0	0	0	0	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	0	1	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	0	1	0	0	0	0	0	0	0	0	0	0
Total	0	1	0	0	1	0	0	0	0	0	0	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	1	0	0	2	0	0
20–24	9	2	7	5	5	5	2	1	11	6	4	10
25–29	17	8	12	18	18	11	21	16	23	23	24	18
30–34	18	24	21	22	20	24	32	31	14	26	36	29
35–39	21	25	32	17	18	29	44	30	28	40	42	44
40–44	43	31	46	37	34	27	45	42	41	37	34	33
45–49	63	58	53	46	38	37	52	55	38	40	32	34
50–54	63	58	45	51	45	42	51	53	41	37	32	41
55–59	31	44	36	25	31	31	30	24	23	29	23	30
60–64	17	21	19	20	17	23	15	16	13	11	11	11
≥65	7	13	17	11	12	11	4	7	5	8	5	5
Region of residence^a												
Northeast	50	58	49	50	52	47	74	54	47	43	45	41
Midwest	39	23	33	27	26	31	32	37	23	41	39	44
South	115	122	115	103	96	97	136	132	111	114	114	125
West	85	81	93	72	66	65	55	51	55	60	45	43
Total	289	284	290	252	238	239	297	274	236	259	242	254

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	1	0	0	0	0
20–24	0	0	1	0	0	2	2	1	1	2	0	0
25–29	2	0	2	4	2	2	7	5	3	2	3	2
30–34	6	2	6	1	1	0	7	7	4	14	7	3
35–39	2	2	5	1	2	2	10	8	7	4	5	4
40–44	7	14	3	3	1	6	13	14	7	9	2	7
45–49	14	8	6	9	4	5	17	10	11	9	7	9
50–54	16	12	9	6	8	6	8	9	10	12	9	7
55–59	15	3	14	6	6	8	5	9	5	9	7	6
60–64	10	7	6	4	6	3	2	4	5	4	3	3
≥65	4	7	5	4	8	5	1	3	3	1	1	1
Region of residence^a												
Northeast	40	21	25	13	19	14	26	25	25	11	17	15
Midwest	5	2	5	3	3	1	11	3	5	9	8	4
South	26	24	17	18	14	16	25	35	18	29	14	17
West	8	7	9	5	2	6	11	6	8	14	6	7
Total	79	55	56	39	38	37	74	69	55	63	45	43
Total												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	3	2	2	1	2	2	5	5	3	3	1	2
20–24	23	18	15	18	12	17	21	16	25	23	12	21
25–29	63	42	42	56	48	41	65	56	55	51	49	46
30–34	106	97	73	75	68	76	104	98	55	78	82	66
35–39	123	104	124	88	95	91	153	112	86	95	106	103
40–44	189	145	142	118	100	89	182	144	128	106	93	97
45–49	267	251	184	147	129	131	216	176	150	122	103	101
50–54	307	260	195	186	149	140	195	170	154	124	113	123
55–59	221	193	181	145	137	154	134	129	104	92	92	84
60–64	125	122	103	100	98	112	65	69	45	59	54	64
≥65	77	81	86	74	83	87	33	38	29	33	37	29
Region of residence^a												
Northeast	483	440	337	292	285	285	362	286	245	216	193	184
Midwest	143	106	89	103	89	95	137	116	95	89	103	98
South	671	571	516	443	392	393	533	496	372	360	343	355
West	208	200	203	170	154	169	139	116	121	121	104	98
Total	1,505	1,317	1,146	1,008	921	941	1,171	1,014	833	787	742	735

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	1	0
25–29	2	0	2	0	0	2	0	1	0	1	1	1
30–34	1	1	1	2	0	3	2	1	1	1	1	0
35–39	0	0	0	0	0	0	2	1	3	2	0	1
40–44	1	1	4	1	1	2	0	0	2	1	1	0
45–49	2	2	1	0	3	0	1	1	0	1	1	1
50–54	1	1	2	2	0	1	0	0	1	2	0	2
55–59	1	0	1	1	1	0	5	0	0	1	2	1
60–64	0	0	0	0	0	0	1	1	1	1	0	0
≥65	0	1	0	0	0	0	1	0	0	0	0	1
Region of residence^a												
Northeast	1	0	0	1	0	0	1	0	0	0	0	0
Midwest	2	0	1	0	0	1	4	0	0	2	2	0
South	1	2	4	0	0	0	3	2	3	5	1	2
West	3	4	6	5	4	7	3	4	5	4	5	5
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	7	7	11	6	5	8	11	6	8	10	7	6
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	1	1	0	0	0	0	0	0
30–34	2	1	1	4	2	1	0	1	0	0	1	1
35–39	5	1	2	2	2	0	2	0	1	0	0	1
40–44	4	1	2	2	1	1	1	1	0	0	1	0
45–49	1	2	0	1	2	1	1	0	1	0	0	0
50–54	1	0	1	2	1	1	0	1	0	0	0	0
55–59	0	1	0	0	1	0	0	0	0	1	0	0
60–64	0	1	0	1	1	0	0	0	0	1	0	0
≥65	0	0	1	1	1	1	0	0	0	1	0	0
Region of residence^a												
Northeast	3	2	3	5	5	2	3	0	0	1	1	1
Midwest	0	0	1	0	2	1	0	0	0	0	1	0
South	4	3	5	2	2	2	0	1	1	0	0	1
West	7	2	1	6	4	1	1	2	2	2	1	1
U.S. dependent areas	0	0	0	0	1	0	0	0	0	0	0	0
Total	14	8	9	13	14	6	4	3	3	3	3	2

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	2	1	1	1	1	2	2	2	1	1	2
20–24	9	7	5	4	2	7	12	8	7	10	4	8
25–29	23	19	11	20	11	13	25	23	17	18	16	17
30–34	37	35	20	19	20	21	46	40	22	24	25	24
35–39	50	41	41	33	40	35	70	53	31	33	37	38
40–44	85	50	44	39	37	30	93	59	59	40	41	40
45–49	111	111	80	57	51	52	110	81	77	51	42	43
50–54	162	138	90	91	64	53	109	84	77	57	56	57
55–59	138	108	89	86	67	85	76	83	59	42	51	41
60–64	69	73	65	59	53	63	34	35	20	35	34	41
≥65	53	49	51	41	41	57	24	20	17	15	22	16
Region of residence^a												
Northeast	209	192	137	124	111	128	162	110	107	94	78	77
Midwest	79	65	38	52	48	49	78	69	61	31	46	44
South	416	336	291	253	204	213	324	279	198	174	182	180
West	37	39	28	20	24	27	37	30	24	26	23	25
U.S. dependent areas	1	0	1	0	0	0	0	0	0	0	1	0
Total	741	633	495	450	388	417	601	488	390	325	329	325
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	1	0	2	1	0	0	1
20–24	5	10	2	8	6	3	5	6	5	6	3	2
25–29	21	18	16	14	15	12	12	14	13	7	6	8
30–34	52	42	27	32	29	29	20	20	21	15	13	10
35–39	58	46	60	41	37	30	27	24	20	20	24	15
40–44	66	55	49	42	31	26	35	29	24	19	15	17
45–49	94	82	57	43	40	40	43	43	26	23	23	16
50–54	78	66	62	43	40	46	30	28	29	17	16	17
55–59	46	49	51	33	37	34	21	16	20	10	11	7
60–64	29	25	16	19	25	26	14	13	6	9	6	9
≥65	19	14	14	17	25	15	3	8	4	8	9	6
Region of residence^a												
Northeast	181	166	123	100	97	94	96	96	66	67	52	51
Midwest	18	15	12	20	11	12	12	6	6	6	8	6
South	109	83	85	68	76	65	44	48	41	38	32	30
West	67	65	65	61	55	63	32	24	27	16	25	17
U.S. dependent areas	93	77	68	45	47	27	25	30	28	8	9	4
Total	469	406	353	293	285	261	210	203	169	135	126	109

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	0	1	0	0	0	0	0	0	0
40–44	0	0	0	0	0	0	0	0	0	0	0	0
45–49	0	1	0	0	0	0	0	0	0	0	0	0
50–54	0	0	0	1	0	0	0	0	0	0	0	0
55–59	0	0	0	0	1	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	0	1	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	0	1	0	0	0	0	0	0	0	0	0	0
U.S. dependent areas	0	0	0	0	1	0	0	0	0	0	0	0
Total	0	1	0	1	2	0	0	0	0	0	0	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	1	0	0	2	0	0
20–24	9	2	7	5	5	5	2	1	11	6	4	10
25–29	17	8	12	18	18	11	21	16	23	23	24	18
30–34	18	24	21	22	20	24	32	31	14	26	36	29
35–39	21	25	32	17	18	29	44	30	28	40	42	44
40–44	43	31	46	37	34	27	45	42	41	37	34	33
45–49	63	59	53	46	38	37	52	55	38	40	32	34
50–54	63	58	45	51	45	42	51	53	41	37	32	41
55–59	31	44	36	25	31	31	30	24	23	29	23	30
60–64	17	21	19	20	17	23	15	16	13	11	11	11
≥65	7	13	17	11	12	11	4	7	5	8	5	5
Region of residence^a												
Northeast	50	58	49	50	52	47	74	54	47	43	45	41
Midwest	39	23	33	27	26	31	32	37	23	41	39	44
South	115	122	115	103	96	97	136	132	111	114	114	125
West	85	81	93	72	66	65	55	51	55	60	45	43
U.S. dependent areas	0	1	0	1	0	0	0	0	0	0	0	0
Total	289	284	290	252	238	239	297	274	236	259	242	254

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	1	0	0	0	0
20–24	0	0	1	0	0	2	2	1	1	2	0	0
25–29	2	0	2	4	2	2	7	5	3	2	3	2
30–34	6	2	6	1	1	0	7	7	4	14	7	3
35–39	2	2	5	1	2	2	10	8	7	4	5	4
40–44	7	14	3	3	1	6	13	14	7	9	2	7
45–49	14	8	6	9	4	5	17	10	11	9	7	9
50–54	16	12	9	6	8	6	8	9	10	12	9	7
55–59	15	3	14	6	6	8	5	9	5	9	7	6
60–64	10	7	6	4	6	3	2	4	5	4	3	3
≥65	4	7	5	4	8	5	1	3	3	1	1	1
Region of residence^a												
Northeast	40	21	25	13	19	14	26	25	25	11	17	15
Midwest	5	2	5	3	3	1	11	3	5	9	8	4
South	26	24	17	18	14	16	25	35	18	29	14	17
West	8	7	9	5	2	6	11	6	8	14	6	7
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	79	55	56	39	38	37	74	69	55	63	45	43
Total												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	3	2	2	1	2	2	5	5	3	3	1	2
20–24	24	20	15	18	13	17	21	16	25	23	12	21
25–29	65	46	43	57	48	41	65	58	56	51	50	46
30–34	116	105	76	79	72	77	107	98	62	79	83	67
35–39	136	116	139	95	100	96	156	116	89	98	109	103
40–44	207	152	148	123	106	91	186	146	133	106	94	98
45–49	286	265	198	156	137	134	223	189	154	123	106	102
50–54	321	274	209	195	159	148	198	175	158	125	113	123
55–59	232	205	192	152	144	158	137	132	108	92	93	85
60–64	125	125	106	103	102	115	67	70	45	60	54	64
≥65	84	83	87	75	87	88	33	38	29	34	37	29
Region of residence^a												
Northeast	483	440	337	292	285	285	362	286	245	216	193	184
Midwest	143	106	89	103	89	95	137	116	95	89	103	98
South	671	571	516	443	392	393	533	496	372	360	343	355
West	208	200	203	170	154	169	139	116	121	121	104	98
U.S. dependent areas	94	77	69	46	49	27	25	30	29	8	10	5
Total	1,599	1,394	1,214	1,054	969	968	1,196	1,044	861	795	752	740

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	1	0	0	1	0	0
25–29	0	1	0	1	0	0	0	2	1	5	1	0
30–34	2	2	1	2	1	0	3	3	2	2	2	1
35–39	0	3	0	0	2	1	2	0	1	4	5	1
40–44	0	0	1	0	0	0	1	1	2	3	5	1
45–49	1	3	0	1	1	2	2	1	0	3	1	3
50–54	0	1	0	1	0	1	0	3	4	4	1	4
55–59	2	0	1	0	0	0	2	2	1	4	2	1
60–64	1	1	0	0	0	0	1	0	2	1	0	1
≥65	1	0	0	0	1	0	1	3	0	0	0	1
Region of residence^a												
Northeast	1	1	1	0	0	0	1	0	1	0	1	0
Midwest	1	6	0	0	1	1	2	4	2	4	6	0
South	1	1	0	1	1	1	1	4	2	16	4	3
West	4	4	3	4	4	2	8	6	8	5	6	9
Total	7	11	4	5	6	4	12	13	13	26	17	13
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	2	1	0	0	0	0
20–24	0	0	0	0	0	0	3	0	6	2	2	3
25–29	0	4	2	2	1	2	6	5	8	3	3	7
30–34	3	3	4	2	1	3	9	6	5	7	9	8
35–39	2	5	4	4	8	4	12	14	12	10	20	8
40–44	8	6	5	5	2	1	11	8	5	8	7	6
45–49	4	5	4	1	6	6	5	6	7	8	4	6
50–54	7	5	5	2	4	1	4	1	4	1	3	7
55–59	2	2	1	2	3	3	0	2	6	5	5	4
60–64	6	2	0	0	1	2	3	2	2	3	3	2
≥65	0	0	1	1	3	2	0	3	1	4	2	3
Region of residence^a												
Northeast	13	7	3	6	6	5	12	11	7	8	16	9
Midwest	6	3	6	6	6	4	8	9	7	9	9	7
South	5	9	10	3	10	10	11	11	16	14	12	16
West	7	14	9	6	6	6	24	16	25	17	19	22
Total	32	32	27	21	28	24	54	47	54	49	56	54

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	2	0	0	0	2	0	1	2	0	0
15–19	8	8	3	2	11	2	39	35	19	18	18	15
20–24	48	44	33	31	37	33	154	154	109	109	108	95
25–29	92	105	80	72	89	81	308	304	238	241	215	193
30–34	158	160	124	121	122	111	482	392	340	329	266	271
35–39	207	176	162	129	148	142	496	420	376	355	359	333
40–44	286	237	194	191	175	138	508	450	374	338	320	318
45–49	344	260	230	202	184	170	465	461	349	342	284	316
50–54	285	246	224	191	195	169	378	349	298	273	253	248
55–59	164	176	161	179	161	153	246	253	209	190	192	214
60–64	108	119	91	92	107	103	152	129	130	119	130	141
≥65	117	108	105	89	107	98	101	88	105	115	90	112
Region of residence^a												
Northeast	341	292	275	242	226	208	584	509	446	396	329	363
Midwest	151	150	110	115	129	105	329	288	287	235	263	270
South	1,273	1,142	976	888	920	848	2,264	2,122	1,703	1,663	1,512	1,527
West	52	56	46	54	61	40	154	115	110	139	130	93
Total	1,817	1,640	1,408	1,299	1,336	1,201	3,330	3,034	2,546	2,432	2,234	2,253
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	1	0	1	1
15–19	1	0	0	0	0	2	2	8	6	1	6	2
20–24	10	14	8	9	16	7	32	35	15	22	30	19
25–29	26	41	37	28	38	17	67	56	45	48	50	51
30–34	69	79	46	62	48	49	84	89	77	59	74	66
35–39	68	76	61	49	57	50	95	101	96	86	81	75
40–44	73	66	65	63	49	51	100	96	86	79	72	67
45–49	76	66	59	55	67	43	92	89	77	77	60	66
50–54	57	63	45	59	46	33	76	86	52	66	75	57
55–59	41	38	35	35	31	21	55	35	48	35	55	43
60–64	21	22	21	22	21	25	34	32	24	29	22	29
≥65	29	28	22	25	17	18	28	27	17	18	35	20
Region of residence^a												
Northeast	154	138	114	104	97	76	230	234	183	152	192	153
Midwest	32	27	18	28	26	15	42	35	32	27	33	35
South	224	245	203	215	209	170	281	276	227	234	219	211
West	62	82	63	59	58	56	113	109	103	106	117	97
Total	472	492	398	406	390	317	665	653	544	519	560	495

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	1	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	0	1
30–34	0	0	0	0	0	0	1	0	1	1	1	4
35–39	0	0	0	1	1	0	0	0	0	1	1	1
40–44	0	0	2	0	0	0	0	0	0	0	0	0
45–49	0	0	0	1	1	1	1	2	0	0	0	0
50–54	0	0	0	1	0	0	1	2	0	0	1	0
55–59	0	0	0	0	0	0	0	0	1	0	0	1
60–64	1	0	0	0	0	0	0	0	1	0	0	0
≥65	0	1	0	0	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	0	0	1	0	0	0	0	0	1
Midwest	0	0	0	0	1	0	0	0	0	1	0	1
South	0	0	1	0	1	1	0	3	1	0	0	1
West	1	1	1	3	0	0	3	2	2	1	3	4
Total	1	1	2	4	2	2	3	5	3	2	3	7
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	5	2	2	0	2	4
20–24	6	5	3	1	4	5	13	22	16	14	18	16
25–29	15	14	15	18	16	13	37	40	40	39	36	41
30–34	22	17	20	16	22	13	78	59	58	53	43	59
35–39	24	27	20	19	18	22	74	67	69	63	69	67
40–44	45	44	34	26	33	33	101	82	73	65	55	57
45–49	50	46	43	40	34	28	96	90	64	73	68	64
50–54	58	47	53	39	46	41	70	74	67	84	64	67
55–59	34	39	31	33	33	38	64	58	60	58	62	58
60–64	22	26	25	28	24	20	30	44	16	27	31	33
≥65	18	34	22	24	36	31	15	17	23	27	25	24
Region of residence^a												
Northeast	69	64	69	52	52	45	101	89	74	61	67	74
Midwest	49	29	32	33	30	34	102	91	82	81	79	78
South	135	153	117	120	144	121	295	292	263	278	247	272
West	42	51	48	39	40	43	84	84	70	83	81	67
Total	295	297	266	244	266	244	582	555	489	503	474	490

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	4	5	1	0	0	2
20–24	3	3	2	2	2	1	13	27	10	8	6	3
25–29	6	4	3	5	5	5	26	16	14	15	16	9
30–34	7	13	6	7	7	3	39	20	18	20	19	14
35–39	15	8	8	4	5	7	35	39	33	24	19	13
40–44	13	9	11	5	7	6	29	36	27	26	21	12
45–49	13	18	19	15	9	7	32	30	22	22	22	19
50–54	13	14	9	12	11	7	15	25	18	13	17	23
55–59	7	13	12	6	6	4	12	23	6	8	9	10
60–64	6	4	2	3	5	2	9	13	10	8	8	4
≥65	2	9	4	8	3	3	8	9	9	5	6	7
Region of residence^a												
Northeast	28	31	23	23	17	16	63	64	45	38	34	34
Midwest	11	7	10	5	6	2	25	16	21	16	17	15
South	44	52	39	35	30	20	112	142	91	80	73	50
West	2	4	5	5	7	7	22	21	12	15	17	17
Total	86	93	76	68	60	45	221	242	169	149	141	115
Total												
Age at diagnosis (yr)												
13–14	0	0	2	0	0	0	2	0	2	2	1	1
15–19	12	8	3	2	11	4	51	52	28	19	25	23
20–24	68	66	46	44	59	47	216	239	155	156	163	136
25–29	138	169	137	126	148	118	444	423	346	352	321	302
30–34	261	274	201	210	202	180	695	567	500	470	414	422
35–39	317	294	254	206	239	226	713	641	588	544	553	498
40–44	425	361	312	291	266	229	750	671	567	518	480	460
45–49	487	397	355	315	303	257	693	679	519	525	439	474
50–54	420	376	336	306	302	252	544	539	443	440	414	406
55–59	249	268	241	255	234	220	378	372	330	300	325	330
60–64	164	174	138	145	157	151	230	219	185	186	193	209
≥65	167	180	155	147	167	153	152	147	156	168	158	168
Region of residence^a												
Northeast	606	533	484	427	398	351	990	906	755	655	638	633
Midwest	250	222	176	187	199	161	508	442	431	374	406	406
South	1,682	1,601	1,346	1,262	1,316	1,172	2,963	2,848	2,302	2,284	2,067	2,080
West	170	211	176	170	175	154	407	353	330	367	373	309
Total	2,709	2,567	2,181	2,046	2,089	1,837	4,867	4,549	3,818	3,680	3,485	3,428

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	1	0	0	1	0	0
25–29	0	1	0	1	0	0	0	2	1	5	1	0
30–34	2	2	1	2	1	0	3	3	2	2	2	1
35–39	0	3	0	0	2	1	2	0	1	4	5	1
40–44	0	0	1	0	0	0	1	1	2	3	5	1
45–49	1	3	0	1	1	2	2	1	0	3	1	3
50–54	0	1	0	1	0	1	0	3	4	4	1	4
55–59	2	0	1	0	0	0	2	2	1	4	2	1
60–64	1	1	0	0	0	0	1	0	2	1	0	1
≥65	1	0	0	0	1	0	1	3	0	0	0	1
Region of residence^a												
Northeast	1	1	1	0	0	0	1	0	1	0	1	0
Midwest	1	6	0	0	1	1	2	4	2	4	6	0
South	1	1	0	1	1	1	1	4	2	16	4	3
West	4	4	3	4	4	2	8	6	8	5	6	9
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	7	11	4	5	6	4	12	13	13	26	17	13
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	2	1	0	0	0	0
20–24	0	0	0	0	0	0	3	0	6	2	2	3
25–29	0	4	2	2	1	2	6	5	8	3	3	7
30–34	3	3	4	2	1	3	9	6	5	7	9	8
35–39	2	5	4	4	8	4	12	14	12	10	20	8
40–44	8	6	5	5	2	1	11	8	5	8	7	6
45–49	4	5	4	1	6	6	5	6	7	8	4	6
50–54	7	5	5	2	4	1	4	1	4	1	3	7
55–59	2	2	1	2	3	3	0	2	6	5	5	4
60–64	6	2	0	0	1	2	3	2	2	3	3	2
≥65	0	0	1	1	3	2	0	3	1	4	2	3
Region of residence^a												
Northeast	13	7	3	6	6	5	12	11	7	8	16	9
Midwest	6	3	6	6	6	4	8	9	7	9	9	7
South	5	9	10	3	10	10	11	11	16	14	12	16
West	7	14	9	6	6	6	24	16	25	17	19	22
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	32	32	27	21	28	24	54	47	54	49	56	54

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	2	0	0	0	2	0	1	2	0	0
15–19	8	8	3	2	11	2	39	35	19	18	18	15
20–24	48	44	33	31	37	33	154	154	109	109	108	95
25–29	92	105	80	73	89	81	308	304	238	242	215	193
30–34	158	160	124	121	122	111	483	392	340	329	266	271
35–39	207	176	162	130	148	142	497	420	376	355	359	333
40–44	287	237	194	192	175	138	508	450	374	338	320	319
45–49	344	260	230	202	185	170	465	463	349	343	284	317
50–54	285	246	226	191	195	169	378	349	299	273	253	248
55–59	164	177	161	179	161	153	246	254	209	190	193	214
60–64	108	120	91	92	107	103	152	129	131	119	130	141
≥65	119	108	105	89	107	98	101	88	105	116	90	112
Region of residence^a												
Northeast	341	292	275	242	226	208	584	509	446	396	329	363
Midwest	151	150	110	115	129	105	329	288	287	235	263	270
South	1,273	1,142	976	888	920	848	2,264	2,122	1,703	1,663	1,512	1,527
West	52	56	46	54	61	40	154	115	110	139	130	93
U.S. dependent areas	3	2	3	2	2	0	2	3	2	3	1	3
Total	1,820	1,642	1,411	1,301	1,338	1,201	3,332	3,037	2,548	2,435	2,235	2,256
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	1	0	1	1
15–19	1	0	0	0	0	2	2	10	8	1	6	3
20–24	11	15	8	11	16	12	35	36	16	23	31	21
25–29	28	42	41	28	41	17	73	58	48	48	52	53
30–34	73	83	48	63	52	53	95	99	90	65	74	70
35–39	77	82	69	54	62	54	105	113	105	91	89	80
40–44	84	76	76	69	55	57	116	112	102	87	76	73
45–49	91	78	71	65	79	46	109	105	83	86	68	74
50–54	68	77	51	70	54	38	93	101	61	73	81	66
55–59	48	53	44	37	38	22	65	48	58	40	62	48
60–64	27	33	31	24	25	30	44	36	26	29	26	29
≥65	36	38	28	31	29	25	38	33	22	24	36	25
Region of residence^a												
Northeast	154	138	114	104	97	76	230	234	183	152	192	153
Midwest	32	27	18	28	26	15	42	35	32	27	33	35
South	224	245	203	215	209	170	281	276	227	234	219	211
West	62	82	63	59	58	56	113	109	103	106	117	97
U.S. dependent areas	73	84	68	45	60	40	110	97	76	47	41	47
Total	545	576	466	451	450	357	775	751	620	566	601	542

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	1	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	0	1
30–34	0	0	0	0	0	0	1	0	1	1	1	4
35–39	0	0	0	1	1	0	0	0	0	1	1	1
40–44	0	0	2	0	0	0	0	0	0	0	1	0
45–49	0	0	0	1	1	1	1	2	0	0	0	0
50–54	0	0	0	2	0	0	1	2	0	0	1	0
55–59	0	0	0	0	0	0	0	0	1	0	0	1
60–64	1	0	0	0	0	0	0	0	1	0	0	0
≥65	0	1	0	0	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	0	0	1	0	0	0	0	0	1
Midwest	0	0	0	0	1	0	0	0	0	1	0	1
South	0	0	1	0	1	1	0	3	1	0	0	1
West	1	1	1	3	0	0	3	2	2	1	3	4
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	1	0
Total	1	1	2	4	2	2	3	5	3	2	4	7
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	5	2	2	0	2	4
20–24	6	5	3	1	4	5	13	22	16	14	18	16
25–29	15	14	15	18	16	13	37	40	40	39	36	41
30–34	22	17	20	16	22	13	78	59	58	53	43	59
35–39	24	27	20	19	18	22	74	67	70	63	69	67
40–44	45	44	34	26	33	33	101	82	73	65	55	57
45–49	50	46	43	40	34	28	96	90	64	73	68	65
50–54	58	47	53	40	46	41	70	74	67	84	64	67
55–59	34	39	31	33	33	38	64	58	60	58	62	58
60–64	22	26	25	28	24	20	30	44	16	27	31	33
≥65	18	34	22	24	36	31	15	17	23	27	25	24
Region of residence^a												
Northeast	69	64	69	52	52	45	101	89	74	61	67	74
Midwest	49	29	32	33	30	34	102	91	82	81	79	78
South	135	153	117	120	144	121	295	292	263	278	247	272
West	42	51	48	39	40	43	84	84	70	83	81	67
U.S. dependent areas	0	0	0	1	0	0	0	0	1	0	0	1
Total	295	297	266	245	266	244	582	555	490	503	474	491

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)

	Male						Female					
	2012	2013	2014	2015	2016	2017	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	4	5	1	0	0	2
20–24	3	3	2	2	2	1	13	27	10	8	6	3
25–29	6	4	3	5	5	5	26	16	14	15	16	9
30–34	7	13	6	7	7	3	39	20	18	20	19	14
35–39	15	8	8	4	5	7	35	39	33	24	19	13
40–44	13	9	11	5	7	6	29	36	27	26	21	12
45–49	13	18	19	15	9	7	32	30	22	22	22	19
50–54	13	14	9	12	11	7	15	25	18	13	17	23
55–59	7	13	12	6	6	4	12	23	6	8	9	10
60–64	6	4	2	3	5	2	9	13	10	8	8	4
≥65	2	9	4	8	3	3	8	9	9	5	6	7
Region of residence^a												
Northeast	28	31	23	23	17	16	63	64	45	38	34	34
Midwest	11	7	10	5	6	2	25	16	21	16	17	15
South	44	52	39	35	30	20	112	142	91	80	73	50
West	2	4	5	5	7	7	22	21	12	15	17	17
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	86	93	76	68	60	45	221	242	169	149	141	115
Total												
Age at diagnosis (yr)												
13–14	0	0	2	0	0	0	2	0	2	2	1	1
15–19	12	8	3	2	11	4	51	54	30	19	25	24
20–24	69	67	46	46	59	52	219	240	156	157	164	138
25–29	140	170	141	127	151	118	450	425	349	353	323	304
30–34	265	278	203	211	206	184	707	577	513	476	414	426
35–39	326	300	262	212	245	230	724	653	597	549	561	503
40–44	437	372	323	297	272	235	766	688	583	526	485	467
45–49	503	409	367	325	315	260	710	697	525	535	447	484
50–54	431	390	345	318	310	257	561	554	453	447	420	415
55–59	256	284	250	257	241	221	388	386	340	305	333	335
60–64	170	185	148	147	162	156	240	223	188	186	197	209
≥65	175	190	161	153	179	160	162	153	161	175	159	173
Region of residence^a												
Northeast	606	533	484	427	398	351	990	906	755	655	638	633
Midwest	250	222	176	187	199	161	508	442	431	374	406	406
South	1,682	1,601	1,346	1,262	1,316	1,172	2,963	2,848	2,302	2,284	2,067	2,080
West	170	211	176	170	175	154	407	353	330	367	373	309
U.S. dependent areas	76	87	71	48	62	40	112	100	78	50	43	50
Total	2,785	2,653	2,252	2,095	2,150	1,877	4,979	4,650	3,896	3,729	3,528	3,478

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 13a. Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States

Race/ethnicity	2012		2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
American Indian/Alaska Native	0	0.0	0	0.0	3	0.7	2	0.4	0	0.0	0	0.0
Asian	14	0.6	16	0.6	10	0.4	10	0.4	10	0.4	3	0.1
Black/African American	167	2.3	120	1.7	111	1.5	88	1.2	81	1.1	60	0.8
Hispanic/Latino ^b	16	0.1	10	0.1	18	0.1	13	0.1	18	0.1	19	0.1
Native Hawaiian/Other Pacific Islander	0	0.0	0	0.0	1	1.0	0	0.0	0	0.0	1	0.9
White	32	0.1	24	0.1	29	0.1	19	0.1	17	0.1	10	0.0
Multiple races	12	0.6	14	0.6	8	0.4	8	0.3	4	0.2	6	0.3
Total	241	0.5	184	0.3	180	0.3	140	0.3	130	0.2	99	0.2

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

^b Hispanics/Latinos can be of any race.

Table 13b. Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States and 6 dependent areas

Race/ethnicity	2012	2013	2014	2015	2016	2017
	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native	0	0	3	2	0	0
Asian	14	16	10	10	10	3
Black/African American	167	120	111	88	81	60
Hispanic/Latino ^a	16	10	18	13	18	19
Native Hawaiian/Other Pacific Islander	0	0	1	0	0	1
White	32	24	29	19	17	10
Multiple races	12	14	8	8	4	6
Total	241	184	180	140	130	99

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a Hispanics/Latinos can be of any race.

Table 14a. Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States

Race/ethnicity	2012		2013		2014		2015		2016		2017		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
American Indian/Alaska Native	0	0.0	0	0.0	1	0.2	0	0.0	1	0.2	2	0.4	29
Asian ^c	1	0.0	0	0.0	0	0.0	2	0.1	1	0.0	0	0.0	51
Black/African American	9	0.1	5	0.1	48	0.7	28	0.4	26	0.4	23	0.3	5,635
Hispanic/Latino ^d	1	0.0	2	0.0	13	0.1	5	0.0	2	0.0	6	0.0	2,031
Native Hawaiian/Other Pacific Islander	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9	6
White	1	0.0	0	0.0	6	0.0	3	0.0	5	0.0	0	0.0	1,521
Multiple races	0	0.0	2	0.1	2	0.1	1	0.0	4	0.2	1	0.0	299
Total^e	12	0.0	9	0.0	70	0.1	39	0.1	39	0.1	33	0.1	9,573

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^a From the beginning of the epidemic through 2017.

^b Rates are per 100,000 population.

^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^d Hispanics/Latinos can be of any race.

^e Cumulative total includes persons whose race/ethnicity is unknown.

Table 14b. Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States and 6 dependent areas

Race/ethnicity	2012	2013	2014	2015	2016	2017	Cumulative ^a
	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native	0	0	1	0	1	2	29
Asian ^b	1	0	0	2	1	0	52
Black/African American	9	5	48	28	27	23	5,647
Hispanic/Latino ^c	1	2	13	5	2	6	2,445
Native Hawaiian/Other Pacific Islander	0	0	0	0	0	1	7
White	1	0	6	3	5	0	1,521
Multiple races	0	2	2	1	4	1	300
Total^d	12	9	70	39	40	33	10,002

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^a From the beginning of the epidemic through 2017.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Cumulative total includes persons whose race/ethnicity is unknown.

Table 15. Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992–2017—United States and 6 dependent areas

Year of diagnosis	United States	United States and dependent areas
	No.	No.
1992	901	950
1993	885	923
1994	813	839
1995	671	693
1996	516	530
1997	336	348
1998	249	256
1999	201	206
2000	133	135
2001	128	129
2002	108	115
2003	75	77
2004	58	60
2005	55	55
2006	40	43
2007	35	36
2008	39	40
2009	16	17
2010	23	23
2011	18	19
2012	12	12
2013	9	9
2014	70	70
2015	39	39
2016	39	40
2017	33	33

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

Table 16. Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2017—United States and 6 dependent areas

Transmission category ^a	Central America		Cuba		Mexico		Puerto Rico		South America		United States		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No. ^b	%
Male adult or adolescent														
Male-to-male sexual contact	390	83.6	258	87.7	880	86.6	372	66.7	619	92.7	2,432	86.9	7,436	85.6
Injection drug use	11	2.4	3	1.0	25	2.5	62	11.2	4	0.6	123	4.4	360	4.1
Male-to-male sexual contact and injection drug use	13	2.7	1	0.4	28	2.7	17	3.1	7	1.1	123	4.4	286	3.3
Heterosexual contact ^c	53	11.3	32	10.8	82	8.1	104	18.6	38	5.7	120	4.3	597	6.9
Other ^d	0	0.0	0	0.0	1	0.1	3	0.4	0	0.0	2	0.1	7	0.1
Subtotal	466	100	294	100	1,016	100	557	100	668	100	2,800	100	8,686	100
Female adult or adolescent														
Injection drug use	3	3.0	1	2.1	3	2.9	16	11.4	2	2.8	68	20.0	141	11.7
Heterosexual contact ^c	96	96.8	37	97.9	91	97.0	121	87.8	56	96.4	271	79.8	1,058	88.0
Other ^d	0	0.2	0	0.0	0	0.1	1	0.9	1	0.9	1	0.2	4	0.3
Subtotal	99	100	38	100	94	100	138	100	58	100	340	100	1,203	100
Total	565	100	332	100	1,110	100	695	100	726	100	3,140	100	9,889	100

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.

^a Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^b Total include persons whose place of birth is not among those listed and persons whose place of birth is unknown.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

**Table 17. Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2017—
United States and 6 dependent areas**

Transmission category ^a	Central America		Cuba		Mexico		Puerto Rico		South America		United States		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No. ^b	%
Male adult or adolescent														
Male-to-male sexual contact	167	76.3	78	78.3	405	78.9	116	48.7	150	86.8	905	75.2	2,564	76.0
Injection drug use	12	5.6	2	2.4	24	4.6	59	24.6	3	1.8	99	8.2	261	7.7
Male-to-male sexual contact and injection drug use	5	2.1	2	2.1	20	4.0	17	7.3	3	1.9	97	8.1	178	5.3
Heterosexual contact ^c	35	16.0	17	17.2	64	12.4	45	19.0	16	9.5	93	7.7	357	10.6
Other ^d	0	0.0	0	0.0	1	0.1	1	0.5	0	0.0	10	0.8	15	0.4
Subtotal	219	100	100	100	513	100	238	100	173	100	1,204	100	3,375	100
Female adult or adolescent														
Injection drug use	2	2.8	1	8.6	4	6.3	16	17.1	0	2.1	60	24.1	109	16.2
Heterosexual contact ^c	62	95.5	13	91.4	52	93.8	73	79.7	19	97.4	177	70.5	542	80.5
Other ^d	1	1.7	0	0.0	0	0.0	3	3.3	0	0.5	14	5.4	22	3.3
Subtotal	65	100	14	100	56	100	92	100	19	100	251	100	673	100
Total	284	100	114	100	569	100	330	100	192	100	1,455	100	4,048	100

Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.

^a Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^b Totals include persons whose place of birth is not among those listed and persons whose place of birth is unknown.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

Table 18a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at death (yr)										
<13	4	0.0	1	0.0	1	0.0	4	0.0	1	0.0
13–14	2	0.0	1	0.0	3	0.0	0	0.0	1	0.0
15–19	23	0.1	9	0.0	13	0.1	11	0.1	10	0.0
20–24	171	0.8	171	0.7	171	0.7	150	0.7	146	0.7
25–29	414	1.9	423	2.0	365	1.7	400	1.8	427	1.9
30–34	695	3.3	629	3.0	642	3.0	594	2.7	614	2.8
35–39	954	4.9	853	4.3	888	4.5	821	4.0	777	3.7
40–44	1,627	7.7	1,470	7.0	1,363	6.6	1,239	6.1	1,071	5.4
45–49	2,634	12.1	2,443	11.5	2,208	10.6	2,011	9.7	1,694	8.1
50–54	3,123	13.8	3,083	13.7	2,988	13.3	2,976	13.3	2,679	12.3
55–59	2,666	12.8	2,732	12.9	2,919	13.6	2,866	13.2	2,816	12.8
60–64	1,864	10.5	1,952	10.8	2,222	12.0	2,167	11.4	2,298	11.8
≥65	2,006	4.6	2,250	5.0	2,462	5.3	2,731	5.7	2,894	5.9
Race/ethnicity										
American Indian/Alaska Native	54	2.3	64	2.7	61	2.6	62	2.6	46	1.9
Asian ^b	72	0.5	75	0.5	63	0.4	81	0.5	95	0.5
Black/African American	7,635	19.7	7,454	19.0	7,416	18.8	7,222	18.1	6,795	16.9
Hispanic/Latino ^c	2,471	4.7	2,558	4.7	2,667	4.8	2,508	4.4	2,497	4.3
Native Hawaiian/Other Pacific Islander	7	1.3	10	1.9	8	1.5	6	1.1	12	2.1
White	5,080	2.6	4,922	2.5	5,078	2.6	5,100	2.6	5,038	2.5
Multiple races	843	14.0	930	15.0	948	14.9	985	15.0	944	14.0
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	6,363	—	6,467	—	6,577	—	6,653	—	6,506	—
Injection drug use	2,527	—	2,407	—	2,451	—	2,311	—	2,133	—
Male-to-male sexual contact and injection drug use	1,281	—	1,329	—	1,332	—	1,383	—	1,299	—
Heterosexual contact ^e	1,642	—	1,625	—	1,584	—	1,595	—	1,591	—
Perinatal	39	—	37	—	32	—	29	—	36	—
Other ^f	76	—	77	—	63	—	79	—	59	—
Subtotal	11,929	9.4	11,943	9.3	12,039	9.3	12,051	9.2	11,624	8.8

Table 18a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States (cont)

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	1,499	—	1,504	—	1,459	—	1,357	—	1,322	—
Heterosexual contact ^e	2,676	—	2,509	—	2,682	—	2,484	—	2,409	—
Perinatal	41	—	33	—	32	—	47	—	45	—
Other ^f	34	—	27	—	33	—	28	—	26	—
Subtotal	4,250	3.2	4,073	3.0	4,205	3.1	3,915	2.9	3,803	2.7
Child (<13 yrs at death)										
Perinatal	3	—	1	—	1	—	2	—	0	—
Other ^f	1	—	0	—	0	—	2	—	1	—
Subtotal	4	0.0	1	0.0	1	0.0	4	0.0	1	0.0
Region of residence^g										
Northeast	3,856	6.9	3,893	6.9	3,779	6.7	3,625	6.4	3,630	6.4
Midwest	1,909	2.8	1,788	2.6	1,840	2.7	1,818	2.7	1,720	2.5
South	7,933	6.8	7,784	6.6	8,032	6.7	7,924	6.5	7,474	6.1
West	2,485	3.4	2,552	3.4	2,594	3.5	2,603	3.4	2,604	3.4
Total^h	16,183	5.2	16,017	5.1	16,245	5.1	15,970	5.0	15,428	4.8

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

^h Includes persons whose race/ethnicity is unknown.

Table 18b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States and 6 dependent areas

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at death (yr)										
<13	4	0.0	1	0.0	1	0.0	4	0.0	1	0.0
13–14	2	0.0	1	0.0	3	0.0	0	0.0	1	0.0
15–19	24	0.1	11	0.1	13	0.1	11	0.1	11	0.1
20–24	175	0.8	174	0.8	173	0.7	152	0.7	150	0.7
25–29	427	2.0	432	2.0	372	1.7	405	1.8	433	1.9
30–34	725	3.4	653	3.0	658	3.0	616	2.8	623	2.8
35–39	999	5.1	884	4.4	908	4.5	841	4.1	801	3.8
40–44	1,675	7.9	1,507	7.1	1,401	6.7	1,276	6.2	1,101	5.5
45–49	2,714	12.4	2,532	11.8	2,271	10.8	2,065	9.8	1,742	8.2
50–54	3,205	14.0	3,174	13.9	3,086	13.5	3,073	13.6	2,737	12.4
55–59	2,721	12.9	2,796	13.0	3,005	13.8	2,933	13.3	2,886	13.0
60–64	1,909	10.6	2,001	10.9	2,283	12.2	2,214	11.5	2,349	11.9
≥65	2,070	4.7	2,319	5.1	2,544	5.4	2,789	5.8	2,972	5.9
Race/ethnicity										
American Indian/Alaska Native	54	—	64	—	61	—	62	—	46	—
Asian ^b	74	—	75	—	65	—	82	—	95	—
Black/African American	7,646	—	7,460	—	7,425	—	7,228	—	6,804	—
Hispanic/Latino ^c	2,923	—	3,014	—	3,129	—	2,907	—	2,863	—
Native Hawaiian/Other Pacific Islander	7	—	12	—	8	—	7	—	14	—
White	5,081	—	4,924	—	5,078	—	5,101	—	5,039	—
Multiple races	844	—	932	—	948	—	986	—	945	—
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	6,422	—	6,551	—	6,664	—	6,731	—	6,578	—
Injection drug use	2,692	—	2,554	—	2,595	—	2,447	—	2,250	—
Male-to-male sexual contact and injection drug use	1,310	—	1,356	—	1,358	—	1,412	—	1,327	—
Heterosexual contact ^e	1,730	—	1,710	—	1,665	—	1,654	—	1,657	—
Perinatal	41	—	39	—	32	—	30	—	42	—
Other ^f	77	—	78	—	65	—	80	—	59	—
Subtotal	12,273	9.5	12,288	9.4	12,379	9.4	12,353	9.3	11,913	8.9

Table 18b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States and 6 dependent areas (cont)

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	1,533	—	1,546	—	1,500	—	1,380	—	1,352	—
Heterosexual contact ^e	2,760	—	2,588	—	2,773	—	2,567	—	2,467	—
Perinatal	43	—	34	—	33	—	48	—	47	—
Other ^f	36	—	27	—	33	—	28	—	26	—
Subtotal	4,373	3.2	4,196	3.1	4,338	3.1	4,022	2.9	3,893	2.8
Child (<13 yrs at death)										
Perinatal	3	—	1	—	1	—	2	—	0	—
Other ^f	1	—	0	—	0	—	2	—	1	—
Subtotal	4	0.0	1	0.0	1	0.0	4	0.0	1	0.0
Region of residence^g										
Northeast	3,856	6.9	3,893	6.9	3,779	6.7	3,625	6.4	3,630	6.4
Midwest	1,909	2.8	1,788	2.6	1,840	2.7	1,818	2.7	1,720	2.5
South	7,933	6.8	7,784	6.6	8,032	6.7	7,924	6.5	7,474	6.1
West	2,485	3.4	2,552	3.4	2,594	3.5	2,603	3.4	2,604	3.4
U.S. dependent areas	467	11.6	468	11.7	473	12.0	409	10.6	379	10.0
Total^h	16,650	5.2	16,485	5.1	16,718	5.2	16,379	5.0	15,807	4.8

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

^h Includes persons whose race/ethnicity is unknown.

Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and cumulative—United States

	2012		2013		2014		2015		2016		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Age at death (yr)											
<13	1	0.0	1	0.0	0	0.0	2	0.0	0	0.0	4,958
13–14	1	0.0	0	0.0	1	0.0	0	0.0	0	0.0	293
15–19	16	0.1	6	0.0	8	0.0	6	0.0	4	0.0	1,305
20–24	128	0.6	124	0.5	117	0.5	109	0.5	87	0.4	10,154
25–29	318	1.5	313	1.5	270	1.2	299	1.3	282	1.2	47,771
30–34	554	2.6	511	2.4	493	2.3	456	2.1	452	2.1	102,990
35–39	779	4.0	701	3.6	713	3.6	646	3.2	607	2.9	129,693
40–44	1,342	6.4	1,218	5.8	1,116	5.4	1,000	5.0	864	4.4	124,680
45–49	2,229	10.3	2,039	9.6	1,823	8.7	1,664	8.0	1,407	6.7	99,894
50–54	2,584	11.4	2,559	11.3	2,505	11.1	2,494	11.2	2,211	10.1	72,613
55–59	2,186	10.5	2,247	10.6	2,366	11.0	2,358	10.8	2,314	10.5	48,255
60–64	1,502	8.4	1,583	8.7	1,803	9.7	1,739	9.1	1,822	9.3	29,702
≥65	1,541	3.6	1,748	3.9	1,917	4.1	2,094	4.4	2,237	4.5	31,105
Race/ethnicity											
American Indian/Alaska Native	41	1.8	52	2.2	43	1.8	51	2.2	37	1.6	2,017
Asian ^c	61	0.4	66	0.4	48	0.3	63	0.4	78	0.4	3,614
Black/African American	6,200	16.0	6,019	15.4	5,980	15.1	5,766	14.4	5,406	13.4	290,379
Hispanic/Latino ^d	2,114	4.0	2,180	4.0	2,253	4.1	2,118	3.7	2,074	3.6	108,240
Native Hawaiian/Other Pacific Islander	6	1.2	7	1.3	5	0.9	4	0.7	8	1.4	374
White	4,038	2.0	3,914	2.0	3,996	2.0	4,024	2.0	3,895	2.0	283,168
Multiple races	721	12.0	811	13.1	807	12.7	841	12.8	789	11.7	15,575
Transmission category^e											
Male adult or adolescent											
Male-to-male sexual contact	5,162	—	5,204	—	5,273	—	5,313	—	5,085	—	329,489
Injection drug use	2,081	—	1,987	—	2,008	—	1,905	—	1,749	—	135,457
Male-to-male sexual contact and injection drug use	1,097	—	1,131	—	1,139	—	1,169	—	1,083	—	54,702
Heterosexual contact ^f	1,334	—	1,306	—	1,286	—	1,268	—	1,277	—	40,243
Perinatal	36	—	32	—	28	—	26	—	31	—	489
Other ^g	64	—	58	—	53	—	66	—	47	—	8,822
Subtotal	9,774	7.7	9,718	7.6	9,787	7.5	9,747	7.4	9,272	7.0	569,201

Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and cumulative—United States (cont)

	2012		2013		2014		2015		2016		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Female adult or adolescent											
Injection drug use	1,238	—	1,258	—	1,194	—	1,106	—	1,074	—	60,273
Heterosexual contact ^f	2,099	—	2,019	—	2,095	—	1,944	—	1,874	—	64,676
Perinatal	41	—	32	—	31	—	45	—	44	—	631
Other ^g	28	—	22	—	25	—	23	—	22	—	3,673
Subtotal	3,406	2.5	3,331	2.5	3,345	2.5	3,118	2.3	3,015	2.2	129,254
Child (<13 yrs at death)											
Perinatal	1	—	1	—	0	—	0	—	0	—	4,500
Other ^g	0	—	0	—	0	—	2	—	0	—	458
Subtotal	1	0.0	1	0.0	0	0.0	2	0.0	0	0.0	4,958
Region of residence^h											
Northeast	3,200	5.7	3,209	5.7	3,041	5.4	2,922	5.2	2,872	5.1	215,127
Midwest	1,500	2.2	1,424	2.1	1,441	2.1	1,428	2.1	1,338	2.0	75,420
South	6,417	5.5	6,308	5.3	6,499	5.4	6,372	5.3	5,962	4.9	277,909
West	2,064	2.8	2,109	2.8	2,151	2.9	2,145	2.8	2,115	2.8	134,957
Totalⁱ	13,181	4.2	13,050	4.1	13,132	4.1	12,867	4.0	12,287	3.8	703,413

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2016.

^b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^d Hispanics/Latinos can be of any race.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

ⁱ Includes persons whose race/ethnicity is unknown.

Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and cumulative—United States and 6 dependent areas

	2012		2013		2014		2015		2016		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Age at death (yr)											
<13	1	0.0	1	0.0	0	0.0	2	0.0	0	0.0	5,201
13–14	1	0.0	0	0.0	1	0.0	0	0.0	0	0.0	303
15–19	17	0.1	8	0.0	8	0.0	6	0.0	5	0.0	1,376
20–24	131	0.6	127	0.5	119	0.5	111	0.5	91	0.4	10,689
25–29	325	1.5	315	1.4	273	1.2	303	1.3	285	1.2	50,009
30–34	572	2.7	526	2.4	506	2.3	473	2.2	458	2.1	107,261
35–39	805	4.1	720	3.6	729	3.6	659	3.2	621	2.9	134,927
40–44	1,381	6.5	1,243	5.9	1,140	5.5	1,025	5.0	886	4.4	129,283
45–49	2,290	10.4	2,103	9.8	1,867	8.8	1,706	8.1	1,438	6.8	103,290
50–54	2,649	11.6	2,625	11.5	2,581	11.3	2,566	11.4	2,255	10.2	74,934
55–59	2,227	10.6	2,295	10.7	2,435	11.2	2,407	10.9	2,362	10.6	49,605
60–64	1,536	8.5	1,622	8.8	1,849	9.8	1,777	9.2	1,857	9.4	30,621
≥65	1,586	3.6	1,796	4.0	1,980	4.2	2,138	4.4	2,291	4.6	32,297
Race/ethnicity											
American Indian/Alaska Native	41	—	52	—	43	—	51	—	37	—	2,018
Asian ^c	62	—	66	—	49	—	63	—	78	—	3,661
Black/African American	6,209	—	6,022	—	5,984	—	5,770	—	5,415	—	290,675
Hispanic/Latino ^d	2,442	—	2,502	—	2,604	—	2,417	—	2,323	—	134,144
Native Hawaiian/Other Pacific Islander	6	—	9	—	5	—	5	—	10	—	391
White	4,039	—	3,916	—	3,996	—	4,025	—	3,896	—	283,272
Multiple races	722	—	813	—	807	—	842	—	790	—	15,589
Transmission category^e											
Male adult or adolescent											
Male-to-male sexual contact	5,202	—	5,268	—	5,334	—	5,374	—	5,132	—	333,758
Injection drug use	2,204	—	2,084	—	2,119	—	2,006	—	1,829	—	146,679
Male-to-male sexual contact and injection drug use	1,123	—	1,154	—	1,161	—	1,194	—	1,107	—	56,775
Heterosexual contact ^f	1,392	—	1,368	—	1,339	—	1,311	—	1,322	—	42,909
Perinatal	38	—	34	—	28	—	27	—	35	—	521
Other ^g	65	—	58	—	55	—	66	—	47	—	8,956
Subtotal	10,024	7.8	9,966	7.6	10,037	7.6	9,976	7.5	9,473	7.1	589,598

Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and cumulative—United States and 6 dependent areas (cont)

	2012		2013		2014		2015		2016		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Female adult or adolescent											
Injection drug use	1,263	—	1,288	—	1,230	—	1,120	—	1,096	—	62,539
Heterosexual contact ^f	2,160	—	2,071	—	2,164	—	2,006	—	1,911	—	68,014
Perinatal	43	—	33	—	32	—	46	—	46	—	666
Other ^g	30	—	22	—	25	—	23	—	22	—	3,777
Subtotal	3,496	2.6	3,414	2.5	3,451	2.5	3,195	2.3	3,076	2.2	134,997
Child (<13 yrs at death)											
Perinatal	1	—	1	—	0	—	0	—	0	—	4,727
Other ^g	0	—	0	—	0	—	2	—	0	—	474
Subtotal	1	0.0	1	0.0	0	0.0	2	0.0	0	0.0	5,201
Region of residence^h											
Northeast	3,200	5.7	3,209	5.7	3,041	5.4	2,922	5.2	2,872	5.1	215,127
Midwest	1,500	2.2	1,424	2.1	1,441	2.1	1,428	2.1	1,338	2.0	75,420
South	6,417	5.5	6,308	5.3	6,499	5.4	6,372	5.3	5,962	4.9	277,909
West	2,064	2.8	2,109	2.8	2,151	2.9	2,145	2.8	2,115	2.8	134,957
U.S. dependent areas	340	8.4	331	8.3	356	9.0	306	7.9	262	6.9	26,383
Totalⁱ	13,521	4.3	13,381	4.2	13,488	4.2	13,173	4.1	12,549	3.8	729,796

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2016.

^b Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^d Hispanics/Latinos can be of any race.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

ⁱ Includes persons whose race/ethnicity is unknown.

Table 20a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Age at death (yr)																
<13	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
13–14	1	1.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
15–19	0	0.0	0	0.0	6	0.2	1	0.0	0	0.0	3	0.0	0	0.0	10	0.0
20–24	0	0.0	2	0.2	82	2.5	30	0.6	0	0.0	23	0.2	9	1.5	146	0.7
25–29	0	0.0	3	0.2	241	7.4	76	1.6	0	0.0	86	0.7	21	4.3	427	1.9
30–34	4	2.4	8	0.5	322	11.5	103	2.3	0	0.0	146	1.2	31	7.9	614	2.8
35–39	2	1.3	7	0.5	371	13.9	155	3.6	2	4.6	189	1.6	51	15.0	777	3.7
40–44	6	4.3	10	0.7	513	20.6	166	4.2	1	2.7	302	2.7	73	26.0	1,071	5.4
45–49	6	4.1	14	1.1	681	26.2	301	8.4	4	11.2	566	4.3	122	47.3	1,694	8.1
50–54	9	5.7	14	1.2	1,060	39.5	484	15.5	1	2.9	928	6.4	183	76.4	2,679	12.3
55–59	6	3.9	10	1.0	1,213	46.8	470	18.5	2	6.3	940	6.1	175	78.0	2,816	12.8
60–64	7	5.4	3	0.3	1,083	50.8	310	16.0	2	8.0	763	5.4	130	72.1	2,298	11.8
≥65	5	1.9	24	1.1	1,222	27.8	401	10.1	0	0.0	1,092	2.9	149	41.1	2,894	5.9
Transmission category^e																
Male adult or adolescent																
Male-to-male sexual contact	21	—	58	—	2,001	—	1,008	—	9	—	3,031	—	378	—	6,506	—
Injection drug use	5	—	9	—	1,053	—	470	—	0	—	454	—	142	—	2,133	—
Male-to-male sexual contact and injection drug use	6	—	3	—	402	—	222	—	0	—	558	—	108	—	1,299	—
Heterosexual contact ^f	5	—	13	—	1,060	—	206	—	0	—	242	—	65	—	1,591	—
Perinatal	1	—	0	—	21	—	7	—	0	—	5	—	2	—	36	—
Other ^g	0	—	1	—	20	—	7	—	0	—	28	—	3	—	59	—
Subtotal	38	4.0	83	1.2	4,557	29.2	1,921	8.6	9	3.9	4,318	5.1	697	32.8	11,624	8.8

Table 20a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States (cont)

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Female adult or adolescent																
Injection drug use	3	—	1	—	642	—	241	—	0	—	328	—	107	—	1,322	—
Heterosexual contact ^f	5	—	11	—	1,550	—	320	—	3	—	384	—	137	—	2,409	—
Perinatal	0	—	0	—	31	—	10	—	0	—	2	—	2	—	45	—
Other ^g	0	—	0	—	14	—	5	—	0	—	6	—	1	—	26	—
Subtotal	8	0.8	12	0.1	2,237	12.8	576	2.6	3	1.3	720	0.8	247	10.9	3,803	2.7
Child (<13 yrs at death)																
Perinatal	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Other ^g	0	—	0	—	1	—	0	—	0	—	0	—	0	—	1	—
Subtotal	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Region of residence^h																
Northeast	0	0.0	20	0.5	1,422	22.3	1,017	12.6	0	0.0	834	2.2	337	36.3	3,630	6.4
Midwest	6	1.5	6	0.3	686	9.7	128	2.4	0	0.0	790	1.5	103	8.0	1,720	2.5
South	15	1.9	21	0.5	4,195	18.0	789	3.7	2	2.3	2,114	3.0	338	15.2	7,474	6.1
West	25	2.4	48	0.6	492	14.1	563	2.5	10	2.3	1,300	3.4	166	7.2	2,604	3.4
Total	46	1.9	95	0.5	6,795	16.9	2,497	4.3	12	2.1	5,038	2.5	944	14.0	15,428	4.8

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 20b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Age at death (yr)								
<13	0	0	1	0	0	0	0	1
13–14	1	0	0	0	0	0	0	1
15–19	0	0	7	1	0	3	0	11
20–24	0	2	83	33	0	23	9	150
25–29	0	3	241	82	0	86	21	433
30–34	4	8	322	112	0	146	31	623
35–39	2	7	371	179	2	189	51	801
40–44	6	10	513	194	2	303	73	1,101
45–49	6	14	681	349	4	566	122	1,742
50–54	9	14	1,060	541	1	928	184	2,737
55–59	6	10	1,216	536	3	940	175	2,886
60–64	7	3	1,085	359	2	763	130	2,349
≥65	5	24	1,224	477	0	1,092	149	2,972
Transmission category^d								
Male adult or adolescent								
Male-to-male sexual contact	21	58	2,004	1,077	9	3,031	378	6,578
Injection drug use	5	9	1,054	586	1	454	142	2,250
Male-to-male sexual contact and injection drug use	6	3	402	249	0	558	109	1,327
Heterosexual contact ^e	5	13	1,061	271	0	242	65	1,658
Perinatal	1	0	22	12	0	5	2	42
Other ^f	0	1	20	7	0	28	3	59
Subtotal	38	83	4,564	2,201	10	4,318	698	11,913

Table 20b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	Asian ^a	Black/African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	3	1	643	270	0	329	107	1,352
Heterosexual contact ^e	5	11	1,551	375	4	384	137	2,467
Perinatal	0	0	31	12	0	2	2	47
Other ^f	0	0	14	5	0	6	1	26
Subtotal	8	12	2,239	662	4	721	247	3,893
Child (<13 yrs at end of year)								
Perinatal	0	0	0	0	0	0	0	0
Other ^f	0	0	1	0	0	0	0	1
Subtotal	0	0	1	0	0	0	0	1
Region of residence^g								
Northeast	0	20	1,422	1,017	0	834	337	3,630
Midwest	6	6	686	128	0	790	103	1,720
South	15	21	4,195	789	2	2,114	338	7,474
West	25	48	492	563	10	1,300	166	2,604
U.S. dependent areas	0	0	9	366	2	1	1	379
Total	46	95	6,804	2,863	14	5,039	945	15,807

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 21a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c
Age at death (yr)																
<13	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	4	0.1	0	0.0	0	0.0	0	0.0	0	0.0	4	0.0
20–24	0	0.0	1	0.1	56	1.7	15	0.3	0	0.0	8	0.1	7	1.1	87	0.4
25–29	0	0.0	3	0.2	170	5.2	54	1.2	0	0.0	41	0.3	14	2.8	282	1.2
30–34	2	1.2	8	0.5	244	8.7	85	1.9	0	0.0	87	0.7	26	6.6	452	2.1
35–39	2	1.3	6	0.4	294	11.0	138	3.2	0	0.0	129	1.1	38	11.2	607	2.9
40–44	5	3.6	8	0.6	435	17.4	134	3.4	1	2.7	221	1.9	60	21.4	864	4.4
45–49	4	2.7	12	0.9	564	21.7	254	7.1	3	8.4	464	3.6	106	41.1	1,407	6.7
50–54	9	5.7	13	1.1	867	32.3	420	13.5	1	2.9	743	5.1	158	65.9	2,211	10.1
55–59	6	3.9	6	0.6	983	38.0	403	15.9	2	6.3	767	5.0	147	65.5	2,314	10.5
60–64	7	5.4	2	0.2	850	39.9	250	12.9	1	4.0	597	4.2	115	63.8	1,822	9.3
≥65	2	0.8	19	0.9	939	21.3	321	8.1	0	0.0	838	2.2	118	32.5	2,237	4.5
Transmission category^d																
Male adult or adolescent																
Male-to-male sexual contact	17	—	46	—	1,548	—	822	—	7	—	2,345	—	299	—	5,085	—
Injection drug use	4	—	8	—	850	—	398	—	0	—	361	—	129	—	1,750	—
Male-to-male sexual contact and injection drug use	5	—	3	—	334	—	191	—	0	—	453	—	97	—	1,083	—
Heterosexual contact ^e	5	—	11	—	842	—	175	—	0	—	186	—	58	—	1,277	—
Perinatal	0	—	0	—	18	—	6	—	0	—	5	—	2	—	31	—
Other ^f	0	—	0	—	16	—	6	—	0	—	23	—	2	—	47	—
Subtotal	31	3.3	68	0.9	3,608	23.1	1,598	7.2	7	3.0	3,373	4.0	587	27.6	9,272	7.0

Table 21a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States (cont)

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c
Female adult or adolescent																
Injection drug use	2	—	1	—	540	—	204	—	0	—	243	—	84	—	1,074	—
Heterosexual contact ^e	4	—	9	—	1,216	—	258	—	1	—	272	—	115	—	1,874	—
Perinatal	0	—	0	—	30	—	10	—	0	—	2	—	2	—	44	—
Other ^f	0	—	0	—	12	—	4	—	0	—	5	—	1	—	22	—
Subtotal	6	0.6	10	0.1	1,798	10.3	476	2.2	1	0.4	522	0.6	202	8.9	3,015	2.2
Child (<13 yrs at death)																
Perinatal	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Other ^f	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Subtotal	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Region of residence^g																
Northeast	0	0.0	13	0.3	1,129	17.7	842	10.4	0	0.0	607	1.6	281	30.3	2,872	5.1
Midwest	3	0.7	5	0.2	529	7.5	106	2.0	0	0.0	605	1.2	90	7.0	1,338	2.0
South	13	1.6	18	0.4	3,354	14.4	646	3.0	2	2.3	1,646	2.3	283	12.7	5,962	4.9
West	21	2.0	42	0.5	394	11.3	480	2.1	6	1.4	1,037	2.7	135	5.9	2,115	2.8
Total	37	1.6	78	0.4	5,406	13.4	2,074	3.6	8	1.4	3,895	2.0	789	11.7	12,287	3.8

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 21b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Age at death (yr)								
<13	0	0	0	0	0	0	0	0
13–14	0	0	0	0	0	0	0	0
15–19	0	0	5	0	0	0	0	5
20–24	0	1	57	18	0	8	7	91
25–29	0	3	170	57	0	41	14	285
30–34	2	8	244	91	0	87	26	458
35–39	2	6	294	152	0	129	38	621
40–44	5	8	435	154	2	222	60	886
45–49	4	12	564	285	3	464	106	1,438
50–54	9	13	867	463	1	743	159	2,255
55–59	6	6	986	447	3	767	147	2,362
60–64	7	2	852	283	1	597	115	1,857
≥65	2	19	941	373	0	838	118	2,291
Transmission category^c								
Male adult or adolescent								
Male-to-male sexual contact	17	46	1,551	867	7	2,345	299	5,132
Injection drug use	4	8	851	476	1	361	129	1,829
Male-to-male sexual contact and injection drug use	5	3	334	214	0	453	98	1,107
Heterosexual contact ^d	5	11	843	218	0	186	58	1,322
Perinatal	0	0	19	9	0	5	2	35
Other ^e	0	0	16	6	0	23	2	47
Subtotal	31	68	3,615	1,790	8	3,373	588	9,473

Table 21b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	2	1	541	225	0	243	84	1,096
Heterosexual contact ^d	4	9	1,217	291	2	273	115	1,911
Perinatal	0	0	30	12	0	2	2	46
Other ^e	0	0	12	4	0	5	1	22
Subtotal	6	10	1,800	533	2	523	202	3,076
Child (<13 yrs at end of year)								
Perinatal	0	0	0	0	0	0	0	0
Other ^e	0	0	0	0	0	0	0	0
Subtotal	0	0	0	0	0	0	0	0
Region of residence^f								
Northeast	0	13	1,129	842	0	607	281	2,872
Midwest	3	5	529	106	0	605	90	1,338
South	13	18	3,354	646	2	1,646	283	5,962
West	21	42	394	480	6	1,037	135	2,115
U.S. dependent areas	0	0	9	249	2	1	1	262
Total	37	78	5,415	2,323	10	3,896	790	12,549

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^f Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 22a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	2,713	5.1	2,594	4.9	2,476	4.7	2,340	4.4	2,225	4.2
13–14	893	10.8	780	9.3	739	8.8	720	8.7	675	8.2
15–19	6,313	29.5	5,712	27.0	5,301	25.2	4,975	23.6	4,629	21.9
20–24	31,850	141.0	32,013	140.3	31,733	138.7	30,858	136.0	29,800	133.1
25–29	53,748	251.2	57,226	265.1	61,377	279.4	65,419	291.7	68,563	299.0
30–34	71,309	340.9	72,584	341.0	74,426	345.8	76,386	352.8	79,729	365.0
35–39	83,532	428.2	83,778	426.8	85,031	427.2	87,741	431.3	90,455	434.5
40–44	122,431	581.9	115,986	555.7	109,812	533.9	102,760	509.2	98,768	500.5
45–49	162,349	748.0	157,037	739.6	150,024	719.2	144,966	696.5	138,717	661.6
50–54	150,072	664.4	158,700	703.1	165,923	736.0	169,315	759.4	169,919	777.6
55–59	103,570	498.4	112,263	529.7	120,732	561.9	130,020	597.2	138,543	630.1
60–64	58,415	327.8	65,295	360.3	73,108	394.1	80,600	423.2	89,322	458.3
≥65	45,040	104.4	52,299	117.1	60,255	130.4	69,816	146.3	80,102	162.6
Race/ethnicity										
American Indian/Alaska Native	2,441	105.6	2,524	108.3	2,645	112.5	2,773	117.0	2,959	124.0
Asian ^b	10,050	64.0	10,809	66.7	11,707	69.9	12,648	73.1	13,621	76.3
Black/African American	371,422	957.9	381,498	974.6	391,895	991.6	402,561	1,008.7	413,587	1,026.6
Hispanic/Latino ^c	185,780	350.3	192,375	355.3	199,515	360.8	206,995	366.3	214,839	372.1
Native Hawaiian/Other Pacific Islander	680	130.5	717	134.6	754	138.8	822	148.2	851	150.4
White	280,244	141.8	286,019	144.7	291,615	147.4	297,019	150.1	302,283	152.8
Multiple races	40,706	678.0	41,417	669.6	41,902	657.6	42,200	643.2	42,410	628.4
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	462,027	—	481,321	—	501,533	—	521,787	—	542,000	—
Injection drug use	76,756	—	75,767	—	74,658	—	73,737	—	72,956	—
Male-to-male sexual contact and injection drug use	54,099	—	54,145	—	54,158	—	54,116	—	54,137	—
Heterosexual contact ^e	70,613	—	72,358	—	74,065	—	75,790	—	77,510	—
Perinatal	4,248	—	4,362	—	4,489	—	4,591	—	4,679	—
Other ^f	2,989	—	2,960	—	2,951	—	2,945	—	2,936	—
Subtotal	670,732	526.2	690,913	536.9	711,854	547.9	732,966	559.0	754,218	570.1

Table 22a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States (cont)

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	51,763	—	51,259	—	50,781	—	50,461	—	50,154	—
Heterosexual contact ^e	160,638	—	164,917	—	169,066	—	173,243	—	177,783	—
Perinatal	4,637	—	4,808	—	4,958	—	5,067	—	5,180	—
Other ^f	1,752	—	1,776	—	1,802	—	1,839	—	1,886	—
Subtotal	218,790	163.7	222,760	165.2	226,607	166.6	230,610	168.1	235,004	169.9
Child (<13 yrs at end of year)										
Perinatal	2,306	—	2,141	—	2,005	—	1,894	—	1,801	—
Other ^f	407	—	453	—	471	—	446	—	424	—
Subtotal	2,713	5.1	2,594	4.9	2,476	4.7	2,340	4.4	2,225	4.2
Region of residence^g										
Northeast	222,448	398.2	225,465	402.3	229,582	408.5	231,781	411.7	236,042	418.8
Midwest	105,960	157.4	109,229	161.7	112,165	165.6	114,831	169.3	118,611	174.5
South	392,077	334.3	405,257	342.2	417,593	348.9	431,307	356.2	442,353	361.3
West	171,750	233.6	176,316	237.5	181,597	242.1	187,997	247.9	194,441	253.7
Total^h	892,235	284.2	916,267	289.7	940,937	295.3	965,916	300.9	991,447	306.6

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 22b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States and 6 dependent areas

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	2,738	5.1	2,613	4.9	2,493	4.7	2,352	4.4	2,238	4.2
13–14	916	10.9	801	9.4	747	8.8	726	8.7	678	8.2
15–19	6,429	29.7	5,801	27.0	5,393	25.3	5,043	23.6	4,677	21.8
20–24	32,275	141.0	32,451	140.4	32,169	138.8	31,260	136.1	30,160	133.1
25–29	54,476	251.7	57,931	265.3	62,126	279.7	66,202	291.9	69,339	299.1
30–34	72,526	342.4	73,765	342.5	75,504	346.9	77,362	353.5	80,711	365.8
35–39	85,158	430.9	85,344	429.3	86,540	429.4	89,252	433.5	91,902	436.4
40–44	124,790	585.7	118,129	559.0	111,841	537.1	104,609	512.1	100,516	503.3
45–49	165,513	753.2	160,092	744.7	152,873	723.9	147,685	701.1	141,250	665.8
50–54	153,053	669.8	161,813	708.6	169,125	741.6	172,506	764.8	173,058	782.8
55–59	105,656	502.5	114,561	534.3	123,147	566.6	132,567	602.1	141,227	635.2
60–64	59,684	330.7	66,640	363.1	74,601	397.3	82,227	426.7	91,127	462.1
≥65	46,274	105.7	53,687	118.5	61,785	131.8	71,563	147.9	82,046	164.2
Race/ethnicity										
American Indian/Alaska Native	2,442	—	2,525	—	2,646	—	2,774	—	2,960	—
Asian ^b	10,097	—	10,856	—	11,753	—	12,699	—	13,673	—
Black/African American	371,728	—	381,811	—	392,213	—	402,872	—	413,891	—
Hispanic/Latino ^c	202,580	—	209,272	—	216,443	—	223,950	—	231,838	—
Native Hawaiian/Other Pacific Islander	702	—	738	—	776	—	848	—	881	—
White	280,301	—	286,084	—	291,690	—	297,094	—	302,359	—
Multiple races	40,723	—	41,431	—	41,916	—	42,216	—	42,427	—
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	466,026	—	485,522	—	505,944	—	526,343	—	546,730	—
Injection drug use	81,035	—	79,946	—	78,731	—	77,725	—	76,854	—
Male-to-male sexual contact and injection drug use	54,975	—	55,009	—	54,992	—	54,946	—	54,951	—
Heterosexual contact ^e	73,073	—	74,842	—	76,576	—	78,328	—	80,072	—
Perinatal	4,381	—	4,495	—	4,618	—	4,719	—	4,803	—
Other ^f	3,028	—	3,001	—	2,991	—	2,984	—	2,976	—
Subtotal	682,518	528.8	702,816	539.5	723,852	550.5	745,045	561.6	766,385	572.7

Table 22b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States and 6 dependent areas (cont)

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	52,993	—	52,466	—	51,953	—	51,608	—	51,274	—
Heterosexual contact ^e	164,704	—	169,008	—	173,149	—	177,301	—	181,828	—
Perinatal	4,763	—	4,931	—	5,078	—	5,190	—	5,298	—
Other ^f	1,771	—	1,794	—	1,819	—	1,858	—	1,906	—
Subtotal	224,232	165.5	228,199	167.0	231,999	168.4	235,957	169.9	240,306	171.6
Child (<13 yrs at end of year)										
Perinatal	2,331	—	2,160	—	2,022	—	1,906	—	1,814	—
Other ^f	407	—	453	—	471	—	446	—	424	—
Subtotal	2,738	5.1	2,613	4.9	2,493	4.7	2,352	4.4	2,238	4.2
Region of residence^g										
Northeast	222,448	398.2	225,465	402.3	229,582	408.5	231,781	411.7	236,042	418.8
Midwest	105,960	157.4	109,229	161.7	112,165	165.6	114,831	169.3	118,611	174.5
South	392,077	334.3	405,257	342.2	417,593	348.9	431,307	356.2	442,353	361.3
West	171,750	233.6	176,316	237.5	181,597	242.1	187,997	247.9	194,441	253.7
U.S. dependent areas	17,253	427.4	17,361	434.6	17,407	442.2	17,438	450.1	17,482	459.2
Total^h	909,488	286.0	933,628	291.5	958,344	297.1	983,354	302.7	1,008,929	308.3

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	323	0.6	281	0.5	301	0.6	277	0.5	287	0.5
13–14	194	2.3	153	1.8	132	1.6	129	1.6	103	1.3
15–19	1,954	9.1	1,699	8.0	1,304	6.2	975	4.6	833	3.9
20–24	8,242	36.5	8,236	36.1	7,503	32.8	6,736	29.7	5,967	26.7
25–29	16,504	77.1	17,353	80.4	17,830	81.2	18,022	80.4	18,136	79.1
30–34	28,189	134.7	28,119	132.1	27,516	127.8	27,259	125.9	27,219	124.6
35–39	40,232	206.2	39,619	201.8	38,785	194.9	38,535	189.4	38,468	184.8
40–44	67,803	322.2	63,219	302.9	58,588	284.8	53,445	264.8	49,921	253.0
45–49	99,057	456.4	94,706	446.1	88,951	426.4	84,190	404.5	78,894	376.3
50–54	96,172	425.8	101,125	448.0	104,838	465.0	105,915	475.0	104,937	480.2
55–59	68,241	328.4	73,729	347.9	78,552	365.6	84,006	385.9	89,088	405.2
60–64	38,687	217.1	43,300	238.9	48,377	260.8	53,107	278.9	58,526	300.3
≥65	30,192	70.0	34,943	78.2	40,132	86.8	46,371	97.2	52,995	107.6
Race/ethnicity										
American Indian/Alaska Native	1,316	57.0	1,348	57.8	1,387	59.0	1,427	60.2	1,488	62.3
Asian ^b	5,239	33.3	5,527	34.1	5,797	34.6	6,075	35.1	6,344	35.5
Black/African American	202,547	522.4	207,722	530.7	210,826	533.4	213,858	535.9	217,071	538.8
Hispanic/Latino ^c	109,988	207.4	112,806	208.3	114,721	207.5	116,759	206.6	118,950	206.0
Native Hawaiian/Other Pacific Islander	367	70.4	381	71.5	393	72.3	410	73.9	417	73.7
White	152,038	76.9	153,989	77.9	154,842	78.3	155,615	78.7	156,307	79.0
Multiple races	24,253	404.0	24,668	398.8	24,802	389.3	24,782	377.7	24,756	366.8
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	244,034	—	251,763	—	256,882	—	262,002	—	267,257	—
Injection drug use	51,501	—	50,843	—	49,994	—	49,101	—	48,293	—
Male-to-male sexual contact and injection drug use	34,968	—	34,873	—	34,530	—	34,184	—	33,894	—
Heterosexual contact ^e	43,154	—	44,417	—	45,302	—	46,077	—	46,908	—
Perinatal	2,341	—	2,407	—	2,448	—	2,509	—	2,549	—
Other ^f	2,040	—	2,037	—	2,021	—	1,984	—	1,958	—
Subtotal	378,039	296.6	386,341	300.2	391,177	301.1	395,857	301.9	400,859	303.0

Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States (cont)

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	31,602	—	31,367	—	31,012	—	30,700	—	30,379	—
Heterosexual contact ^e	82,204	—	84,761	—	86,518	—	88,284	—	89,938	—
Perinatal	2,522	—	2,631	—	2,692	—	2,743	—	2,804	—
Other ^f	1,100	—	1,101	—	1,109	—	1,106	—	1,107	—
Subtotal	117,428	87.8	119,860	88.9	121,331	89.2	122,833	89.5	124,228	89.8
Child (<13 yrs at end of year)										
Perinatal	300	—	258	—	268	—	242	—	248	—
Other ^f	23	—	23	—	33	—	35	—	39	—
Subtotal	323	0.6	281	0.5	301	0.6	277	0.5	287	0.5
Region of residence^g										
Northeast	131,321	235.1	132,224	235.9	132,938	236.5	132,609	235.6	133,552	237.0
Midwest	55,395	82.3	56,725	84.0	57,632	85.1	58,221	85.8	59,409	87.4
South	210,210	179.2	217,024	183.3	220,719	184.4	224,861	185.7	227,331	185.7
West	98,864	134.5	100,509	135.4	101,520	135.4	103,276	136.2	105,082	137.1
Total^h	495,790	157.9	506,482	160.2	512,809	160.9	518,967	161.7	525,374	162.5

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States and 6 dependent areas

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	328	0.6	284	0.5	304	0.6	279	0.5	290	0.5
13–14	198	2.4	158	1.9	133	1.6	130	1.6	104	1.3
15–19	1,998	9.2	1,735	8.1	1,334	6.3	994	4.7	847	4.0
20–24	8,351	36.5	8,343	36.1	7,602	32.8	6,827	29.7	6,046	26.7
25–29	16,696	77.1	17,545	80.4	18,028	81.2	18,216	80.3	18,311	79.0
30–34	28,551	134.8	28,468	132.2	27,834	127.9	27,538	125.8	27,503	124.7
35–39	40,903	207.0	40,238	202.4	39,362	195.3	39,072	189.8	38,972	185.1
40–44	68,991	323.8	64,292	304.3	59,581	286.1	54,340	266.0	50,719	254.0
45–49	100,977	459.5	96,507	448.9	90,571	428.9	85,688	406.8	80,241	378.2
50–54	98,051	429.1	103,123	451.6	106,886	468.7	107,913	478.4	106,898	483.5
55–59	69,645	331.2	75,267	351.0	80,144	368.7	85,695	389.2	90,843	408.6
60–64	39,558	219.2	44,215	240.9	49,403	263.1	54,199	281.3	59,722	302.9
≥65	31,027	70.9	35,889	79.2	41,164	87.8	47,550	98.3	54,309	108.7
Race/ethnicity										
American Indian/Alaska Native	1,317	—	1,349	—	1,388	—	1,428	—	1,489	—
Asian ^b	5,256	—	5,544	—	5,814	—	6,093	—	6,363	—
Black/African American	202,715	—	207,891	—	210,994	—	214,027	—	217,236	—
Hispanic/Latino ^c	119,236	—	122,150	—	124,018	—	125,988	—	128,134	—
Native Hawaiian/Other Pacific Islander	380	—	392	—	404	—	424	—	433	—
White	152,068	—	154,023	—	154,879	—	155,651	—	156,344	—
Multiple races	24,260	—	24,674	—	24,808	—	24,789	—	24,765	—
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	246,086	—	253,890	—	259,045	—	264,176	—	269,461	—
Injection drug use	54,018	—	53,327	—	52,420	—	51,485	—	50,640	—
Male-to-male sexual contact and injection drug use	35,528	—	35,425	—	35,067	—	34,718	—	34,424	—
Heterosexual contact ^e	44,544	—	45,830	—	46,733	—	47,518	—	48,354	—
Perinatal	2,419	—	2,487	—	2,526	—	2,585	—	2,623	—
Other ^f	2,061	—	2,059	—	2,041	—	2,004	—	1,980	—
Subtotal	384,656	298.0	393,018	301.7	397,833	302.6	402,487	303.4	407,482	304.5

Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States and 6 dependent areas (cont)

	2012		2013		2014		2015		2016	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	32,326	—	32,087	—	31,722	—	31,398	—	31,058	—
Heterosexual contact ^e	84,259	—	86,861	—	88,603	—	90,341	—	91,980	—
Perinatal	2,598	—	2,705	—	2,767	—	2,820	—	2,877	—
Other ^f	1,107	—	1,109	—	1,117	—	1,115	—	1,118	—
Subtotal	120,290	88.8	122,762	89.9	124,209	90.1	125,675	90.5	127,033	90.7
Child (<13 yrs at end of year)										
Perinatal	305	—	261	—	271	—	244	—	251	—
Other ^f	23	—	23	—	33	—	35	—	39	—
Subtotal	328	0.6	284	0.5	304	0.6	279	0.5	290	0.5
Region of residence^g										
Northeast	131,321	235.1	132,224	235.9	132,938	236.5	132,609	235.6	133,552	237.0
Midwest	55,395	82.3	56,725	84.0	57,632	85.1	58,221	85.8	59,409	87.4
South	210,210	179.2	217,024	183.3	220,719	184.4	224,861	185.7	227,331	185.7
West	98,864	134.5	100,509	135.4	101,520	135.4	103,276	136.2	105,082	137.1
U.S. dependent areas	9,484	235.0	9,582	239.9	9,537	242.3	9,474	244.5	9,431	247.7
Total^h	505,274	158.9	516,064	161.2	522,346	161.9	528,441	162.6	534,805	163.4

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 24a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Age at end of year (yr)																
<13	6	1.3	113	4.3	1,391	19.2	286	2.1	3	2.8	287	1.1	139	5.9	2,225	4.2
13–14	3	4.3	24	5.9	432	38.6	97	4.9	1	6.3	86	2.0	32	10.7	675	8.2
15–19	7	3.9	59	5.6	2,898	97.0	963	20.0	0	0.0	492	4.3	204	29.0	4,629	21.9
20–24	123	63.5	418	33.0	17,111	518.3	6,543	135.7	24	53.7	4,212	34.7	1,362	220.2	29,800	133.1
25–29	250	131.4	1,084	70.7	36,394	1,115.3	15,293	328.3	71	136.9	12,239	96.0	3,226	654.6	68,563	299.0
30–34	290	176.0	1,420	91.4	37,074	1,321.7	20,040	445.3	86	173.5	17,165	138.7	3,647	927.4	79,729	365.0
35–39	330	218.3	1,683	116.1	38,793	1,450.6	23,917	552.8	114	260.4	21,441	181.2	4,160	1,225.6	90,455	434.5
40–44	320	228.0	2,134	149.9	40,765	1,633.3	25,959	652.4	115	305.1	25,147	221.1	4,292	1,527.9	98,768	500.5
45–49	462	315.5	2,186	168.7	53,752	2,069.6	32,439	905.0	120	335.9	43,594	334.0	6,051	2,345.0	138,717	661.6
50–54	454	287.1	1,757	151.5	63,891	2,379.5	34,784	1,115.0	124	356.1	61,449	425.1	7,264	3,032.0	169,919	777.6
55–59	350	225.3	1,138	108.5	54,206	2,092.8	25,393	999.2	87	275.0	51,466	334.3	5,714	2,546.1	138,543	630.1
60–64	216	168.0	801	86.4	36,080	1,692.7	15,254	788.5	58	232.0	33,271	234.9	3,498	1,939.6	89,322	458.3
≥65	148	57.2	804	37.8	30,800	700.1	13,871	348.7	48	97.3	31,434	82.5	2,821	777.7	80,102	162.6
Transmission category^e																
Male adult or adolescent																
Male-to-male sexual contact	1,511	—	9,220	—	168,389	—	124,081	—	602	—	214,817	—	22,951	—	542,000	—
Injection drug use	218	—	432	—	35,514	—	20,254	—	23	—	13,762	—	2,660	—	72,956	—
Male-to-male sexual contact and injection drug use	272	—	374	—	15,821	—	11,602	—	41	—	22,282	—	3,685	—	54,138	—
Heterosexual contact ^f	163	—	963	—	49,108	—	15,044	—	35	—	9,612	—	2,548	—	77,510	—
Perinatal	5	—	29	—	2,670	—	1,164	—	1	—	547	—	254	—	4,679	—
Other ^g	13	—	70	—	849	—	433	—	2	—	1,429	—	134	—	2,936	—
Subtotal	2,182	230.1	11,088	154.7	272,351	1,747.4	172,579	774.5	703	304.3	262,448	312.6	32,233	1,517.4	754,218	570.1

Table 24a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States (cont)

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Female adult or adolescent																
Injection drug use	241	—	182	—	24,946	—	9,498	—	25	—	12,408	—	2,764	—	50,155	—
Heterosexual contact ^f	510	—	2,139	—	110,892	—	31,001	—	118	—	26,053	—	6,916	—	177,783	—
Perinatal	9	—	29	—	3,083	—	1,190	—	1	—	588	—	272	—	5,180	—
Other ^g	11	—	70	—	925	—	285	—	1	—	499	—	86	—	1,886	—
Subtotal	771	77.8	2,420	29.9	139,845	800.9	41,974	191.4	145	63.2	39,548	45.3	10,038	442.7	235,004	169.9
Child (<13 yrs at end of year)																
Perinatal	6	—	75	—	1,137	—	260	—	3	—	195	—	125	—	1,801	—
Other ^g	0	—	38	—	254	—	26	—	0	—	92	—	14	—	424	—
Subtotal	6	1.3	113	4.3	1,391	19.2	286	2.1	3	2.8	287	1.1	139	5.9	2,225	4.2
Region of residence^h																
Northeast	156	123.6	2,928	78.2	91,772	1,440.9	70,543	874.4	57	268.9	55,872	150.6	14,238	1,535.3	236,042	418.8
Midwest	346	84.7	1,360	62.3	51,422	726.1	13,671	258.9	40	125.6	46,709	90.3	4,936	383.6	118,611	174.5
South	730	92.2	2,743	65.8	239,648	1,026.3	69,034	320.4	146	167.7	113,558	161.6	16,322	732.3	442,353	361.3
West	1,727	162.9	6,590	85.0	30,745	882.7	61,591	269.6	608	142.8	86,144	222.2	6,914	299.8	194,441	253.7
Total	2,959	124.0	13,621	76.3	413,587	1,026.6	214,839	372.1	851	150.4	302,283	152.8	42,410	628.4	991,447	306.6

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 24b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Age at end of year (yr)								
<13	6	113	1,393	295	4	287	140	2,238
13–14	3	24	432	100	1	86	32	678
15–19	7	59	2,898	1,011	0	492	204	4,677
20–24	123	418	17,114	6,894	26	4,213	1,365	30,160
25–29	250	1,085	36,407	16,048	76	12,241	3,226	69,339
30–34	290	1,424	37,086	20,998	91	17,168	3,647	80,711
35–39	330	1,689	38,814	25,324	120	21,445	4,163	91,902
40–44	320	2,141	40,794	27,662	117	25,153	4,292	100,516
45–49	462	2,192	53,806	34,890	123	43,607	6,056	141,250
50–54	454	1,765	63,936	37,855	125	61,460	7,267	173,058
55–59	351	1,150	54,248	28,003	90	51,482	5,714	141,227
60–64	216	804	36,113	17,014	58	33,278	3,499	91,127
≥65	148	809	30,850	15,744	50	31,447	2,822	82,046
Transmission category^d								
Male adult or adolescent								
Male-to-male sexual contact	1,511	9,253	168,460	128,628	620	214,866	22,962	546,730
Injection drug use	218	439	35,551	24,104	24	13,766	2,660	76,854
Male-to-male sexual contact and injection drug use	272	375	15,828	12,401	42	22,287	3,686	54,951
Heterosexual contact ^e	164	965	49,169	17,536	38	9,616	2,548	80,072
Perinatal	5	29	2,671	1,287	1	547	254	4,803
Other ^f	13	70	849	473	2	1,429	134	2,976
Subtotal	2,183	11,130	272,527	184,428	726	262,510	32,245	766,385

Table 24b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	241	184	24,961	10,596	25	12,411	2,764	51,274
Heterosexual contact ^e	510	2,147	110,997	34,913	124	26,064	6,919	181,828
Perinatal	9	29	3,086	1,304	1	588	273	5,298
Other ^f	11	71	927	302	1	499	86	1,906
Subtotal	771	2,430	139,971	47,115	151	39,562	10,042	240,306
Child (<13 yrs at end of year)								
Perinatal	6	75	1,139	269	4	195	126	1,814
Other ^f	0	38	254	26	0	92	14	424
Subtotal	6	113	1,393	295	4	287	140	2,238
Region of residence^g								
Northeast	156	2,928	91,772	70,543	57	55,872	14,238	236,042
Midwest	346	1,360	51,422	13,671	40	46,709	4,936	118,611
South	730	2,743	239,648	69,034	146	113,558	16,322	442,353
West	1,727	6,590	30,745	61,591	608	86,144	6,914	194,441
U.S. dependent areas	1	52	304	16,999	30	76	17	17,482
Total	2,960	13,673	413,891	231,838	881	302,359	42,427	1,008,929

Note. Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 25a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Age at end of year (yr)																
<13	1	0.2	6	0.2	188	2.6	42	0.3	1	0.9	28	0.1	21	0.9	287	0.5
13–14	2	2.9	2	0.5	65	5.8	13	0.7	1	6.3	12	0.3	8	2.7	103	1.3
15–19	2	1.1	13	1.2	565	18.9	158	3.3	0	0.0	56	0.5	39	5.6	833	3.9
20–24	22	11.4	55	4.3	3,693	111.9	1,261	26.2	5	11.2	576	4.7	354	57.2	5,967	26.7
25–29	54	28.4	210	13.7	10,488	321.4	4,042	86.8	18	34.7	2,307	18.1	1,017	206.4	18,136	79.1
30–34	99	60.1	412	26.5	13,661	487.0	7,170	159.3	26	52.4	4,464	36.1	1,387	352.7	27,219	124.6
35–39	146	96.6	602	41.5	17,395	650.5	10,829	250.3	51	116.5	7,461	63.0	1,984	584.5	38,468	184.8
40–44	169	120.4	960	67.4	21,337	854.9	13,943	350.4	52	138.0	10,974	96.5	2,484	884.3	49,921	253.0
45–49	260	177.5	1,178	90.9	31,397	1,208.8	19,579	546.3	68	190.4	22,578	173.0	3,829	1,483.9	78,894	376.3
50–54	263	166.3	1,054	90.9	39,834	1,483.5	23,129	741.4	80	229.7	35,510	245.7	5,062	2,112.9	104,937	480.2
55–59	237	152.6	753	71.8	34,744	1,341.4	17,775	699.4	51	161.2	31,492	204.6	4,026	1,793.9	89,088	405.2
60–64	135	105.0	545	58.8	23,547	1,104.7	10,884	562.6	32	128.0	20,854	147.2	2,521	1,397.9	58,526	300.3
≥65	98	37.9	554	26.0	20,157	458.2	10,125	254.5	32	64.9	19,995	52.5	2,024	558.0	52,995	107.6
Transmission category^e																
Male adult or adolescent																
Male-to-male sexual contact	694	—	4,124	—	78,847	—	62,521	—	295	—	108,526	—	12,226	—	267,257	—
Injection drug use	126	—	247	—	23,281	—	14,095	—	10	—	8,572	—	1,958	—	48,293	—
Male-to-male sexual contact and injection drug use	170	—	217	—	10,413	—	7,538	—	24	—	13,028	—	2,502	—	33,894	—
Heterosexual contact ^f	94	—	580	—	28,968	—	9,991	—	20	—	5,550	—	1,699	—	46,908	—
Perinatal	2	—	12	—	1,465	—	653	—	1	—	270	—	146	—	2,549	—
Other ^g	11	—	50	—	462	—	306	—	1	—	1,032	—	97	—	1,958	—
Subtotal	1,097	115.7	5,230	73.0	143,436	920.3	95,104	426.8	351	151.9	136,979	163.2	18,628	876.9	400,859	303.0

Table 25a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States (cont)

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Female adult or adolescent																
Injection drug use	119	—	94	—	15,453	—	6,186	—	13	—	6,594	—	1,917	—	30,379	—
Heterosexual contact ^f	258	—	961	—	55,807	—	16,756	—	50	—	12,120	—	3,982	—	89,938	—
Perinatal	5	—	10	—	1,685	—	669	—	1	—	275	—	158	—	2,804	—
Other ^g	8	—	43	—	502	—	193	—	1	—	311	—	49	—	1,107	—
Subtotal	390	39.4	1,108	13.7	73,447	420.6	23,804	108.5	65	28.3	19,300	22.1	6,107	269.3	124,228	89.8
Child (<13 yrs at end of year)																
Perinatal	1	—	5	—	164	—	36	—	1	—	22	—	19	—	248	—
Other ^g	0	—	1	—	24	—	6	—	0	—	6	—	2	—	39	—
Subtotal	1	0.2	6	0.2	188	2.6	42	0.3	1	0.9	28	0.1	21	0.9	287	0.5
Region of residence^h																
Northeast	81	64.2	1,368	36.5	52,002	816.5	41,498	514.4	23	108.5	29,710	80.1	8,846	953.9	133,552	237.0
Midwest	172	42.1	581	26.6	25,453	359.4	7,345	139.1	16	50.2	23,070	44.6	2,771	215.3	59,409	87.4
South	331	41.8	1,125	27.0	123,337	528.2	35,931	166.8	48	55.1	57,252	81.5	9,302	417.4	227,331	185.7
West	904	85.3	3,270	42.2	16,279	467.4	34,176	149.6	330	77.5	46,275	119.3	3,837	166.4	105,082	137.1
Total	1,488	62.3	6,344	35.5	217,071	538.8	118,950	206.0	417	73.7	156,307	79.0	24,756	366.8	525,374	162.5

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 25b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Age at end of year								
<13	1	6	189	43	2	28	21	290
13–14	2	2	65	14	1	12	8	104
15–19	2	13	565	172	0	56	39	847
20–24	22	55	3,694	1,337	6	576	355	6,046
25–29	54	210	10,493	4,211	19	2,307	1,017	18,311
30–34	99	413	13,667	7,445	27	4,465	1,387	27,503
35–39	146	604	17,404	11,317	55	7,462	1,984	38,972
40–44	169	963	21,351	14,721	53	10,976	2,484	50,719
45–49	260	1,179	31,426	20,887	70	22,581	3,833	80,241
50–54	263	1,060	39,864	25,042	81	35,519	5,064	106,898
55–59	238	756	34,764	19,495	53	31,501	4,026	90,843
60–64	135	546	23,567	12,055	32	20,857	2,522	59,722
≥65	98	556	20,187	11,395	34	20,004	2,025	54,309
Transmission category^d								
Male adult or adolescent								
Male-to-male sexual contact	694	4,138	78,889	64,627	304	108,552	12,233	269,461
Injection drug use	126	249	23,297	16,421	11	8,574	1,958	50,640
Male-to-male sexual contact and injection drug use	170	217	10,418	8,060	24	13,032	2,502	34,424
Heterosexual contact ^e	95	580	29,007	11,395	21	5,552	1,699	48,354
Perinatal	2	12	1,466	726	1	270	146	2,623
Other ^f	11	50	462	328	1	1,032	97	1,981
Subtotal	1,098	5,246	143,539	101,557	362	137,011	18,635	407,482

Table 25b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	119	94	15,462	6,853	13	6,597	1,917	31,058
Heterosexual contact ^e	258	963	55,855	18,740	54	12,122	3,983	91,980
Perinatal	5	10	1,688	738	1	275	159	2,877
Other ^f	8	44	503	203	1	311	49	1,118
Subtotal	390	1,111	73,508	26,534	69	19,305	6,109	127,033
Child (<13 yrs at end of year)								
Perinatal	1	5	165	37	2	22	19	251
Other ^f	0	1	24	6	0	6	2	39
Subtotal	1	6	189	43	2	28	21	290
Region of residence^g								
Northeast	81	1,368	52,002	41,498	23	29,710	8,846	133,552
Midwest	172	581	25,453	7,345	16	23,070	2,771	59,409
South	331	1,125	123,337	35,931	48	57,252	9,302	227,331
West	904	3,270	16,279	34,176	330	46,275	3,837	105,082
U.S. dependent areas	1	19	165	9,184	16	37	9	9,431
Total	1,489	6,363	217,236	128,134	433	156,344	24,765	534,805

Note. Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 26. Diagnoses of HIV infection, by area of residence, 2016 and 2017—United States and 6 dependent areas

Area of residence	2016						2017					
	Adults and adolescents		Children		Total		Adults and adolescents		Children		Total	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Alabama	665	16.3	0	0.0	665	13.7	653	15.9	3	0.4	656	13.5
Alaska	37	6.1	0	0.0	37	5.0	29	4.8	0	0.0	29	3.9
Arizona	722	12.6	2	0.2	724	10.5	764	13.1	3	0.3	767	10.9
Arkansas	310	12.5	0	0.0	310	10.4	290	11.6	1	0.2	291	9.7
California	5,116	15.6	13	0.2	5,129	13.1	4,495	13.6	5	0.1	4,500	11.4
Colorado	424	9.2	0	0.0	424	7.7	440	9.4	1	0.1	441	7.9
Connecticut	261	8.5	2	0.4	263	7.3	262	8.5	2	0.4	264	7.4
Delaware	112	13.9	0	0.0	112	11.8	124	15.2	1	0.7	125	13.0
District of Columbia	343	58.2	1	1.1	344	50.3	319	53.6	2	2.0	321	46.3
Florida	4,708	26.6	18	0.6	4,726	22.9	4,783	26.6	17	0.6	4,800	22.9
Georgia	2,480	29.1	8	0.4	2,488	24.1	2,588	30.0	7	0.4	2,595	24.9
Hawaii	78	6.5	0	0.0	78	5.5	79	6.6	2	0.9	81	5.7
Idaho	47	3.4	0	0.0	47	2.8	46	3.3	0	0.0	46	2.7
Illinois	1,472	13.7	8	0.4	1,480	11.5	1,255	11.7	10	0.5	1,265	9.9
Indiana	481	8.7	1	0.1	482	7.3	517	9.3	2	0.2	519	7.8
Iowa	133	5.1	4	0.8	137	4.4	126	4.8	0	0.0	126	4.0
Kansas	146	6.1	1	0.2	147	5.1	118	4.9	0	0.0	118	4.1
Kentucky	334	9.0	2	0.3	336	7.6	349	9.4	2	0.3	351	7.9
Louisiana	1,122	28.9	2	0.2	1,124	24.0	1,031	26.6	2	0.2	1,033	22.1
Maine	53	4.6	0	0.0	53	4.0	29	2.5	0	0.0	29	2.2
Maryland	1,104	21.8	4	0.4	1,108	18.4	1,026	20.2	3	0.3	1,029	17.0
Massachusetts	633	10.8	1	0.1	634	9.3	605	10.3	2	0.2	607	8.8
Michigan	745	8.9	1	0.1	746	7.5	777	9.2	1	0.1	778	7.8
Minnesota	292	6.4	4	0.4	296	5.4	278	6.0	1	0.1	279	5.0
Mississippi	429	17.4	0	0.0	429	14.4	428	17.3	0	0.0	428	14.3
Missouri	509	10.0	7	0.7	516	8.5	504	9.8	2	0.2	506	8.3
Montana	21	2.4	1	0.6	22	2.1	32	3.6	0	0.0	32	3.0
Nebraska	76	4.9	0	0.0	76	4.0	88	5.6	0	0.0	88	4.6
Nevada	512	20.9	0	0.0	512	17.4	494	19.7	1	0.2	495	16.5
New Hampshire	40	3.5	0	0.0	40	3.0	34	2.9	0	0.0	34	2.5
New Jersey	1,161	15.3	5	0.4	1,166	13.0	1,108	14.6	1	0.1	1,109	12.3
New Mexico	138	8.0	0	0.0	138	6.6	114	6.6	0	0.0	114	5.5
New York	2,832	16.8	2	0.1	2,834	14.3	2,768	16.4	4	0.1	2,772	14.0
North Carolina	1,392	16.3	9	0.6	1,401	13.8	1,311	15.2	4	0.2	1,315	12.8
North Dakota	45	7.2	0	0.0	45	6.0	36	5.8	0	0.0	36	4.8
Ohio	976	10.0	4	0.2	980	8.4	1,020	10.4	1	0.1	1,021	8.8
Oklahoma	293	9.1	1	0.1	294	7.5	302	9.3	0	0.0	302	7.7
Oregon	223	6.4	1	0.2	224	5.5	198	5.6	0	0.0	198	4.8
Pennsylvania	1,138	10.4	3	0.2	1,141	8.9	1,093	10.0	1	0.1	1,094	8.5
Rhode Island	69	7.6	0	0.0	69	6.5	83	9.1	0	0.0	83	7.8
South Carolina	744	17.8	2	0.3	746	15.0	714	16.9	4	0.5	718	14.3
South Dakota	40	5.7	1	0.6	41	4.8	37	5.2	0	0.0	37	4.3
Tennessee	708	12.7	8	0.7	716	10.8	688	12.2	1	0.1	689	10.3
Texas	4,508	19.9	8	0.2	4,516	16.2	4,358	19.0	6	0.1	4,364	15.4
Utah	137	5.8	0	0.0	137	4.5	116	4.8	0	0.0	116	3.7
Vermont	5	0.9	0	0.0	5	0.8	19	3.5	0	0.0	19	3.0
Virginia	902	12.8	3	0.2	905	10.8	868	12.2	5	0.4	873	10.3
Washington	428	7.0	3	0.3	431	5.9	439	7.1	2	0.2	441	6.0
West Virginia	67	4.3	0	0.0	67	3.7	78	5.0	0	0.0	78	4.3
Wisconsin	227	4.7	0	0.0	227	3.9	259	5.3	0	0.0	259	4.5
Wyoming	21	4.3	0	0.0	21	3.6	10	2.1	0	0.0	10	1.7
Subtotal	39,459	14.6	130	0.2	39,589	12.2	38,182	14.0	99	0.2	38,281	11.8
U.S. dependent areas												
American Samoa	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Guam	4	3.2	0	0.0	4	2.4	6	4.7	0	0.0	6	3.6
Northern Mariana Islands	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Puerto Rico	534	18.2	0	0.0	534	15.7	445	15.4	0	0.0	445	13.3
Republic of Palau	2	11.2	0	0.0	2	9.4	0	0.0	0	0.0	0	0.0
U.S. Virgin Islands	13	14.7	0	0.0	13	12.1	7	7.9	0	0.0	7	6.5
Subtotal	553	17.0	0	0.0	553	14.5	458	14.3	0	0.0	458	12.3
Total	40,012	14.6	130	0.2	40,142	12.3	38,640	14.0	99	0.2	38,739	11.8

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address). Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

Table 27. Stage 3 (AIDS), by area of residence, 2016, 2017, and cumulative—United States and 6 dependent areas

Area of residence	2016						2017						Cumulative ^a		
	Adults and adolescents		Children		Total		Adults and adolescents		Children		Total				
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	Adults and adolescents	Children	Total
Alabama	298	7.3	1	0.1	299	6.2	294	7.2	0	0.0	294	6.0	12,571	80	12,651
Alaska	22	3.6	0	0.0	22	3.0	13	2.2	0	0.0	13	1.8	861	6	867
Arizona	293	5.1	0	0.0	293	4.2	306	5.2	2	0.2	308	4.4	14,512	51	14,563
Arkansas	110	4.4	0	0.0	110	3.7	141	5.6	0	0.0	141	4.7	5,412	38	5,450
California	2,201	6.7	5	0.1	2,206	5.6	1,879	5.7	0	0.0	1,879	4.8	177,127	714	177,841
Colorado	178	3.8	0	0.0	178	3.2	171	3.6	0	0.0	171	3.0	11,320	34	11,354
Connecticut	140	4.6	0	0.0	140	3.9	121	3.9	0	0.0	121	3.4	16,943	184	17,127
Delaware	71	8.8	0	0.0	71	7.5	58	7.1	0	0.0	58	6.0	4,548	29	4,577
District of Columbia	187	31.7	0	0.0	187	27.3	147	24.7	0	0.0	147	21.2	20,928	191	21,119
Florida	2,239	12.7	3	0.1	2,242	10.9	2,179	12.1	8	0.3	2,187	10.4	136,876	1,571	138,447
Georgia	1,104	13.0	4	0.2	1,108	10.7	1,295	15.0	6	0.3	1,301	12.5	51,268	264	51,532
Hawaii	33	2.7	0	0.0	33	2.3	31	2.6	2	0.9	33	2.3	3,566	20	3,586
Idaho	24	1.8	0	0.0	24	1.4	19	1.4	0	0.0	19	1.1	888	4	892
Illinois	682	6.3	3	0.1	685	5.3	604	5.6	3	0.1	607	4.7	44,109	288	44,397
Indiana	231	4.2	0	0.0	231	3.5	251	4.5	1	0.1	252	3.8	11,513	63	11,576
Iowa	61	2.3	1	0.2	62	2.0	60	2.3	0	0.0	60	1.9	2,509	15	2,524
Kansas	59	2.5	0	0.0	59	2.0	61	2.5	0	0.0	61	2.1	3,673	17	3,690
Kentucky	181	4.9	0	0.0	181	4.1	157	4.2	0	0.0	157	3.5	6,770	39	6,809
Louisiana	559	14.4	1	0.1	560	12.0	503	13.0	3	0.4	506	10.8	25,355	150	25,505
Maine	16	1.4	0	0.0	16	1.2	22	1.9	1	0.6	23	1.7	1,427	10	1,437
Maryland	583	11.5	1	0.1	584	9.7	581	11.4	0	0.0	581	9.6	40,162	339	40,501
Massachusetts	271	4.6	0	0.0	271	4.0	269	4.6	1	0.1	270	3.9	24,736	233	24,969
Michigan	378	4.5	1	0.1	379	3.8	334	4.0	0	0.0	334	3.4	20,099	121	20,220
Minnesota	133	2.9	0	0.0	133	2.4	145	3.1	0	0.0	145	2.6	6,952	33	6,985
Mississippi	275	11.1	0	0.0	275	9.2	246	9.9	0	0.0	246	8.2	10,050	58	10,108
Missouri	228	4.5	2	0.2	230	3.8	176	3.4	1	0.1	177	2.9	14,352	68	14,420
Montana	15	1.7	0	0.0	15	1.4	11	1.2	0	0.0	11	1.0	560	3	563
Nebraska	35	2.2	0	0.0	35	1.8	33	2.1	0	0.0	33	1.7	2,100	12	2,112
Nevada	241	9.8	0	0.0	241	8.2	192	7.7	0	0.0	192	6.4	8,245	28	8,273
New Hampshire	22	1.9	0	0.0	22	1.6	12	1.0	0	0.0	12	0.9	1,353	10	1,363
New Jersey	527	7.0	2	0.1	529	5.9	488	6.4	1	0.1	489	5.4	58,875	812	59,687
New Mexico	63	3.6	1	0.3	64	3.1	45	2.6	0	0.0	45	2.2	3,520	10	3,530
New York	1,605	9.5	3	0.1	1,608	8.1	1,451	8.6	1	0.0	1,452	7.3	201,308	2,420	203,728
North Carolina	598	7.0	1	0.1	599	5.9	592	6.9	0	0.0	592	5.8	24,925	145	25,070
North Dakota	15	2.4	0	0.0	15	2.0	14	2.2	0	0.0	14	1.9	249	2	251

Table 27. Stage 3 (AIDS), by area of residence, 2016, 2017, and cumulative—United States and 6 dependent areas (cont)

Area of residence	2016						2017						Cumulative ^a		
	Adults and adolescents		Children		Total		Adults and adolescents		Children		Total		Adults and adolescents	Children	Total
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b			
Ohio	475	4.9	0	0.0	475	4.1	421	4.3	0	0.0	421	3.6	21,293	151	21,444
Oklahoma	152	4.7	1	0.1	153	3.9	145	4.5	0	0.0	145	3.7	6,671	27	6,698
Oregon	100	2.9	0	0.0	100	2.4	95	2.7	0	0.0	95	2.3	7,735	18	7,753
Pennsylvania	541	5.0	1	0.1	542	4.2	559	5.1	1	0.1	560	4.4	42,919	372	43,291
Rhode Island	29	3.2	0	0.0	29	2.7	37	4.0	0	0.0	37	3.5	3,193	29	3,222
South Carolina	366	8.8	1	0.1	367	7.4	429	10.1	1	0.1	430	8.6	19,201	122	19,323
South Dakota	21	3.0	0	0.0	21	2.4	9	1.3	0	0.0	9	1.0	415	7	422
Tennessee	307	5.5	0	0.0	307	4.6	308	5.5	1	0.1	309	4.6	17,770	71	17,841
Texas	2,078	9.2	5	0.1	2,083	7.5	1,903	8.3	0	0.0	1,903	6.7	97,391	411	97,802
Utah	47	2.0	0	0.0	47	1.5	41	1.7	0	0.0	41	1.3	2,954	21	2,975
Vermont	7	1.3	0	0.0	7	1.1	13	2.4	0	0.0	13	2.1	572	6	578
Virginia	387	5.5	1	0.1	388	4.6	370	5.2	0	0.0	370	4.4	22,631	191	22,822
Washington	170	2.8	1	0.1	171	2.3	191	3.1	0	0.0	191	2.6	14,898	33	14,931
West Virginia	43	2.8	0	0.0	43	2.4	39	2.5	0	0.0	39	2.1	2,040	11	2,051
Wisconsin	103	2.1	0	0.0	103	1.8	104	2.1	0	0.0	104	1.8	6,083	39	6,122
Wyoming	11	2.3	0	0.0	11	1.9	6	1.3	0	0.0	6	1.0	348	2	350
Subtotal	18,515	6.8	39	0.1	18,554	5.7	17,571	6.4	33	0.1	17,604	5.4	1,235,776	9,573	1,245,349
U.S. dependent areas															
American Samoa	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0	1
Guam	5	4.0	0	0.0	5	3.0	4	3.2	0	0.0	4	2.4	109	2	111
Northern Mariana Islands	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	7	0	7
Puerto Rico	263	9.0	0	0.0	263	7.7	190	6.6	0	0.0	190	5.7	35,080	406	35,486
Republic of Palau	1	5.6	0	0.0	1	4.7	0	0.0	0	0.0	0	0.0	6	0	6
U.S. Virgin Islands	8	9.1	1	5.2	9	8.4	5	5.7	0	0.0	5	4.7	806	21	827
Subtotal	277	8.5	1	0.2	278	7.3	199	6.2	0	0.0	199	5.3	36,009	429	36,438
Total	18,792	6.9	40	0.1	18,832	5.8	17,770	6.4	33	0.1	17,803	5.4	1,271,785	10,002	1,281,787

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2017.

^b Rates are per 100,000 population.

Table 28. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Alabama	5	21.0	33	58.8	8,037	758.8	405	285.0	3	153.5	3,435	124.9	679	1,493.5	12,643	309.9
Alaska	171	207.4	22	56.7	100	492.9	69	183.6	3	42.6	285	73.7	41	129.9	691	114.3
Arizona	599	274.7	195	103.5	1,991	841.0	4,686	287.3	19	182.3	7,710	229.1	431	479.8	15,676	273.1
Arkansas	5	26.8	17	45.0	2,401	647.5	364	232.6	5	86.6	2,437	131.2	283	820.8	5,516	222.3
California	316	224.7	4,894	100.2	21,235	1,127.1	46,251	389.7	232	192.1	48,831	372.2	4,361	594.5	126,129	385.1
Colorado	66	220.5	128	87.8	1,796	992.6	2,686	299.4	12	202.7	7,209	219.6	265	323.6	12,215	264.2
Connecticut	10	163.5	91	65.7	3,415	1,134.2	3,487	799.7	5	481.2	3,047	141.9	230	578.4	10,286	335.1
Delaware	3	116.0	7	22.0	1,857	1,097.4	263	415.3	1	373.1	935	177.7	125	956.8	3,191	395.7
District of Columbia	11	854.0	72	283.2	10,459	3,939.5	1,138	1,943.3	8	2,787.5	2,303	1,013.6	499	4,544.6	14,495	2,459.9
Florida	61	131.9	515	104.6	49,547	1,896.2	25,134	588.3	42	385.4	30,189	301.0	2,512	1,158.8	108,003	610.8
Georgia	23	114.2	233	67.5	35,166	1,343.6	3,559	505.3	15	300.5	9,776	207.1	2,565	2,285.5	51,350	602.4
Hawaii	9	337.3	392	83.1	158	680.7	297	284.9	236	214.4	1,262	446.2	269	130.6	2,623	218.4
Idaho	13	85.6	8	40.3	96	1,078.9	171	114.9	2	88.0	775	67.4	37	170.5	1,102	80.7
Illinois	32	192.8	455	76.7	16,703	1,116.5	6,826	410.0	21	720.9	9,790	142.8	1,899	1,520.4	35,728	332.3
Indiana	7	53.6	185	152.4	3,956	800.0	1,027	315.3	1	53.9	5,415	120.7	406	579.0	10,997	199.5
Iowa	5	68.0	54	84.7	509	610.6	249	192.3	0	0.0	1,602	70.0	136	471.2	2,555	98.1
Kansas	9	46.2	35	49.3	732	540.3	502	206.1	1	51.9	1,493	79.6	151	334.9	2,926	122.4
Kentucky	5	61.3	49	92.6	2,245	771.1	467	423.8	1	50.3	3,810	119.0	257	568.7	6,836	184.3
Louisiana	30	120.5	66	93.6	13,742	1,137.0	935	517.7	6	383.9	4,936	209.9	367	909.1	20,085	517.8
Maine	7	98.3	7	51.2	240	1,710.1	101	629.7	0	0.0	1,146	105.4	41	286.5	1,543	133.9
Maryland	18	144.3	205	62.2	23,913	1,607.6	2,179	495.4	3	118.7	4,225	156.7	1,963	2,203.6	32,506	642.8
Massachusetts	28	271.3	395	103.1	5,836	1,470.7	5,380	888.2	5	219.5	8,069	184.2	345	440.5	20,060	342.5
Michigan	27	57.1	131	51.4	8,613	765.7	906	250.0	3	135.9	5,236	81.0	501	367.2	15,422	183.7
Minnesota	105	233.5	150	70.1	2,854	1,142.1	827	399.8	4	201.0	3,838	100.9	282	393.3	8,065	175.6
Mississippi	10	86.6	18	69.4	6,898	767.4	307	457.5	1	116.8	1,804	124.8	386	1,968.8	9,458	383.0
Missouri	11	49.8	76	75.3	5,319	930.1	689	377.9	5	91.1	5,634	136.1	368	477.0	12,104	237.4
Montana	24	50.7	3	42.3	21	497.7	39	141.3	2	320.0	476	61.8	27	157.8	592	67.7
Nebraska	25	208.1	39	104.2	587	840.2	328	230.1	1	108.8	1,057	82.6	48	239.6	2,086	133.5
Nevada	52	244.6	278	129.5	2,257	1,087.3	2,337	367.2	28	187.9	3,952	305.7	288	458.9	9,194	375.2
New Hampshire	0	0.0	10	33.4	141	1,035.3	158	443.3	0	0.0	812	76.6	51	381.7	1,173	101.5
New Jersey	11	103.2	322	44.1	15,941	1,645.6	10,053	712.0	7	279.6	6,813	156.2	2,251	2,602.3	35,452	468.2
New Mexico	260	176.6	12	44.6	186	581.9	1,568	196.4	0	0.0	1,165	165.3	91	421.0	3,283	189.5
New York	56	115.2	1,774	119.6	48,049	1,973.1	44,524	1,477.7	19	260.1	23,588	244.9	9,511	4,279.5	127,934	759.7
North Carolina	170	178.4	168	71.1	18,768	1,041.6	2,390	360.3	10	194.9	7,581	135.3	1,216	1,059.7	30,310	355.7
North Dakota	13	46.0	4	41.7	133	815.6	25	133.9	0	0.0	184	34.0	17	194.6	376	60.3

Table 28. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas (cont)

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Ohio	11	56.7	103	48.6	9,330	798.4	1,393	450.0	2	60.6	9,426	119.1	885	622.0	21,258	217.6
Oklahoma	303	117.0	76	105.7	1,382	587.6	603	212.0	8	187.0	3,227	145.2	327	224.2	5,926	183.8
Oregon	52	136.0	132	85.0	468	754.5	940	244.4	18	139.4	4,938	181.6	201	223.8	6,749	195.0
Pennsylvania	37	238.1	275	75.1	17,303	1,533.5	6,050	900.1	19	619.1	10,772	125.5	1,699	1,357.0	36,159	331.9
Rhode Island	7	188.8	33	104.9	556	1,091.6	657	542.5	1	179.2	1,078	156.5	64	448.2	2,396	263.0
South Carolina	13	82.8	37	55.3	11,484	1,043.4	789	396.5	4	163.1	3,976	145.1	405	841.6	16,718	400.7
South Dakota	74	141.9	5	50.6	116	974.1	34	164.2	1	277.8	280	46.8	15	143.2	525	74.6
Tennessee	11	68.1	68	69.9	9,033	994.5	825	338.6	4	146.3	5,719	134.9	527	777.5	16,190	290.4
Texas	46	58.9	870	79.8	31,261	1,160.7	27,494	331.6	26	139.9	21,848	214.2	3,249	1,291.4	84,802	374.8
Utah	21	91.8	60	97.8	252	1,022.6	605	200.7	6	27.2	1,730	90.9	60	163.5	2,737	115.3
Vermont	0	0.0	11	118.6	66	1,097.8	47	506.6	1	625.0	513	101.2	27	355.5	665	122.9
Virginia	13	67.0	277	60.1	12,422	928.0	1,997	343.0	7	137.1	6,011	132.7	808	598.7	21,565	305.0
Washington	127	165.0	427	80.7	1,978	882.6	1,826	279.7	49	123.8	7,538	171.9	815	425.0	12,769	209.4
West Virginia	3	88.3	6	46.8	363	675.5	83	388.5	0	0.0	1,221	84.1	94	521.4	1,774	113.6
Wisconsin	26	63.7	83	65.3	2,255	795.0	828	298.0	1	63.3	2,688	66.0	188	339.0	6,070	124.9
Wyoming	12	128.7	2	43.1	26	490.8	55	128.5	0	0.0	211	50.9	8	123.6	314	65.0
Subtotal	2,953	152.3	13,508	88.6	412,196	1,247.3	214,553	485.2	848	184.2	301,996	176.3	42,271	962.5	989,222	365.5
U.S. dependent areas^e																
American Samoa	0	—	0	—	0	—	0	—	1	—	0	—	0	—	1	2.6
Guam	0	—	45	—	3	—	7	—	19	—	10	—	8	—	92	72.8
Northern Mariana Islands	0	—	1	—	0	—	1	—	2	—	2	—	1	—	7	17.4
Puerto Rico	1	—	2	—	2	—	16,782	—	1	—	19	—	2	—	16,809	572.6
Republic of Palau	0	—	2	—	0	—	1	—	6	—	0	—	0	—	9	50.5
U.S. Virgin Islands	0	—	2	—	297	—	199	—	0	—	45	—	5	—	551	625
Subtotal	1	—	52	—	302	—	16,990	—	29	—	76	—	16	—	17,469	538.1
Total	2,954	—	13,560	—	412,498	—	231,543	—	877	—	302,072	—	42,287	—	1,006,691	367.6

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Numbers less than 12, and rates based on these numbers, should be interpreted with caution

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population.

^e Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

Table 29. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Alabama	0	0.0	12	21.4	3,587	338.6	217	152.7	1	51.2	1,442	52.4	341	750.0	5,600	137.3
Alaska	95	115.2	14	36.1	43	211.9	41	109.1	2	28.4	164	42.4	23	72.8	382	63.2
Arizona	304	139.4	73	38.7	861	363.7	2,264	138.8	10	96.0	3,834	113.9	228	253.8	7,575	132.0
Arkansas	2	10.7	4	10.6	1,025	276.4	180	115.0	3	52.0	1,144	61.6	161	467.0	2,519	101.5
California	163	115.9	2,467	50.5	11,765	624.4	26,273	221.4	112	92.7	27,387	208.7	2,375	323.8	70,547	215.4
Colorado	32	106.9	52	35.7	820	453.2	1,357	151.3	5	84.5	2,987	91.0	153	186.9	5,406	116.9
Connecticut	7	114.5	44	31.8	2,107	699.8	2,231	511.7	5	481.2	1,848	86.1	154	387.3	6,396	208.4
Delaware	2	77.3	4	12.6	1,184	699.7	156	246.3	1	373.1	543	103.2	73	558.7	1,963	243.5
District of Columbia	6	465.8	30	118.0	5,873	2,212.1	559	954.6	2	696.9	972	427.8	274	2,495.4	7,717	1,309.7
Florida	25	54.1	228	46.3	28,171	1,078.1	12,662	296.4	13	119.3	16,120	160.7	1,540	710.4	58,760	332.3
Georgia	9	44.7	90	26.1	17,874	682.9	1,892	268.6	4	80.1	4,857	102.9	1,482	1,320.5	26,209	307.5
Hawaii	3	112.4	226	47.9	83	357.6	171	164.0	144	130.8	709	250.7	160	77.7	1,496	124.6
Idaho	5	32.9	2	10.1	41	460.8	95	63.8	0	0.0	385	33.5	25	115.2	553	40.5
Illinois	9	54.2	204	34.4	8,477	566.7	3,698	222.1	9	309.0	4,723	68.9	1,074	859.9	18,194	169.2
Indiana	3	23.0	84	69.2	1,880	380.2	556	170.7	0	0.0	2,748	61.3	236	336.6	5,507	99.9
Iowa	3	40.8	21	32.9	265	317.9	153	118.2	0	0.0	922	40.3	73	252.9	1,437	55.2
Kansas	2	10.3	14	19.7	356	262.8	282	115.8	0	0.0	791	42.2	80	177.4	1,525	63.8
Kentucky	3	36.8	16	30.2	1,091	374.7	272	246.8	0	0.0	1,924	60.1	145	320.9	3,451	93.0
Louisiana	13	52.2	25	35.5	7,097	587.2	495	274.1	2	128.0	2,546	108.2	207	512.8	10,386	267.8
Maine	3	42.1	5	36.6	86	612.8	55	342.9	0	0.0	615	56.6	20	139.8	784	68.0
Maryland	4	32.1	82	24.9	12,806	860.9	1,218	276.9	1	39.6	2,070	76.8	1,162	1,304.4	17,343	342.9
Massachusetts	16	155.1	199	51.9	3,407	858.6	3,109	513.3	2	87.8	4,354	99.4	199	254.1	11,287	192.7
Michigan	11	23.2	51	20.0	4,480	398.3	478	131.9	2	90.6	2,715	42.0	285	208.9	8,022	95.6
Minnesota	57	126.8	75	35.1	1,353	541.4	456	220.5	0	0.0	1,680	44.2	160	223.1	3,781	82.3
Mississippi	2	17.3	9	34.7	3,330	370.5	167	248.9	0	0.0	877	60.7	228	1,162.9	4,613	186.8
Missouri	9	40.7	35	34.7	2,774	485.0	370	202.9	3	54.7	2,896	70.0	229	296.8	6,316	123.9
Montana	18	38.0	1	14.1	12	284.4	21	76.1	1	160.0	271	35.2	18	105.2	342	39.1
Nebraska	10	83.3	20	53.4	303	433.7	172	120.7	1	108.8	524	41.0	31	154.8	1,061	67.9
Nevada	26	122.3	128	59.6	1,112	535.7	1,154	181.3	13	87.2	1,908	147.6	160	254.9	4,501	183.7
New Hampshire	0	0.0	7	23.4	71	521.3	95	266.5	0	0.0	406	38.3	32	239.5	611	52.9
New Jersey	6	56.3	146	20.0	8,215	848.0	5,241	371.2	1	39.9	3,382	77.5	1,387	1,603.4	18,380	242.8
New Mexico	133	90.4	4	14.9	88	275.3	855	107.1	0	0.0	711	100.9	56	259.1	1,847	106.6
New York	32	65.8	817	55.1	28,098	1,153.8	26,942	894.2	5	68.5	12,342	128.2	5,946	2,675.4	74,203	440.7
North Carolina	75	78.7	52	22.0	8,435	468.1	1,129	170.2	2	39.0	3,245	57.9	625	544.7	13,563	159.2
North Dakota	10	35.4	3	31.3	62	380.2	13	69.6	0	0.0	84	15.5	11	125.9	183	29.3

Table 29. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas (cont)

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Ohio	5	25.8	37	17.5	4,353	372.5	681	220.0	0	0.0	4,525	57.2	474	333.1	10,076	103.1
Oklahoma	150	57.9	31	43.1	647	275.1	305	107.2	3	70.1	1,590	71.5	170	116.6	2,896	89.8
Oregon	31	81.1	59	38.0	261	420.8	537	139.6	9	69.7	2,858	105.1	104	115.8	3,859	111.5
Pennsylvania	14	90.1	128	34.9	9,635	853.9	3,396	505.3	8	260.7	5,897	68.7	1,061	847.4	20,139	184.9
Rhode Island	3	80.9	17	54.0	320	628.3	390	322.1	1	179.2	598	86.8	28	196.1	1,357	149.0
South Carolina	6	38.2	20	29.9	6,305	572.9	432	217.1	3	122.3	2,001	73.0	253	525.7	9,020	216.2
South Dakota	42	80.6	1	10.1	49	411.5	19	91.8	1	277.8	113	18.9	9	85.9	234	33.2
Tennessee	6	37.1	33	33.9	4,364	480.5	450	184.7	2	73.2	2,956	69.7	319	470.7	8,130	145.8
Texas	21	26.9	360	33.0	15,541	577.0	14,729	177.6	7	37.7	11,437	112.1	1,810	719.4	43,906	194.1
Utah	10	43.7	24	39.1	123	499.1	337	111.8	3	13.6	905	47.5	30	81.7	1,432	60.3
Vermont	0	0.0	5	53.9	34	565.5	29	312.6	1	625.0	265	52.3	15	197.5	349	64.5
Virginia	6	30.9	128	27.8	5,720	427.3	1,007	173.0	4	78.4	2,816	62.2	451	334.2	10,132	143.3
Washington	75	97.4	217	41.0	1,044	465.8	1,021	156.4	30	75.8	4,038	92.1	495	258.1	6,925	113.5
West Virginia	1	29.4	1	7.8	184	342.4	50	234.0	0	0.0	697	48.0	56	310.6	989	63.3
Wisconsin	11	26.9	32	25.2	1,060	373.7	460	165.6	0	0.0	1,344	33.0	101	182.1	3,008	61.9
Wyoming	8	85.8	1	21.6	11	207.7	36	84.1	0	0.0	113	27.3	6	92.7	175	36.2
Subtotal	1,487	76.7	6,338	41.6	216,883	656.3	118,908	268.9	416	90.4	156,279	91.2	24,735	563.2	525,087	194.0
U.S. dependent areas^e																
American Samoa	0	—	0	—	0	—	0	—	1	—	0	—	0	—	1	2.6
Guam	0	—	16	—	1	—	1	—	8	—	4	—	5	—	35	27.7
Northern Mariana Islands	0	—	1	—	0	—	0	—	2	—	0	—	0	—	3	7.5
Puerto Rico	1	—	0	—	1	—	9,070	—	0	—	6	—	1	—	9,079	309.3
Republic of Palau	0	—	1	—	0	—	0	—	4	—	0	—	0	—	5	28.1
U.S. Virgin Islands	0	—	1	—	162	—	112	—	0	—	27	—	3	—	305	346.0
Subtotal	1	—	19	—	164	—	9,183	—	15	—	37	—	9	—	9,428	290.4
Total	1,488	—	6,357	—	217,047	—	128,091	—	431	—	156,316	—	24,744	—	534,515	195.2

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population.

^e Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

Table 30. Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico

MSA of residence	Diagnosis, 2017 ^a			Prevalence of diagnosed HIV infection, year-end 2016 ^b	
	No.	Rate ^c	Rank ^d	No.	Rate ^c
Akron, OH	50	7.1	79	937	133.4
Albany–Schenectady–Troy, NY	61	6.9	83	2,107	238.7
Albuquerque, NM	37	4.1	103	1,653	182.3
Allentown–Bethlehem–Easton, PA–NJ	48	5.7	89	596	71.4
Atlanta–Sandy Springs–Roswell, GA	1,607	27.3	3	32,043	552.9
Augusta–Richmond County, GA–SC	89	14.8	28	2,305	387.5
Austin–Round Rock, TX	290	13.7	35	5,848	283.8
Bakersfield, CA	149	16.7	18	1,485	167.8
Baltimore–Columbia–Towson, MD	443	15.8	23	17,013	607.4
Baton Rouge, LA	224	26.9	5	5,097	610.0
Birmingham–Hoover, AL	182	15.8	22	4,004	349.1
Boise City, ID	22	3.1	105	260	37.6
Boston–Cambridge–Newton, MA–NH ^e	456	9.4	61	13,830	287.8
Boston Division	240	11.9	—	7,965	398.3
Cambridge Division	209	8.8	—	5,571	234.6
Bridgeport–Stamford–Norwalk, CT	51	5.4	94	2,602	274.1
Buffalo–Cheektowaga–Niagara Falls, NY	99	8.7	65	2,509	221.1
Cape Coral–Fort Myers, FL	81	11.0	49	2,103	291.1
Charleston–North Charleston, SC	117	15.1	26	2,550	334.7
Charlotte–Concord–Gastonia, NC–SC	394	15.6	25	8,014	323.7
Chattanooga, TN–GA	51	9.2	63	1,154	209.1
Chicago–Naperville–Elgin, IL–IN–WI	1,104	11.6	45	29,822	312.4
Chicago Division	984	13.4	—	27,256	371.6
Elgin Division	36	5.6	—	417	65.5
Gary Division	46	6.6	—	1,177	167.8
Lake County Division	38	4.4	—	972	111.4
Cincinnati, OH–KY–IN	271	12.4	41	4,028	186.0
Cleveland–Elyria, OH	209	10.2	58	5,222	253.5
Colorado Springs, CO	35	4.8	96	902	126.9
Columbia, SC	170	20.6	9	3,923	479.9
Columbus, OH	276	13.3	38	5,528	270.1
Dallas–Fort Worth–Arlington, TX	1,300	17.6	16	26,092	359.7
Dallas Division	995	20.3	—	20,394	424.0
Fort Worth Division	305	12.3	—	5,698	233.2
Dayton, OH	80	10.0	59	1,583	197.7
Deltona–Daytona Beach–Ormond Beach, FL	94	14.5	29	1,804	283.3
Denver–Aurora–Lakewood, CO	316	10.9	50	9,301	326.1
Des Moines–West Des Moines, IA	39	6.0	88	820	129.2
Detroit–Warren–Dearborn, MI	520	12.1	43	9,818	228.0
Detroit Division	322	18.4	—	6,675	380.0
Warren Division	198	7.7	—	3,143	123.3
Durham–Chapel Hill, NC	80	14.1	31	2,215	396.3
El Paso, TX	150	17.8	15	2,064	245.4
Fayetteville–Springdale–Rogers, AR–MO	28	5.2	95	616	117.3
Fresno, CA	158	16.0	21	1,811	184.9
Grand Rapids–Wyoming, MI	59	5.6	91	1,196	114.0
Greensboro–High Point, NC	143	18.8	12	2,627	347.2
Greenville–Anderson–Mauldin, SC	94	10.5	54	1,970	222.7
Harrisburg–Carlisle, PA	48	8.4	68	383	67.4
Hartford–West Hartford–East Hartford, CT	98	8.1	70	3,267	270.0
Honolulu (Urban), HI	60	6.1	87	1,583	159.5

Table 30. Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, 2017 ^a			Prevalence of diagnosed HIV infection, year-end 2016 ^b	
	No.	Rate ^c	Rank ^d	No.	Rate ^c
Houston–The Woodlands–Sugar Land, TX	1,340	19.4	11	28,581	420.4
Indianapolis–Carmel–Anderson, IN	282	13.9	32	5,414	269.9
Jackson, MS	137	23.7	6	2,911	502.3
Jacksonville, FL	353	23.5	7	6,759	457.8
Kansas City, MO–KS	183	8.6	66	4,545	215.8
Knoxville, TN	66	7.5	75	1,252	144.3
Lakeland–Winter Haven, FL	94	13.7	36	2,247	336.9
Lancaster, PA	23	4.2	101	174	32.3
Las Vegas–Henderson–Paradise, NV	446	20.2	10	7,703	357.2
Lexington–Fayette, KY	50	9.8	60	1,076	212.3
Little Rock–North Little Rock–Conway, AR	137	18.6	13	2,157	294.1
Los Angeles–Long Beach–Anaheim, CA	1,832	13.7	34	54,845	411.5
Anaheim Division	304	9.5	—	6,596	207.6
Los Angeles Division	1,528	15.0	—	48,249	475.3
Louisville/Jefferson County, KY–IN	171	13.2	39	3,502	272.6
Madison, WI	27	4.1	102	717	110.7
McAllen–Edinburg–Mission, TX	94	10.9	51	1,278	150.3
Memphis, TN–MS–AR	288	21.4	8	6,926	514.9
Miami–Fort Lauderdale–West Palm Beach, FL	2,177	35.3	1	53,269	872.2
Fort Lauderdale Division	683	35.3	—	19,135	998.1
Miami Division	1,181	42.9	—	26,243	959.0
West Palm Beach Division	313	21.3	—	7,891	542.8
Milwaukee–Waukesha–West Allis, WI	144	9.1	64	3,100	196.7
Minneapolis–St. Paul–Bloomington, MN–WI	234	6.5	85	6,882	193.5
Modesto, CA	43	7.8	73	673	124.3
Nashville–Davidson–Murfreesboro–Franklin, TN	197	10.4	55	5,003	267.7
New Haven–Milford, CT	89	10.3	56	3,229	375.5
New Orleans–Metairie, LA	344	27.0	4	7,679	604.1
New York–Newark–Jersey City, NY–NJ–PA ^e	3,266	16.1	20	138,830	684.7
Nassau County Division	194	6.8	—	6,003	209.9
New York Division	2,597	17.9	—	118,072	814.3
Newark Division	458	18.1	—	13,683	542.8
North Port–Sarasota–Bradenton, FL	83	10.3	57	1,901	241.1
Ogden–Clearfield, UT	11	1.7	107	359	55.0
Oklahoma City, OK	159	11.5	46	2,697	196.5
Omaha–Council Bluffs, NE–IA	53	5.7	90	482	52.2
Orlando–Kissimmee–Sanford, FL	718	28.6	2	11,316	461.3
Oxnard–Thousand Oaks–Ventura, CA	68	8.0	72	974	114.4
Palm Bay–Melbourne–Titusville, FL	55	9.3	62	1,497	259.0
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD	842	13.8	33	23,920	393.6
Camden Division	125	10.0	—	2,874	229.8
Montgomery County Division	77	3.9	—	667	34.0
Philadelphia Division	540	25.2	—	18,066	844.7
Wilmington Division	100	13.8	—	2,313	319.6
Phoenix–Mesa–Scottsdale, AZ	562	11.9	44	11,685	251.4
Pittsburgh, PA	126	5.4	93	846	36.1
Portland–South Portland, ME	14	2.6	106	816	154.5
Portland–Vancouver–Hillsboro, OR–WA	158	6.4	86	5,321	219.6
Providence–Warwick, RI–MA	118	7.3	78	3,423	211.8
Provo–Orem, UT	9	1.5	108	183	30.4
Raleigh, NC	145	10.9	52	3,742	286.8

Table 30. Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, 2017 ^a			Prevalence of diagnosed HIV infection, year-end 2016 ^b	
	No.	Rate ^c	Rank ^d	No.	Rate ^c
Richmond, VA	187	14.4	30	3,212	250.5
Riverside–San Bernardino–Ontario, CA	490	10.7	53	11,412	252.3
Rochester, NY	75	7.0	81	2,929	271.6
Sacramento–Roseville–Arden-Arcade, CA	163	7.0	80	4,880	212.6
St. Louis, MO–IL	311	11.1	48	6,868	244.7
Salt Lake City, UT	83	6.9	82	1,928	162.6
San Antonio–New Braunfels, TX	389	15.7	24	6,425	264.8
San Diego–Carlsbad, CA	405	12.1	42	12,677	382.2
San Francisco–Oakland–Hayward, CA ^e	635	13.4	37	23,031	490.1
Oakland Division	312	11.1	—	8,168	292.6
San Francisco Division	307	18.5	—	14,065	854.7
San Jose–Sunnyvale–Santa Clara, CA	162	8.1	69	3,032	152.3
San Juan–Carolina–Caguas, PR	317	15.0	27	9,375	435.1
Santa Rosa, CA	28	5.6	92	1,431	284.0
Scranton–Wilkes-Barre–Hazleton, PA	24	4.3	98	297	53.5
Seattle–Tacoma–Bellevue, WA	303	7.8	74	9,204	242.0
Seattle Division	254	8.5	—	7,809	265.3
Tacoma Division	49	5.6	—	1,395	162.3
Spokane–Spokane Valley, WA	24	4.3	99	590	106.3
Springfield, MA	47	7.4	77	2,127	337.3
Stockton–Lodi, CA	63	8.5	67	1,268	172.7
Syracuse, NY	22	3.4	104	1,284	195.5
Tampa–St. Petersburg–Clearwater, FL	561	18.1	14	12,308	405.3
Toledo, OH	45	7.5	76	987	163.3
Tucson, AZ	116	11.3	47	2,422	239.2
Tulsa, OK	80	8.1	71	1,862	188.6
Virginia Beach–Norfolk–Newport News, VA–NC	285	16.5	19	4,818	279.7
Washington–Arlington–Alexandria, DC–VA–MD–WV	1,087	17.5	17	20,038	325.8
Silver Spring Division	202	15.4	—	3,869	298.5
Washington Division	885	18.0	—	16,169	333.1
Wichita, KS	29	4.5	97	886	137.4
Winston-Salem, NC	88	13.2	40	1,841	278.2
Worcester, MA–CT	62	6.6	84	2,015	215.1
Youngstown–Warren–Boardman, OH–PA	23	4.2	100	720	132.2
Subtotal for MSAs (population of ≥500,000)	31,025	13.8	—	790,466	355.5
Metropolitan areas (population of 50,000–499,999)	4,907	8.4	—	100,328	172.0
Nonmetropolitan areas	2,314	5.0	—	55,032	119.3
Total^f	38,726	11.8	—	1,008,264	308.5

Abbreviation: MSA, metropolitan statistical area.

Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

MSA definitions for this report can be found at <http://www.census.gov/programs-surveys/metro-micro.html>.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^c Rates are per 100,000 population.

^d Based on rate.

^e Counts of diagnoses of HIV infection for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of <500,000.

^f Includes persons whose county of residence is unknown.

Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico

MSA of residence	Diagnosis, cumulative ^{a,b}							
	Diagnosis, 2017 ^b			Adults or adolescents	Children	Total	Prevalence of stage 3 (AIDS), year-end 2016 ^c	
	No.	Rate ^d	Rank ^e	No.	No.	No.	No.	Rate ^d
Akron, OH	17	2.4	90	985	1	986	410	58.4
Albany–Schenectady–Troy, NY	32	3.6	68	2,674	27	2,701	1,207	136.7
Albuquerque, NM	12	1.3	104	1,856	4	1,860	943	104.0
Allentown–Bethlehem–Easton, PA–NJ	35	4.2	59	1,797	18	1,815	305	36.5
Atlanta–Sandy Springs–Roswell, GA	698	11.9	10	34,876	146	35,022	16,356	282.2
Augusta–Richmond County, GA–SC	148	24.7	1	2,823	26	2,849	1,145	192.5
Austin–Round Rock, TX	102	4.8	48	6,488	26	6,514	3,058	148.4
Bakersfield, CA	44	4.9	46	2,183	9	2,192	842	95.1
Baltimore–Columbia–Towson, MD	298	10.6	11	26,219	229	26,448	9,214	329.0
Baton Rouge, LA	128	15.3	2	5,918	26	5,944	2,679	320.6
Birmingham–Hoover, AL	75	6.5	29	3,665	25	3,690	1,689	147.3
Boise City, ID	12	1.7	103	458	0	458	88	12.7
Boston–Cambridge–Newton, MA–NH ^f	192	4.0	62	17,331	163	17,494	7,632	158.8
Boston Division	112	5.6	—	10,708	97	10,805	4,464	223.2
Cambridge Division	78	3.3	—	6,234	65	6,299	3,023	127.3
Bridgeport–Stamford–Norwalk, CT	34	3.6	70	4,335	57	4,392	1,541	162.3
Buffalo–Cheektowaga–Niagara Falls, NY	48	4.2	57	3,097	20	3,117	1,287	113.4
Cape Coral–Fort Myers, FL	49	6.6	26	2,340	25	2,365	1,211	167.6
Charleston–North Charleston, SC	51	6.6	27	2,841	25	2,866	1,326	174.0
Charlotte–Concord–Gastonia, NC–SC	159	6.3	31	6,293	30	6,323	3,492	141.1
Chattanooga, TN–GA	22	4.0	63	1,371	3	1,374	615	111.4
Chicago–Naperville–Elgin, IL–IN–WI	521	5.5	41	39,463	265	39,728	14,987	157.0
Chicago Division	448	6.1	—	36,107	242	36,349	13,675	186.4
Elgin Division	14	2.2	—	826	9	835	226	35.5
Gary Division	40	5.7	—	1,465	9	1,474	565	80.5
Lake County Division	19	2.2	—	1,065	5	1,070	521	59.7
Cincinnati, OH–KY–IN	101	4.6	54	4,032	21	4,053	1,971	91.0
Cleveland–Elyria, OH	97	4.7	52	5,515	47	5,562	2,472	120.0
Colorado Springs, CO	8	1.1	105	760	5	765	405	57.0
Columbia, SC	105	12.7	5	4,729	26	4,755	2,163	264.6
Columbus, OH	117	5.6	39	4,993	24	5,017	2,492	121.7

Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, cumulative ^{a,b}							
	Diagnosis, 2017 ^b			Adults or adolescents	Children	Total	Prevalence of stage 3 (AIDS), year-end 2016 ^c	
	No.	Rate ^d	Rank ^e	No.	No.	No.	No.	Rate ^d
Dallas–Fort Worth–Arlington, TX	574	7.8	19	28,328	66	28,394	13,313	183.5
Dallas Division	441	9.0	—	22,357	39	22,396	10,408	216.4
Fort Worth Division	133	5.3	—	5,971	27	5,998	2,905	118.9
Dayton, OH	29	3.6	69	1,672	14	1,686	817	102.0
Deltona–Daytona Beach–Ormond Beach, FL	49	7.5	21	2,152	18	2,170	1,060	166.4
Denver–Aurora–Lakewood, CO	125	4.3	56	8,817	24	8,841	3,997	140.2
Des Moines–West Des Moines, IA	20	3.1	78	796	4	800	451	71.1
Detroit–Warren–Dearborn, MI	216	5.0	45	13,917	79	13,996	5,158	119.8
Detroit Division	141	8.0	—	10,841	62	10,903	3,585	204.1
Warren Division	75	2.9	—	3,076	17	3,093	1,573	61.7
Durham–Chapel Hill, NC	40	7.0	23	1,710	10	1,720	914	163.5
El Paso, TX	49	5.8	37	2,210	10	2,220	1,137	135.2
Fayetteville–Springdale–Rogers, AR–MO	10	1.9	100	538	6	544	311	59.2
Fresno, CA	67	6.8	24	2,254	11	2,265	1,010	103.1
Grand Rapids–Wyoming, MI	27	2.5	88	1,251	6	1,257	601	57.3
Greensboro–High Point, NC	36	4.7	51	1,854	19	1,873	952	125.8
Greenville–Anderson–Mauldin, SC	66	7.4	22	2,152	7	2,159	1,069	120.9
Harrisburg–Carlisle, PA	25	4.4	55	1,679	9	1,688	165	29.0
Hartford–West Hartford–East Hartford, CT	46	3.8	65	5,959	46	6,005	2,030	167.8
Honolulu (Urban), HI	27	2.7	84	2,437	14	2,451	882	88.8
Houston–The Woodlands–Sugar Land, TX	620	9.0	14	35,656	182	35,838	14,939	219.8
Indianapolis–Carmel–Anderson, IN	119	5.9	35	5,580	27	5,607	2,690	134.1
Jackson, MS	84	14.5	4	3,726	31	3,757	1,371	236.6
Jacksonville, FL	180	12.0	8	8,553	80	8,633	3,796	257.1
Kansas City, MO–KS	73	3.4	73	6,087	18	6,105	2,489	118.2
Knoxville, TN	22	2.5	89	1,369	8	1,377	632	72.8
Lakeland–Winter Haven, FL	43	6.3	32	2,621	22	2,643	1,319	197.7
Lancaster, PA	13	2.4	91	922	23	945	76	14.1
Las Vegas–Henderson–Paradise, NV	168	7.6	20	6,835	27	6,862	3,732	173.0
Lexington–Fayette, KY	18	3.5	71	1,054	1	1,055	544	107.3
Little Rock–North Little Rock–Conway, AR	71	9.6	12	2,003	15	2,018	932	127.1

Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, cumulative ^{a,b}							
	Diagnosis, 2017 ^b			Adults or adolescents	Children	Total	Prevalence of stage 3 (AIDS), year-end 2016 ^c	
	No.	Rate ^d	Rank ^e	No.	No.	No.	No.	Rate ^d
Los Angeles–Long Beach–Anaheim, CA	810	6.1	34	73,428	309	73,737	29,368	220.3
Anaheim Division	108	3.4	—	8,813	46	8,859	3,652	114.9
Los Angeles Division	702	6.9	—	64,615	263	64,878	25,716	253.3
Louisville/Jefferson County, KY–IN	67	5.2	43	3,398	30	3,428	1,642	127.8
Madison, WI	13	2.0	99	702	5	707	338	52.2
McAllen–Edinburg–Mission, TX	32	3.7	66	1,162	13	1,175	705	82.9
Memphis, TN–MS–AR	160	11.9	9	7,630	23	7,653	3,296	245.0
Miami–Fort Lauderdale–West Palm Beach, FL	917	14.9	3	70,504	1,009	71,513	27,960	457.8
Fort Lauderdale Division	301	15.5	—	21,593	265	21,858	10,112	527.5
Miami Division	449	16.3	—	36,869	513	37,382	13,159	480.9
West Palm Beach Division	167	11.4	—	12,042	231	12,273	4,689	322.5
Milwaukee–Waukesha–West Allis, WI	45	2.9	83	3,363	20	3,383	1,534	97.3
Minneapolis–St. Paul–Bloomington, MN–WI	120	3.3	74	6,093	24	6,117	3,133	88.1
Modesto, CA	21	3.8	64	926	6	932	441	81.5
Nashville–Davidson–Murfreesboro–Franklin, TN	70	3.7	67	5,304	26	5,330	2,484	132.9
New Haven–Milford, CT	27	3.1	77	5,196	74	5,270	2,085	242.4
New Orleans–Metairie, LA	160	12.5	6	11,565	80	11,645	4,014	315.8
New York–Newark–Jersey City, NY–NJ–PA ^f	1,649	8.1	15	229,235	3,012	232,247	79,260	390.9
Nassau County Division	112	3.9	—	9,531	117	9,648	3,450	120.6
New York Division	1,323	9.1	—	193,040	2,512	195,552	68,202	470.3
Newark Division	202	8.0	—	24,705	370	25,075	6,961	276.1
North Port–Sarasota–Bradenton, FL	44	5.5	40	2,524	29	2,553	1,076	136.5
Ogden–Clearfield, UT	4	0.6	107	340	4	344	189	28.9
Oklahoma City, OK	81	5.9	36	3,153	4	3,157	1,292	94.1
Omaha–Council Bluffs, NE–IA	16	1.7	102	1,449	5	1,454	217	23.5
Orlando–Kissimmee–Sanford, FL	302	12.0	7	12,288	94	12,382	5,937	242.0
Oxnard–Thousand Oaks–Ventura, CA	18	2.1	98	1,295	5	1,300	533	62.6
Palm Bay–Melbourne–Titusville, FL	30	5.1	44	1,887	12	1,899	886	153.3

Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, cumulative ^{a,b}							
	Diagnosis, 2017 ^b			Adults or adolescents	Children	Total	Prevalence of stage 3 (AIDS), year-end 2016 ^c	
	No.	Rate ^d	Rank ^e	No.	No.	No.	No.	Rate ^d
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD	398	6.5	28	35,739	317	36,056	13,252	218.1
Camden Division	33	2.6	—	3,988	43	4,031	1,378	110.2
Montgomery County Division	44	2.2	—	2,954	12	2,966	312	15.9
Philadelphia Division	272	12.7	—	25,029	238	25,267	10,166	475.3
Wilmington Division	49	6.8	—	3,768	24	3,792	1,396	192.9
Phoenix–Mesa–Scottsdale, AZ	227	4.8	49	10,579	32	10,611	5,483	118.0
Pittsburgh, PA	52	2.2	95	4,149	22	4,171	421	18.0
Portland–South Portland, ME	12	2.3	94	749	2	751	404	76.5
Portland–Vancouver–Hillsboro, OR–WA	63	2.6	87	6,142	9	6,151	2,961	122.2
Providence–Warwick, RI–MA	51	3.1	76	4,853	45	4,898	1,948	120.6
Provo–Orem, UT	5	0.8	106	165	3	168	85	14.1
Raleigh, NC	77	5.8	38	3,191	20	3,211	1,746	133.8
Richmond, VA	86	6.6	25	4,613	36	4,649	1,386	108.1
Riverside–San Bernardino–Ontario, CA	215	4.7	53	11,608	63	11,671	6,893	152.4
Rochester, NY	45	4.2	58	3,737	17	3,754	1,652	153.2
Sacramento–Roseville–Arden–Arcade, CA	80	3.4	72	5,198	31	5,229	2,589	112.8
St. Louis, MO–IL	113	4.0	61	7,955	45	8,000	3,412	121.6
Salt Lake City, UT	22	1.8	101	2,085	9	2,094	994	83.8
San Antonio–New Braunfels, TX	160	6.5	30	7,190	32	7,222	3,353	138.2
San Diego–Carlsbad, CA	161	4.8	47	15,985	72	16,057	6,912	208.4
San Francisco–Oakland–Hayward, CA ^f	258	5.5	42	46,469	102	46,571	13,376	284.7
Oakland Division	107	3.8	—	12,184	53	12,237	4,838	173.3
San Francisco Division	146	8.8	—	32,563	44	32,607	8,063	490.0
San Jose–Sunnyvale–Santa Clara, CA	52	2.6	86	4,912	17	4,929	1,856	93.2
San Juan–Carolina–Caguas, PR	132	6.2	33	25,125	279	25,404	4,718	219.0
Santa Rosa, CA	11	2.2	97	2,166	8	2,174	943	187.2
Scranton–Wilkes–Barre–Hazleton, PA	3	0.5	108	740	7	747	148	26.7
Seattle–Tacoma–Bellevue, WA	114	2.9	80	11,366	27	11,393	4,843	127.4
Seattle Division	96	3.2	—	10,015	18	10,033	4,101	139.4
Tacoma Division	18	2.1	—	1,351	9	1,360	742	86.3
Spokane–Spokane Valley, WA	13	2.3	92	691	1	692	337	60.7

Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, cumulative ^{a,b}							
	Diagnosis, 2017 ^b			Adults or adolescents	Children	Total	Prevalence of stage 3 (AIDS), year-end 2016 ^c	
	No.	Rate ^d	Rank ^e	No.	No.	No.	No.	Rate ^d
Springfield, MA	30	4.7	50	2,611	28	2,639	1,202	190.6
Stockton–Lodi, CA	23	3.1	79	1,524	15	1,539	707	96.3
Syracuse, NY	15	2.3	93	1,635	10	1,645	732	111.4
Tampa–St. Petersburg–Clearwater, FL	288	9.3	13	15,104	117	15,221	6,888	226.8
Toledo, OH	16	2.7	85	1,070	15	1,085	457	75.6
Tucson, AZ	42	4.1	60	2,577	12	2,589	1,245	123.0
Tulsa, OK	33	3.3	75	2,064	11	2,075	960	97.2
Virginia Beach–Norfolk–Newport News, VA–NC	137	7.9	16	6,458	66	6,524	2,008	116.6
Washington–Arlington–Alexandria, DC–VA–MD–WV	490	7.9	18	39,866	330	40,196	9,788	159.1
Silver Spring Division	84	6.4	—	4,067	27	4,094	1,927	148.7
Washington Division	406	8.3	—	35,799	303	36,102	7,861	161.9
Wichita, KS	19	2.9	81	1,073	2	1,075	456	70.7
Winston-Salem, NC	53	7.9	17	1,463	11	1,474	750	113.3
Worcester, MA–CT	27	2.9	82	2,588	22	2,610	1,220	130.2
Youngstown–Warren–Boardman, OH–PA	12	2.2	96	773	0	773	332	61.0
Subtotal for MSAs (population of ≥500,000)	14,043	6.3	—	1,074,829	8,644	1,083,473	418,764	188.3
Metropolitan areas (population of 50,000–499,999)	2,348	4.0	—	123,600	851	124,451	52,405	89.8
Nonmetropolitan areas	1,239	2.7	—	67,006	440	67,446	29,381	63.7
Total^g	17,794	5.4	—	1,270,856	9,979	1,280,835	534,454	163.5

Abbreviation: MSA, metropolitan statistical area.

Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico.

Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

MSA definitions for this report can be found at <http://www.census.gov/programs-surveys/metro-micro.html>.

^a From the beginning of the epidemic through 2017.

^b Data are based on residence at time of diagnosis of HIV infection.

^c Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^d Rates are per 100,000 population.

^e Based on rate.

^f Counts of stage 3 (AIDS) classifications for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of <500,000.

^g Includes persons whose county of residence is unknown.

Web Addresses for Reports of State and Local HIV Surveillance

Alabama	http://www.alabamapublichealth.gov/hiv/publications.html
Alaska	http://epibulletins.dhss.alaska.gov/Bulletin/DisplayClassificationBulletins/46
Arizona	http://www.azdhs.gov/phs/edc/odis/hiv-epidemiology/reports/index.php?pg=annual
Arkansas	https://www.healthy.arkansas.gov/programs-services/topics/hiv-aids-sti-surveillance
California	https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OAsre.aspx
Chicago	https://www.cityofchicago.org/city/en/depts/cdph/provdrs/health_data_and_reports/svcs/get_sti_hiv_datainchicago.html
Colorado	https://www.colorado.gov/pacific/cdphe/stihiv-data-and-trends
Connecticut	https://portal.ct.gov/DPH/AIDS--Chronic-Diseases/Surveillance/Connecticut-HIV-Statistics
Delaware	http://www.dhss.delaware.gov/dhss/dph/epi/disstatshiv.html
District of Columbia	https://dchealth.dc.gov/service/hiv-reports-and-publications
Florida	http://www.floridahealth.gov/diseases-and-conditions/aids/surveillance/index.html
Georgia	https://dph.georgia.gov/data-fact-sheet-summaries#SurveillanceSummaries
Guam	http://dphss.guam.gov/content/hiv-surveillance-program
Hawaii	http://health.hawaii.gov/harmreduction/hiv-aids/data-and-statistics/
Houston	http://www.houstontx.gov/health/HIV-STD/
Idaho	http://healthandwelfare.idaho.gov/Health/FamilyPlanningSTDHIV/STDStatistics/tabid/393/Default.aspx
Illinois	http://dph.illinois.gov/topics-services/diseases-and-conditions/hiv-aids/hiv-surveillance/update-reports
Indiana	http://www.in.gov/isdh/23266.htm
Iowa	http://idph.iowa.gov/hivstdhiv/hiv/data
Kansas	http://www.kdheks.gov/sti_hiv/hiv_std_update.html
Kentucky	https://chfs.ky.gov/agencies/dph/dehp/hab/Pages/reports-stats.aspx
Los Angeles	http://publichealth.lacounty.gov/dhsp/Reports.htm
Louisiana	http://new.dhh.louisiana.gov/index.cfm/newsroom/category/63
Maine	http://www.maine.gov/dhhs/mecdc/infectious-disease/hiv-std/data/index.shtml
Maryland	http://phpa.dhmm.maryland.gov/OIDEOR/CHSE/Pages/statistics.aspx
Massachusetts	https://www.mass.gov/lists/hivaids-epidemiologic-profiles
Michigan	http://www.michigan.gov/mdch/0,4612,7-132-2940_2955_2982_46000_46003---,00.html
Minnesota	http://www.health.state.mn.us/divs/idepc/diseases/hiv/stats/index.html
Mississippi	http://www.msdc.state.ms.us/msdcsite/index.cfm/14,0,150,134,html
Missouri	http://health.mo.gov/data/hivstdaids/data.php
Montana	https://dphhs.mt.gov/publichealth/cdepi/diseases/HIV_HCV
Nebraska	http://dhhs.ne.gov/publichealth/Pages/dpc_hiv.aspx
Nevada	http://dpbh.nv.gov/Programs/HIV-OPHIE/dta/Publications/HIV/AIDS_Surveillance_Program_(HIV-OPHIE)-_Publications/
New Hampshire	http://www.dhhs.nh.gov/data/index.htm
New Jersey	http://www.nj.gov/health/hivstdtb/hiv-aids/statmap.shtml
New Mexico	http://nmhealth.org/data/infectious/20/
New York	http://www.health.state.ny.us/diseases/aids/statistics/index.htm
New York City	http://www1.nyc.gov/site/doh/data/data-sets/hiv-aids-surveillance-and-epidemiology-reports.page
North Carolina	http://epi.publichealth.nc.gov/cd/stds/figures.html
North Dakota	https://www.ndhealth.gov/hiv/Data/
Ohio	http://www.odh.ohio.gov/healthstats/disease/hivdata/hivcov.aspx
Oklahoma	https://www.ok.gov/health/Disease_Prevention_Preparedness/HIV_STD_Service/Fact_Sheets_-_OK_Data/index.html
Oregon	https://www.oregon.gov/oha/ph/DiseasesConditions/CommunicableDisease/DiseaseSurveillanceData/HIVData/Pages/index.aspx
Pennsylvania	https://www.health.pa.gov/topics/programs/HIV/Pages/Annual-Summary.aspx
Philadelphia	http://www.phila.gov/health/AACO/AACODataResearch.html
Puerto Rico	http://www.salud.gov.pr/Estadisticas-Registros-y-Publicaciones/Pages/Publicaciones-sobre-la-salud.aspx
Rhode Island	http://health.ri.gov/publications/bytopic.php?parm=HIV
San Francisco	http://www.sfdph.org/dph/files/reports/default.asp
South Carolina	http://www.dhec.sc.gov/Health/DiseasesandConditions/InfectiousDiseases/HIVandSTDs/DataandReports/
South Dakota	http://doh.sd.gov/diseases/infectious/HIV-AIDS/Prevention.aspx
Tennessee	https://www.tn.gov/health/health-program-areas/statistics/health-data/hiv-data.html
Texas	http://www.dshs.state.tx.us/hivstd/reports/default.shtm
U.S. Virgin Islands	https://doh.vi.gov/programs/communicable-diseases
Utah	http://health.utah.gov/epi/diseases/hivaids/surveillance/index.html
Vermont	http://www.healthvermont.gov/immunizations-infectious-disease/hiv/surveillance
Virginia	http://www.vdh.virginia.gov/disease-prevention/disease-prevention/hiv-aids-sexually-transmitted-disease-std-hepatitis-reports/
Washington	http://www.doh.wa.gov/DataandStatisticalReports/DiseasesandChronicConditions/HIVAIDSData.aspx
West Virginia	http://www.dhhr.wv.gov/oeps/std-hiv-hep/HIV_AIDS/Pages/HIVSurveillance.aspx
Wisconsin	http://dhs.wisconsin.gov/aids-hiv/Stats/index.htm
Wyoming	https://health.wyo.gov/publichealth/communicable-disease-unit/hivaids-surveillance-program/

Note. Electronic reports are not available for the following areas: American Samoa and the Northern Mariana Islands.